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Abstract 
Genes outside the Major Histocompatibility Complex (MHC) create a general 
susceptibility to autoimmunity in non-obese diabetic (NOD) mice. The current study has 
utilized NOD.H-2k and control B 10.BR (B 10.H-2k) congenic mice to study dendritic cell 
generation, both in vitro and in vivo, in an attempt to explore cellular processes which 
might be affected by non-MHC NOD genes. 
Initial in vitro results revealed that NOD.H-2k bone marrow cells cultured in the 
presence of GM-CSF and IL-4 generated a reduced yield of dendritic cells. This was 
underpinned by heterogeneous proliferation and elevated levels of apoptosis in NOD.H-
2k cultures. Both of these phenotypes appeared unique to the NOD.H-2k background as 
the response to growth factor stimulation of bone marrow cells from other H-2k congenic 
strains was comparable to the response of cells from the B 10.H-2k strain. Using allelic 
variants of Ly5 to distinguish between strain-specific cells, it was determined that B l0.H-
2k myeloid precursors in co-culture with NOD.H-2k precursors develop normally into 
dendritic cells. This indicated that the inability of NOD.H-2k myeloid precursors to 
generate substantial numbers of dendritic cells in vitro was a cell-intrinsic feature of 
NOD.H-2k myeloid precursors. 
To assess the relative physiological capacity of NOD.H-2k and B 10.H-2k 
myeloid precursors to reconstitute irradiated hosts and generate dendritic cells in vivo, 
mixed bone chimeric mice were constructed. A mixed inoculum comprising a 1: 1 mixture 
of bone marrow cells from B 10.H-2k and NOD.H-2k mice was used to reconstitute 
irradiated B 10.H-2k recipients . Reconstitution of recipients was analyzed by flow 
cytometry, again using allelic variants of Ly5 to distinguish between donor cells. 
Surprisingly, the myeloid lineage of cells in recipient mice was disproportionately derived 
from the NOD.H-2k donor while the lymphoid compartment was even between the two 
donors. Interestingly, the skewing towards NOD.H-2k-derived dendritic cells in the 
spleen was accounted for predominantly by the CDSa- negative subset, reflecting a 
similar and unique bias observed in unmanipulated N<;:)D.H-2k mice. 
Overall, findings from this study demonstrate for the first time that non-MHC 
NOD genes confer on myeloid precursors a cell-intrinsic phenotype which alters dendritic 
cell generation both in vitro and in vivo. It is conceivable that dysregulation of antigen 
presenting cell function of dendritic cells may explain the breach of peripheral tolerance 
mechanisms in NOD mice. 
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1 
General Introduction 
1.1 Insulin-dependent Diabetes Mellitus 
The Non-obese Diabetic (NOD) mouse is a model for human Insulin-dependent 
Diabetes Mellitus (IDDM), also known as Type I or autoimmune diabetes (Baxter and 
Cooke, 1995; Wicker et al, 1995; Tisch and McDevitt, 1996; Vyse and Todd, 1996; 
Delovitch and Singh, 1997). NOD mice spontaneously develop autoimmune diabetes 
with pathology remarkably similar to that observed in human patients. Patients with 
autoimmune diabetes are at constant risk of severe hypoglycemia due to pharmacologic 
administration of insulin. A large fraction of the patients develop a series of morbid and 
often fatal complications including renal failure, proliferative retinopathy leading to 
blindness and neuropathic syndromes due to chronic hyperglycemia. As in humans, 
susceptibility to autoimmune diabetes in NOD mice is multifactorial and is underpinned 
by the complex interplay of genetic and environmental factors. Overt disease results from 
T cell-mediated destruction of insulin-secreting p cells in the pancreatic islets of 
Langerhans. Genetic mapping in NOD mice has led to the discovery of at least 15 
susceptibility loci (termed ldd), which include MHC (lddl) and non-MHC-linked (ldd2-
l 5) genes. Although the NOD MHC is necessary, it is insufficient to induce diabetes, 
thus emphasizing the importance of non-IVIHC NOD genes in diabetes susceptibility. 
1. 2 Origin of the NOD mouse 
The NOD mouse was discovered at the Shionogi Research Laboratories in Japan 
during the derivation of a spontaneously cataract prone CTS strain (Kikutani and Makino, 
1992). The NOD mouse strain originated from Swiss albino stock and was derived from 
ICR outbred mice. The discovery, in 197 4, of a female mouse exhibiting diabetic 
symptoms without obesity spurred the development of the NOD strain. Selective breeding 
using the offspring of the female mouse was performed, and the NOD strain was 
established in 1980. The NOD-related non-obese non-diabetic (NON) strain was also 
developed at this time. In 1985, breeding pairs of NOD mice obtained from the breeding 
nucleus maintained at Shionogi were taken to the USA. NOD/Lt, the line derived from 
these mice, is currently maintained by Dr. E. Leiter at the Jackson Laboratory, Bar 
Harbor, Maine1 USA. Most of the colonies around the world are derived from this 
colony. 
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1.3 The Pathology and Natural History of IDDM 
Autoimmune diabetes is a biphasic disease characterized by an initial leukocytic 
infiltration into islets, termed insulitis, followed by overt disease which is precipitated by 
the destruction of insulin-secreting ~ cells. The first islet abnormality is manifested by the 
swelling of blood vessels around the islets. This is accompanied by the coming into 
prominence of the perivascular connective tissue. These early signs of inflammation 
trigger the initial infiltrate into islets and elevated numbers of infiltrating leukocytes can be 
detected in NOD mice as early as 3 weeks of age. This initial infiltrate precedes 
lymphocytic infiltration and comprises dendritic cells and macrophages (Jansen et al, 
1994). At this stage elevated numbers of infiltrating dendritic cells and macrophages 
accumulate in the periductal areas but remain outside the islet proper. Subsequent 
lymphocytic infiltration entails direct invasion of islets by infiltrating cells. Diabetes is the 
final clinical outcome when most of the ~ cell mass has been destroyed. Insulin 
production as a result is insufficient to maintain glucose homeostasis, leading to 
hyperglycemia and its associated clinical consequences. Insulitis is more severe in female 
NOD mice and is indicative of their relatively increased susceptibility to overt diabetes. In 
high incidence NOD colonies, overt diabetes occurs at 18-20 weeks of age. The 
cumulative incidence for diabetes is 80-90% in females compared with 10-40% in males. 
This pronounced gender bias is not seen in human patients. Environmental factors 
affecting disease incidence in NOD colonies include diet, viral infection and temperature 
(Elliot et al, 1988; Oldstone, 1990; Williams et al, 1990; Pozzilli et al, 1993). There is a 
positive correlation between disease incidence and the level of sanitation in NOD 
colonies. Germ-free NOD mice have nearly 100% disease incidence. Correspondingly, a 
North-South gradient of disease incidence is observed in human populations (Karvonen 
et al, 1993). Inhabitants of Northern Europe are more susceptible to autoimmune diabetes 
than those resident in the tropics. 
1.4 The Role of T cells in IDDM 
The effector and cellular mechanisms by which~ cells are destroyed remain to be 
fully elucidated. In a longitudinal study of prediabetic NOD mice, Miyazaki et al (1985) 
demonstrated, by immunohistochemical analyses, the predominance of T cells in 
pancreatic islets. Both CD4 and CDS T cells are the most prominent cells in insulitic 
lesions of NOD mice although their respective roles in the pathology of autoimmune 
diabetes remains unclear (Miller et al, 1988). The absence of insulitis and diabetes in 
athymic NOD nude mice and neonatally thymectomized NOD mice demonstrate that T 
cells are essential for diabetes induction (Yagi et al,1992). Also, antibody-mediated 
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depletion of T cells in NOD mice was found to reduce the incidence of diabetes (Koike et 
al, 1987). Further direct evidence for the implication of T cells in diabetes induction came 
in studies involving the adoptive transfer of diabetogenic T cells into non-diabetic 
recipients (Bendelac et al, 1987; Christianson et al, 1993). Prior to the study by Bendelac 
et al ( 1987), diabetes induction studies used adoptive transfer of diabetogenic 
lymphocytes into irradiated, adult and non-diabetic NOD mice. In these studies the 
complete ablation of endogenous T cells could not be assumed and the ref ore complicated 
interpretation of results obtained (Wicker et al, 1986; Miller et al, 1988) Therefore, 
Bendelac et al ( 1987) developed a neonatal model for diabetes transfer using syngeneic 
cells from diabetic donors. It was shown that splenocytes from diabetic NOD mice could 
accelerate the onset of diabetes in recipient neonates. This model was also used to 
investigate the role of specific subsets of T cells in diabetes induction. By antibody-
mediated depletion of appropriate subsets of T cells from splenocytes, it was shown that 
both CD4 and CDS T cells were required. 
The relative contribution of CD4 and CDS T cells in diabetes induction was 
demonstrated in adoptive transfer experiments using the NOD-SCID (severe combined 
immunodeficiency) mice, which are free of both insulitis and diabetes, as recipients 
(Christianson et al,1993). This study employed a NOD congenic stock, NOD-NON-
Thy 1 a as donors. As in neonates, the contribution of endogenous T cells in recipients 
was eliminated and the contribution of allotype-tagged, transferred T cells could be 
unequivocally established. Use of NOD-SCID as recipients also bypassed the need for 
irradiation. It was shown in this model that splenic lymphocytes from diabetic NOD-
NON-Thyl a could efficiently transfer diabetes to all unmanipulated NOD-SCID females 
within 30 days post-transfer. The presence of donor T cells in spleen and pancreas was 
confirmed by flow cytometry. This study also demonstrated the differential diabetogenic 
potential of prediabetic versus diabetic CD4 T cells versus CDS T cells. Whereas CD4 T 
cells from diabetic mice efficiently induce diabetes in NOD-SCID recipients, CDS T cells 
from diabetic mice were incapable of inducing diabetes. However, both CD4 and CDS T 
cells from prediabetic donors were required to transfer diabetes to NOD-SCID recipients. 
That CD4 T cells alone were capable of initiating diabetes was demonstrated by 
Haskins and McDuffie (1990). This study showed that an accelerated onset of diabetes 
could be observed by injecting young, unmanipulated NOD mice (2-3 weeks of age) with 
in vitro primed islet reactive CD4 T cell clones derived from NOD mice. Prior to transfer 
the clones were activated for 3-4 days by restimulation with antigen and antigen 
presenting cells, and then expanded for 3-4 days in the presence of Interleukin (IL)-2 
alone. It was concluded from this study that primed CD4 T cells were sufficient to initiate 
diabetes. However, these results do not rule out a role for CDS T cells. Further evidence 
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that CD4 T cells alone may be the effectors of ~ cell destruction came in a study by Wang 
et al ( 1991). It was demonstrated in this study that destruction of transplanted syngeneic 
islets by spontaneously diabetic NOD mice is CD4 T cell-dependent. A subsequent study 
by Wong et al ( 1996) showed that an islet reactive CD8 T cell clone can transfer the rapid 
onset of diabetes in both irradiated NOD and unmanipulated NOD-SCID mice. This 
disease transfer was shown to occur independent of CD4 T cells but required prior 
stimulation of the CD8 clones in the presence of the costimulatory molecule, B7. 
Evidence supporting the need for CD8 T cells in the initiation of autoimmune 
diabetes has also come from the development of a NOD mouse strain lacking the 
expression of ~2-microglobulin (~2-m) (Katz et al, 1993a; Wicker et al, 1994a; Serreze et 
al, 1994 ). Disruption of ~2-m results in almost total lack of cell surface MHC Class I 
expression and therefore CD8 T cells (Gosgrove et al,1991; Koller et al,1989; Zijlstra et 
al, 1989). Introduction of the ~2-m mutation on the NOD background by selective 
backcrossing (4-8 generations) confers NOD mice resistant to both insulitis and diabetes 
for more than 7 months of age. In light of the evidence to date, there is a consensus that 
both CD4 and CD8 T cells are required as effectors for diabetes induction. 
1.4.1 T helper (Th) Subsets in Autoimmune Diabetes 
As in the case of the relative role of T cell subsets in autoimmune diabetes, data 
obtained to date regarding the functional role of Th subsets remains conflicting. CD4 T 
helper cells may be subdivided into distinct subsets, Th 1 and Th 2, on the basis of their 
cytokine profiles (Mosmann et al, 1986). These subsets exert reciprocal down-regulatory 
effects mediated by their respective cytokines. The signature cytokines of Th 1 cells 
include IL-2, Interferon (IFN)-y and Tumor necrosis factor (TNF)-a, which promote 
cellular immunity. On the other hand, the signature cytokines of Th2 cells include IL-4 
and IL-10, which promote humoral immunity. 
Evidence for the immunopathology of autoimmune diabetes to be considered in 
the context of the Thl/2 paradigm is provided by a number of studies using NOD mice. It 
has been demonstrated that administration of cytokines or monoclonal antibody treatment 
that promote Th 1 or Th2 CD4 T cells exercerbate and prevent diabetes , respectively 
(Trembleau et al, 1995; Rapoport et al, 1993). In vivo administration of recombinant IL-4 
to prediabetic NOD mice was shown to prevent diabetes. Biweekly intraperitoneal , 
injections of 50ng of IL-4 into 6 week old NOD mice showed cumulative diabetes 
incidence of <10% (1/12) by 20 weeks of age, compared with 75% (9/12) disease 
incidence in untreated controls. Similarly, a previous study showed that administration of 
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anti-IFNy monoclonal antibody could prevent the onset of cyclophosphamide-induced 
diabetes (Debray-Sachs et al, 1991). Biweekly intraperitoneal injections of 2mg of anti-
IFNy monoclonal antibody into 8 week old female NOD showed cyclophosphamide-
induced diabetes incidence at 70% (7/10), compared with 85% (11/13) disease incidence 
in untreated controls, followed for 40 days. Prevention of diabetes is also observed by 
the in vivo administration of recombinant human (rhu) IL-10 into NOD mice (Pennline et 
al, 1994). Groups of 9-10 week old NOD mice received daily subcutaneous injections of 
rhuIL-10 ( 1 µg) or control protein, and were followed for at least 15 weeks thereafter. At 
15 weeks post-treatment, the cumulative incidence of diabetes in the treated group was 
25% (5/20) compared with 85% (17/20) in the control group. 
Conversely, administration of IL-12 into young, prediabetic NOD mice accelerates 
the onset of diabetes (Trembleau et al, 1995). IL-12 is a key cytokine which promotes 
Thl type response both in vitro (Manetti et al, 1993; Hsieh et al, 1993) and in vivo 
(Afonso et al, 1994). In studying the role of IL-12 in autoimmune diabetes Trembleau et 
al (1995) used prediabetic, 8-10 week old female NOD mice which received daily 
intraperitoneal injections of 0.3µg IL-12 for the first 7 days, followed by injections of 
0.15µg IL-12 for the next 24 days. All (10/10) treated mice developed diabetes 4 weeks 
post-treatment, compared with 1/10 for untreated controls. Furthermore, this study tested 
IFNy and IL-4 production by islet-infiltrating CD4 T cells, following IL-12 
administration. In vitro stimulation of purified CD4 T cells with anti-T cell receptor 
monoclonal antibody showed that CD4 T cells from NOD mice injected with IL-12 
produced 4-fold higher amounts of IFNy than from untreated controls. In contrast, IL-4 
production was decreased in pancreas-infiltrating CD4 T cells from IL-12 treated as 
compared with control NOD mice. 
Similarly, islet-specific TNFa expression (Green et al, 1998) or administration of 
TNFa into NOD female neonates accelerates the onset of diabetes (Yang et al, 1994 ). 
Correspondingly, neonatal neutralization of TNFa using anti-TNFa monoclonal 
antibody rendered almost complete protection to NOD mice, as seen by the absence of 
insulitis in treated mice. However, TNFa neutralization initiated in 4 week old NOD mice 
merely delayed the onset of diabetes, suggesting that TNFa has a critical role in the early 
development of islet autoimmunity by influencing lymphocyte recruitment. 
Evidence for a Thl-mediated immunopathology in autoimmune diabetes is also 
provided by studying the ratio of signature cytokine transcripts in leukocyte-infiltrating 
islets using quantitative RT-PCR (Fox and Danska, 1997). Fox and Danska (1997) have 
shown that a high ratio of IFNy/IL-4 expression can be observed in the islet-infiltrated T 
cells of 4-6 week old NOD mice. This ratio appears to be predictive of both the onset of 
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destructive insulitis and high incidence of diabetes in female NOD mice. In contrast, a 
high reciprocal ratio is detected in the islet-infiltrated T cells of male NOD mice. The 
predominance of IL-4 in male NOD mice is predictive of the onset of non-destructive 
insulitis and low incidence of diabetes. 
1.4.2 Costimulation and Th Subsets in NOD Mice 
Activation of T cells requires at least two signals. Firstly, antigen specific signal is 
transmitted through the T cell receptor, which recognizes antigenic peptides in the context 
of MHC molecules on the surface of antigen presenting cells. Secondly, costimulatory 
signals are delivered by antigen presenting cell-expressed B7.1 (CD80) and B7.2 (CD86) 
by engaging their receptor, CD28, on T cells (Linsley and Ledbetter, 1993; June et al, 
1994). Co stimulatory signals mediated through CD28 appear to be critical in maintaining 
T cell responses. In an attempt to study the role of CD28-mediated costimulation in 
autoimmune diabetes, Lenschow et al ( 1996) introduced a CD28 null mutation or a 
transgene encoding the cytotoxic T lymphocyte antigen (CTLA)-4 fused to 
immunoglobulin (CTLA-4-Ig, a CD28 antagonist) onto the NOD background by 
backcrossing. Contrary to expectation, both the CD28-deficient NOD mice and NOD 
mice carrying the CTLA-4Ig transgene displayed a more rapid and severe onset of 
diabetes compared with control littermates. Further analysis of these mice revealed that 
disruption of CD28/B7 interactions resulted in the generation of Th 1 type cytokines in 
favor of Th2 cytokines. 
1.4.3 The Role of TGFp in IDDM 
Protection from autoimmune diabetes can also be achieved by islet-specific 
transforming growth factor (TGF)Pl transgene expression (King et al, 1998). TGFPl 
belongs to the regulatory Th3 group of cytokines and has been shown to inhibit cell 
growth and inflammation (Gray et al, 1994; Sitnicka et al, 1996; Strober et al, 1997). 
Evidence supporting the anti-inflammatory role of TGFP 1 has come from the TGFP 1-
deficient (TGFP 1-I-) mice. These mice develop mutiple-organ inflammatory disease 
which is lethal by 3-5 weeks of age (Shull et al, 1992). Besides its anti-inflammatory 
role, TGFP 1 appears to be capable of active immunosuppression in models of oral 
tolerance (Strober et al, 1997; Weiner, 1997). Furthermore, TGFPl appears to have a 
reciprocal relationship with IFNy in regulating mucosal inflammation and autoreactive T 
cells in situ (Strober et al, 1997). However, the mechanism by which TGF~l engages in 
its reciprocal relationship with IFNy is unknown. Taking into account the overall effects 
of TGFP 1, King et al ( 1998) postulated that TGFP 1 may also prevent autoimmune 
diabetes. As expected, female NOD mice expressing islet-specific TGFPl have 30% 
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diabetes incidence compared with 75% in non-transgenic littermates. In vitro stimulation 
of T cells from NOD mice expressing islet-TGF~ 1 reveals a preference of these T cells 
for macrophages over B cells as antigen presenting cells. Furthermore, in vitro 
stimulation of T cells from islet TGFP 1 expressing NOD mice results in the polarization 
of islet-specific responses towards a Th2 type phenotype. 
To view the pathology of autoimmune diabetes exclusively in the context of the 
Th 1/2 paradigm is an oversimplification as cytokines are pleiotropic and regulate several 
phenomena besides Th subsets. Evidence which negates the conventional role of the 
Th 1/2 subsets in autoimmune diabetes is provided in a number of studies. NOD mice 
deficient in the prototypical Th 1 cytokine, IFNy, develop diabetes with delayed onset but 
with similar incidence to that observed in wild type NOD mice (Hultgren et al, 1996). 
Conversely, NOD mice deficient in the IFNyreceptor a chain showed a marked reduction 
in insulitis and were completely protected from spontaneous and cyclophosphamide-
induced diabetes (Wang et al, 1997). Protection from diabetes in IFNy receptor a chain 
deficient NOD mice did not correlate with global imbalances in the Th 1/2 cell ratio. 
Instead, resistance to diabetes in these mice reflected potential defects in antigen 
presenting cell or in the islet p cell targets or both. 
Experiments using transgenic mice expressing IL-10 in islets and their offspring 
from backcrosses to NOD mice have demonstrated that pancreatic IL-10 did not inhibit 
but, instead, accelerated autoimmune diabetes (Lee et al, 1994; Wogensen et al, 1994; 
Moritani et al, 1994 ). It came as a surprise that localized production of IL-10 accelerated 
the onset and increased the prevalence of diabetes. More that 90% of islet-IL-IO NOD 
mice developed diabetes at 5-10 weeks of age, when none of the non-transgenic 
littermates had disease. Further contradictory evidence against the Th 1/2 paradigm comes 
from adoptive transfer experiments using islet-reactive Th clones. Katz et al (1995) 
employed the BDC2.5 T cell receptor transgenic mouse to generate CD4 T cells with 
identical T cell receptor specificity but different effector phenotypes. The T cell receptor 
transgenic BDC2.5 CD4 T cells are specific for unknown islet antigen and restricted by 
the NOD MHC (Katz et al, 1993b). Naive CD4 T cells can differentiate into Thl or Th2, 
depending on the cytokine milieu present at the time of initial activation (Swain, 1994 ). 
Thl or Th2 effectors can be generated in vitro in the presence of appropriate cytokines. 
Effectors thus generated when transferred into mice remain stable for months. Katz et al 
(1995) found that transferred Thl-like cells (95% purity) actively promoted diabetes in 
neonatal NOD recipients. In contrast, Th2-like cells infiltrated the islets but did not induce 
disease. Surprisingly, Th2-like cells when co-transferred with Thl-like cells did not 
I 8 confer diabetes resistance to recipient mice. A similar study involving islet-reactive CD4 T 
cell clones, isolated from the spleen of unprimed NOD mice, was carried out by Akhtar et 
al ( 1995). It was shown that a single injection of Th 1 effectors, as determined by 
cytokine secretion profile in vitro, inhibited adoptive transfer of diabetes into 
unmanipulated, non-diabetic female NOD mice for the entire 12 month observation 
period. Most recently, it has been demonstrated that diabetes develops equivalently in 
NOD mice deficient in IL-12 expression and in normal NOD controls (Trembleau et al, 
1999). IL-12, therefore, is dispensable for diabetes development in NOD mice. 
1. 5 Humoral Response and Autoantigens in Type 1 
Diabetes 
Although many autoimmune diseases are characterized by the presence of 
autoantibodies, a direct role for autoantibodies in the pathological process of diabetes 
remains controversial. Autoantibodies against several islet autoantigens, including insulin 
(Palmer et al, 1983), glutamic acid decarboxylase 65 (GAD65) (Baekkeskov et al, 1982; 
Baekkeshov, 1990), and IA-2 (a tyrosine phosphatase) (Hawkes et al, 1996) are 
detectable in the sera of humans with IDDM for several years prior to the onset of overt 
diabetes. The presence of antibodies against these antigens can predict subsequent 
development of diabetes in prediabetic relatives with a sensitivity of >80% (Hagopian et 
al, 1993 a and b; Verge et al, 1998). In contrast to humans, autoantibodies to putative 
antigens in the NOD mouse have been difficult to detect (Myers et al, 1998; Mackay et al, 
1996). 
1.5.1 Insulin and GAD as Autoantigens 
The two most studied autoantigens in autoimmune diabetes are insulin and its 
precursors and the enzyme GAD. Insulin is expressed in copious quantities in the islets. 
Expression of insulin, however, is not restricted to islets as it has recently been shown 
that there are thymic cells that express peripheral antigens, such as insulin and GAD, in 
humans (Vafiadis et al, 1997; Pugliese et al, 1997; Sospedra et al, 1998) and in rodent 
models of IDDM (Smith et al, 1997; Heath et al, 1998). Islets within NOD mice have 
been shown to contain CD4 T cells that recognize insulin (Daniel et al, 1995). These CD4 
T cells specifically recognize an insulin-derived peptide consisting of amino acids 9-23 of 
the ~ chain of insulin and are capable of adoptively transferring diabetes (Daniel and 
Wagmann, 1996). An overlapping CD8 T cell epitope, consisting of amino acids 15-23 
of the ~ chain of insulin, has recently been identified (Wong et al, 1999). The insulin p 
chain is, therefore, an obvious target for both pathogenic CD4 and CDS T cells in the 
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NOD mouse. Interestingly, a CD4 T cell clone, with HLA-DR restriction, isolated from a 
recently diagonosed diabetic patient was demonstrated to be specific for insulin ~ chain 
11-27 (Schloot et al, 1998). 
The other major putative autoantigen in humans is GAD. GAD is present in two 
isoforrns, GAD65 and GAD67, which catalyze the biosynthesis of the neurotransmitter y-
arninobutyric acid. GAD is primarily located in neuroendocrine tissues and the 
distribution of the two isoforrns differs between humans and the NOD mouse. GAD65 is 
predominant in the pancreas of humans. In contrast, GAD67 is more abundant in the 
islets of mice (Kirn et al, 1993; Petersen et al, 1993). The physiological function of GAD 
in the islets remains to be determined. CD4 T cell reactivity to GAD (Zekzer et al, 1998) 
has been detected in young NOD mouse, ahead of detectable reactivity to any other 
antigens (Kaufman et al, 1993; Tisch et al, 1993). It has subsequently been demonstrated 
that diabetes in NOD mice can be prevented by administration of GAD in various ways 
(Tian et al, 1996a and b). To date no CDS T cells reactive to GAD have been isolated 
from NOD mice but they have been found in humans (Panina-Bordignon et al, 1995). 
T cell reactivity in IDDM patients can be detected to a region of GAD homologous 
to the Coxsackie B P2-C viral protein (Atkinson et al, 1994 ). The fact that Coxsackie B 
viral infections have been implicated in cases of IDDM has led to the hypothesis that the 
phenomenon of molecular mimicry rnay contribute towards diabetes development. It has 
been demonstrated in the BDC2.5 T cell receptor transgenic mouse model of diabetes 
(Katz et al, 1993b ), where T cells are specific for an unknown islet antigen (Bergman and 
Haskins, 1994 ), that infection with Coxsackie B4 virus accelerated the onset of diabetes 
(Horwitz et al, 1998). Since no T cell response to the virus was observed, it was implied 
that the acceleration in diabetes was due to inflammation and bystander activation and not 
molecular rnirnicry. 
Most recent evidence implicating GAD as a key autoantigen in NOD mice has been 
provided in a study by Yoon et al (1999). This study employed a transgenic model in 
which expression of both isoforrns of GAD were prevented using an antisense construct 
under the rat insulin prornotor (RIP). In the transgenic line with the greatest apparent 
reduction of both isof orrns in the islets, insulitis and diabetes were abolished. Cells from 
this transgenic line were unable to transfer diabetes. Conversely, diabetic splenocytes 
were unable to adoptively transfer disease into this transgenic line. The mechanism for 
diabetes suppression in this model, however, remains to be elucidated. 
Besides insulin and GAD, ICAS 12 (IA-2) (Christie et al, 1994; Hawkes et al, 
1996; Solirnena et al, 1996) and Heat Shock Protein (HSP)60 are two other putative 
autoantigens. Although ICA512 is important in the prediction of type 1 diabetes in 
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humans, its importance in NOD mice remains unclear. Inspite of antibodies against 
HSP60 being detected in the NOD mouse, corresponding antibodies in humans are as yet 
undiscovered. 
To address the role of B cells in autoimmune pathology in the NOD mouse, 
Serreze et al (1996) produced a stock of NOD mice deficient in B lymphocytes. This was 
accomplished by the congenic transfer of an immunoglobulin (lg)µ gene functionally 
disrupted by homologous recombination. NOD.lgµ-/- mice are resistant to diabetes and 
this resistance can not be overcome by infusions of immunoglobulin from diabetic NOD 
donors (Serreze et al, 1998). However, susceptibility to diabetes was restored in 
NOD.lgµ-/- mice reconstituted with syngeneic bone marrow admixed with NOD B 
lymphocytes. A direct role for B cells in the pathology of autoimmune diabetes remains 
unclarified as a previous report (Yang et al, 1997) contradicts the finding of Serreze et al 
by demonstrating that a proportion of NOD.lgµ-/- mice (29%) develop diabetes. 
1. 6 The Genetic Basis of Autoimmune Diabetes 
Besides being a model for human IDDM, the NOD mouse also serves as a model 
for studying complex polygenic diseases since 15-20 different loci are linked to disease 
development (Wicker et al, 1995; Baxter amd Cook, 1995; Vyse and Todd, 1996). Loci 
contributing to diabetes susceptibility are termed ldd. The first susceptibility locus 
recognized is linked to the MHC and is termed lddl. Studies with MHC congenic strains 
of mice have demonstrated that the NOD MHC is necessary but insufficient to induce 
diabetes. This observation indicates the need for epistatic interaction between MHC and 
non-MHC NOD genes for diabetes development. Current evidence suggests that the 
genotype of the MHC on the NOD background determines target tissue for autoimmune 
destruction, while non-MHC NOD genes appear to confer overall susceptibility to 
autoimmunity. 
1.6.1 The MHC 
Genetic analyses undertaken in human populations and in NOD mice have 
implicated the MHC as a strong predisposing factor to autoimmune diabetes (Thorsby, 
1993; Hattori et al, 1986). In human patients, MHC-associated diabetes susceptibility and 
resistance are predominantly, but not exclusively, determined by polymorphisms at the 
HLA-DQ B locus (Todd et al, 1987). Similarly, susceptibility and resistance to IDDM in 
the NOD mouse are also linked to the MHC (H-2 in mice). The diabetes prone NOD mice 
are homozygous for a unique H-2 haplotype, H-2g7. 
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1.6.2 MHC class II 
The demonstration that particular MHC Class II molecules have positive, neutral 
or negative association with human autoimmune diabetes has prompted intense 
investigation and speculation on the NOD MHC (Nepom, 1990a and b; Sheehy, 1992). 
Consequently, the NOD MHC class II allele has received a lot of attention. The unique 
NOD H-2g7 carries a non-productive I-Ea chain due to a deletion mutation in its 
promoter region (Acha-Orbea and McDevitt, 1987). The I-Aa chain is ide:ntical to that in 
the H-2d haplotype but the I-AP chain is novel and shares an intriguing similarity with 
diabetes-associated DQP chains (Todd et al, 1987). Most murine I-AP chains (counterpart 
of human DQP chain) carry histidine and aspartic acid at positions 56 and 57, which are 
replaced in NOD by praline and serine, respectively (Hattori et al, 1986; Acha-Orbea, 
1987). In humans, presence of aspartic acid in DQP alleles is associated with resistance to 
diabetes, while presence of alanine, serine or valine is associated with susceptibility to 
diabetes. The crystal structure of HLA-DRl reveals the formation of a salt-bridge 
between aspartic acid at position 57 and arginine at position 7 6 of the a chain (Brown et 
al, 1993). This observation supports the hypothesis that the P chain residue 57 influences 
peptide binding of MHC class II molecules. Indeed, Carrasco-Merin et al (1996) have 
presented evidence suggesting that I-Ag7 is relatively unstable and binds some peptides 
poorly. 
Introduction of transgenic non-NOD MHC I-A or I-E into the NOD background 
reduces or prevents insulitis and diabetes (Lund et al, 1990; Slattery et al, 1990; Singer et 
al, 1996; Pilstrom and Bohme, 1997). Results from such studies are, however, difficult 
to interpret due to possible secondary effects of transgene introduction. These effects may 
arise as result of the site of transgene integration or the copy number of the transgene. 
Furthermore, introduction of I-Ag7 itself as a transgene into the NOD background is 
protective (Wherret et al, 1997). Interestingly, it has recently been postulated that 
unpaired or poorly paired I-AP chains adversely affect B cell viability (Labrecque et al, 
1999). Unpaired or poorly paired I-AP chains result from transgenic overexpression of 
I-AP, exceeding the available pool of I-Aa or invariant chain (chaperone involved in 
MHC class II biosynthesis) and triggering cell toxicity aspect of the unfolded protein 
stress response. 
The actual number and location of MHC-linked diabetogenic gene/s remains to be 
elucidated. The recombination frequency within the MHC region is low or MHC-linked 
genes are in linkage disequilibrium, making it difficult to fine map a gene by standard 
linkage analysis in breeding studies using inbred strains. Hattori et al ( 1999) introduced a 
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recombinational hotspot from the B 10.A mouse into the region between the MHC class I 
Kand class II A of the NOD mouse to dissect the MHC region. Replacement of the NOD 
region between MHC class I K and class II A with the same region in B 1 0.A mice 
prevented the development of diabetes. Thus, in addition to MHC class II genes, there is 
at least 1 other diabetogenic gene linked to the MHC. 
1.6.3 The NOD MHC (lddl) is Diabetogenic 
In outcross-backcross studies of NOD with diabetes-resistant strains C3H (Hattori 
et al, 1986) and NON (non-obese non-diabetic strain which is closely related to NOD) 
(Prochazka et al, 1987), diabetic progeny were homozygous for the NOD MHC, 
indicating the presence of MHC-linked recessive susceptibility gene/s. However, Wicker 
et al ( 1987, 1989), using the B 10 strain as outcross partner, also identified rare diabetic 
MHC heterozygotes that had only one dose of the NOD MHC. The B 10 strain was used 
in this latter study since it is diabetes-resistant and, as observed in NOD, does not express 
I-E MHC class II (Mathis, 1983). The use of B 10 eliminated the possibility of diabetes-
resistance conferred by I-E when C3H and NON strains are used as outcross partners. 
These initial mapping studies established the link between autoimmune diabetes and the 
NOD MHC, which appeared dominant but with low penetrance. 
1.6.4 Analysis of MHC Congenic Strains 
The effects of a single ldd locus can be studied by constructing ldd congenic 
strains. A number of lddl congenic strains have been developed by introgressing the 
MHC from a non-diabetic strain onto the NOD background, and vice versa (Wicker et al, 
1992; Prochazka et al, 1989). Congenic strains are identical at the locus of interest but 
genetically disparate in all other regions. Construction of a congenic strain begins by 
outcrossing two strains, one provides the genetic background and the other the locus to 
be introgressed. Progeny from this initial outcross are then repeatedly backcrossed to the 
strain providing the genetic background. Introduction of MHC from a disease-resistant 
strain onto the NOD background renders diabetes resistance to NOD mice. However, the 
reciprocal congenic does not confer diabetes susceptibility to disease-resistant strains. 
Neither of the two MHC congenic strains, NOD.H-2b in which the MHC was derived 
from the Bl0 strain and the NOD.H-2b from the B6 strain, develop insulitis or diabetes 
(Wicker et al, 1992; Wicker et al, 1995). In reciprocal MHC congenics, the NOD MHC 
expressed on the B 10 or B6 genetic backgrounds does not confer insulitis or diabetes to 
these resistant strains (Wicker et al, 1995). 
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The construction of NOD.H-2 congenic strains have also underscored the 
contribution of non-MHC NOD genes towards autoimmune pathology. NOD.H-2k or h4 
and NOD.H-2b congenic strains get neither insulitis nor diabetes but are autoimmune 
prone with different target tissue specificities (Podolin et al, 1993; Robinson et al, 1997). 
The NOD.H-2k or h4 congenic mice get autoimmune thyroiditis while the NOD.H-2b 
congenic mice get autoimmune sialitis. These studies suggest that on the NOD 
background, the genotype of the MHC determines target tissue for autoimmune 
destruction, while non-MHC NOD genes confer an overall susceptibility to 
autoimmunity. 
1.6.5 Genetic Mapping of non-MHC Idd in NOD Mice 
The availability of substantial pedigrees of both diabetic and non-diabetic progeny, 
generated by the crossing of NOD with disease-resistant strains, and the demonstration of 
microsatellite (short dinucleotide repeats, >105 per genome) polymorphism between 
inbred strains of mice (Love et al, 1990) have facilitated mapping of diabetes 
susceptibility loci in NOD mice (Todd et al, 1991). 
Screening the NOD mouse for non-MHC susceptibility loci is accomplished by 
first crossing NOD mice with a disease-resistant MHC congenic strain (B l0.H-2g7). The 
Fl hybrids are then backcrossed to NOD and the incidence of diabetes assessed in the 
backcross progeny. Non-MHC susceptibility loci are then mapped by analysing the 
associations of microsatellites with disease. Polymerase chain reaction (PCR) 
amplification of microsatellites allows easy scoring of allelic variants on the basis of size 
differences (Hearne et al, 1992). To detect susceptibility loci, diabetic progeny from the 
backcross are typed at polymorphic loci, and the number of homozygotes and 
heterozygotes is assessed. No linkage to disease will result in equal numbers of 
homozygote and heterozygote individuals to be observed. An excess of homozygotes in 
the diabetic population indicates the presence of a NOD susceptibility locus. Excess of 
heterozygotes in the diabetic population indicates either the presence of a dominant 
susceptibility allele from the non-diabetic strain or the presence of recessive protective 
NOD allele. Such a mapping strategy has been employed to identify the majority of non-
MHC loci conferring susceptibility to autoimmune diabetes to NOD mice ( Todd et al, 
1991 ; Prochazka et al, 1987; Ghosh et al, 1993). 
The contribution of non-MHC NOD genes to diabetes becomes apparent when 
NOD mice are outcrossed to B 10 or non-obese non-diabetic (NON) genetic backgrounds. 
The NON strain is related to the NOD strain but, as the name suggests, is resistant to 
diabetes (Kikutani and Makino, 1992). The contribution of the BIO versus NON genetic 
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backgrounds to diabetes is illustrated when (NOD x B lO.H-2g7) Fl and (NOD x 
NON.H-2g7) Fl are analyzed for diabetes incidence (Wicker et al, 1995). All of the 
(NOD x B lO.H-2g7) Fl remain diabetes-free. In contrast, a significant percentage of 
(NOD x NON.H-2g7) Fl develop insulitis (7 /30, 23%) and diabetes (3/80, 4% ). These 
differential diabetogenic potentials between B 10 and NON genetic backgrounds reflect 
differences in alleles carried at the non-MHC-linked loci. 
Further evidence implicating non-MHC NOD genes in diabetes induction comes 
from the study of congenic NOD mice carrying resistance alleles at two Idd loci (Wicker 
et al, 1994b ). Wicker et al ( 1994b) developed NOD congenic strains which express the 
B 10 or B6 alleles at Idd3 and/or Iddl 0. Analysis of diabetes incidence in these strains 
demonstrate that non-NOD alleles at Idd3 and Iddl O individually provide partial 
protection to diabetes. However, epistatic interaction between resistance alleles at both 
Idd3 and Iddl O on the NOD background results in virtually complete protection from 
diabetes. 
The Idd3 locus overlaps between autoimmune diabetes in the NOD mouse and the 
mouse experimental autoimmune encephalomyelitis (EAE) model for human multiple 
sclerosis, suggesting the possible presence of genes common to both these diseases 
(Vyse and Todd, 1996). A recent study investigated whether this overlap was due to a 
shared "autoimmunity gene" or merely random grouping of 2 unrelated genes (Encinas et 
al, 1999). In addition to becoming spontaneously diabetic, NOD mice can also develop 
EAE. The latter can be induced by immunization with peptide antigens derived from the 
EAE autoantigen, myelin (Bernard et al, 1997). In EAE induction studies using NOD 
congenic lines carrying B6-derived regions encompassing increasingly smaller congenic 
intervals of the Idd3 locus, Encinas et al ( 1999) demonstrate that an EAE resistance gene 
colocalizes with a diabetes resistance gene in a genetic interval less than 0.15 cM. This 
interval contains the IL-2 gene known to be polymorphic between NOD and B6 mice 
(Ghosh et al, 1993; Denny et al, 1997). IL-2 is a possible candidate gene for autoimmune 
diabetes and EAE susceptibility because of its role in T cell development and 
differentiation (Denny et al, 1997). IL-2 is essential for the maintenance of tolerance as 
IL-2-/- mice are prone to severe autoimmunity (Sadlack et al, 1995). 
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1.6.6 Concluding Remarks 
Overall, advances in mapping susceptibility loci in NOD mice, along with the 
creation of congenic strains with increasingly narrower intervals, will facilitate 
identification and understanding the function of ldd genes. It is hoped that the study of 
NOD mice will provide insights into the genetics and pathophysiology of Type 1 diabetes 
in humans. Elucidation of disease-linked molecular and biochemical pathways in NOD 
mice will encourage development of protocols for advance diagnosis, cure or subsequent 
therapeutic intervention. 
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1. 7 Dendritic Cells 
Dendritic cells form a specialized system of antigen presenting cells which are 
critical in initiating and modulating primary T cell-mediated immune responses 
(Steinman, 1991; Cella et al, 1997; Hart, 1997; Banchereau and Steinman, 1998). 
Dendritic cells derive their name from their unusual dendritic morphology characterized 
by irregular cell shape and numerous cytoplasmic processes which are either dendritic 
(spiny) or sheet-like. Besides their obvious function in dendritic cell migration and in 
providing a large surf ace area, cytoplasmic processes have also been speculated to be 
involved in antigen capture and direct interaction with T cells. Dendritic cells 
constitutively express high levels of cell surface Major Histocompatibility Complex 
(MHC) molecules and possess potent accessory function for the stimulation of naive T 
cells. 
Interest in the physiological function of dendritic cells has stimulated research 
which has led to the elucidation of their origin and definition of their general 
characteristics. Dendritic cells are myeloid-derived and are present in trace quantities in 
most tissue where they act as mobile sentinels of the immune system by constantly 
sampling the extracellular milieu for antigen. When viewed in situ, such as in skin, 
airways or ly1nphoid organs, dendritic cells appear stellate. Dendritic cells inhabit discrete 
anatomic regions of lymphoid and non-lymphoid organs and are interconnected by their 
n1igratory nature. Peripheral or tissue dendritic cells share characteristic structure, 
phenotype and function. They are considered to be phenotypically and functionally 
immature. Immature dendritic cells are characterized by their ability to acquire and 
process antigen and subsequently migrate, via blood or afferent lymph, to draining lymph 
node. Peptide epitopes generated as a result of antigen processing are displayed in the 
context of cell surface MHC molecules for recognition by the naive T cells in the draining 
lymph node. The process of antigen encounter, migration and interaction with T cells 
triggers maturation of dendritic cells. Maturation of dendritic cells entails the up-
regulation of their immunostimulatory capacity at the expense of their ability to acquire 
and process complex antigen. 
Most recently, research has also uncovered phenotypic heterogeneity among 
dendritic cells resident in secondary lymphoid tissue, with potential functional 
specialization within subsets present. Overall, dendritic cells play a pivotal role in both 
innate and adaptive immunity, and provide a nexus between the two arms of immunity. 
Besides acting as sentinels against pathogens invading tissue, dendritic cells also appear 
to be important in the initiation and maintenance of autoimmune responses against 
peripheral tissue. Consistent with the latter, there is now emerging evidence that dendritic 
cells may be critical in the induction of peripheral tolerance mechanisms. 
* It was subsequently demonstrated that Transforming Growth Factor (TGF)-~ is a crucial 
factor in the cytokine cocktail required for Langerhans cell development (Strobl et al, 1996). 
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1.7.1 Origin and Differentiation of Dendritic Cells 
As with all other Leukocyte Common Antigen (CD45) positive celJ.s, dendritic 
cells originate from hematopoietic stem cells and their progenitors in the bone marrow. 
Dendritic cells were discovered in mice by Steinman and Cohn (1973 , 1974) . Dendritic 
cells were shown to be of myeloid origin during their initial in vivo characterization 
(Steinman et al, 1974). This was demonstrated in allogeneic bone marrow chimeric mice. 
Parental strain mice when irradiated and reconstituted with bone marrow cells from Fl 
hybrid mice developed splenic dendritic cells, as determined by morphological criteria, 
expressing donor MHC on their cell surface. A similar study demonstrated that epidermal 
dendritic cells (Langerhans cells) were also of myeloid origin (Frelinger et al, 1979). An 
early study with human bone marrow also shed light on the origin of dendritic cells 
(Goordyal and Isaacson, 1985). This initial study with human bone marrow cells 
demonstrated immunohistochemicall y that bone marrow colonies generated in me thy 1 
cellulose medium, supplemented with placental conditioned medium as source of growth 
factors, contained both macrophages and Langerhans cells. 
The availability of recombinant growth factors enabled investigation of the effects 
of specific growth factors on hematopoietic precursors. Further evidence for a common 
precursor for dendritic cells and myeloid cells arose from in vitro culture of myeloid 
precursors stimulated with Granulocyte and Macrophage Colony Stimulating Factor 
(GM-CSF). In mice, dendritic cells precursors are present in both bone marrow and 
blood, and generate dendritic cells, granulocytes and macrophages in response to GM-
CSF stimulation (Inaba et al, 1992 a,b; Inaba et al , 1993a). In humans, CD34+ 
precursors isolated from bone marrow, cord and peripheral blood, generate dendritic cells 
in response to stimulation with GM-CSF and other growth factors (Young et al, 1995; 
Reid et al , 1992; Strunk et al, 1996; Caux et al, 1992). In particular, the combination of 
GM-CSF and TNFa synergize to generate Langerhans cells from CD34+ cord blood 
* precursors (Caux et al , 1992) . Dendritic cells also develop from CD14+ human 
peripheral blood monocytes cultured in the presence of GM-CSF and IL-4 (Sallusto and 
Lanzavecchia, 1994 ). Dendritic cells generated under these culture conditions have the 
characteristics of immature dendritic cells and can be induced to mature by inflammatory 
stimuli provided by TNFa, IL-1, Lipopolysaccharide (LPS) and anti-CD40 monoclonal 
antibody. The immature dendritic cells generated from monocyte precursors still retain the 
Macrophage Colony Stimulating Factor (M-CSF) receptor which is down-regulated 
following the induction of maturation. The emerging paradigm thus is that pluripotent 
precursors , of myeloid origin, may develop into dendritic cells , macrophages or 
granulocytes, depending on the external stimuli. 
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As mentioned above, human monocytes can be induced to develop into dendritic 
cells when cultured in the presence of GM-CSF and IL-4 (Sallusto and Lanzavecchia, 
1994). However, whether physiological stimuli triggered the development of monocytes 
into dendritic cells in vivo remained unclear until recently. Initial in vitro evidence 
provided by Randolph et al (1998) demonstrated that human monocytes differentiate into 
dendritic cells in an in vitro model of transendothelial trafficking without the addition of 
exogenous cytokines. In this model, monocytes, transiently resident in the subendothelial 
matrix, efficiently developed into dendritic cells in response to phagocytic stimulus. The 
nascent dendritic cells migrated across the endothelium in the ablumenal-to-lumenal 
direction, a migratory path that parallels the migration of dendritic cells from the 
periphery into the lumen of an afferent lymphatic vessel. Importantly, monocytes that 
remained in the subendothelial matrix differentiated into macrophages. This data support 
the concept that monocytes can develop into dendritic cells under physiological 
conditions. Indeed evidence indicating that monocytes can serve as precursors for 
dendritic cells in vivo has come from a recent study (Randolph et al, 1999). This study 
employs murine models to demonstrate that monocytes become lymph node dendritic 
cells in vivo following administration of fluorescent latex beads. Inflammatory 
monocytes phagocytosed subcutaneously administered beads and mainly differentiated 
into tissue resident macrophages. However, a significant minority of monocytes, bearing 
beads, migrated to the draining lymph node, acquired dendritic cell markers and became 
resident in the paracortical regions of the lymph node. Furthermore, the transport of 
beads to draining lymph node was markedly reduced in the monocyte-deficient 
osteopetrotic (op) mouse (Wiktor-Jedrzejczak et al , 1991) although monocyte-
independent dendritic cell populations were intact in the op mouse (Witmer-Pack et al, 
1993). This suggests that monocytes serve as precursors for a subset of dendritic cells 
initiating in peripheral tissue. Overall, the study by Randolph et al ( 1999) provide 
important evidence regarding the mysterious ontogenic relationship of dendritic cells with 
monocytes and macrophages. 
1. 8 General Features of Dendritic Cells 
The generally accepted current model of dendritic cell development assigns 
dichotomy of function on dendritic cells, dependent on the stage of their maturation. The 
phenotype and function of dendritic cells are intimately-linked with whether they are 
immature or mature as will be outlined next. 
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1.8.1 Immature Dendritic cells and Antigen Handling 
Immature tissue dendritic cells are characterized by their optimal ability to actively 
acquire and process antigen, and their inabilty to stimulate naive T cells. Numerous 
features of immature dendritic cells enable them to fulfil their sentinel role in peripheral 
tissue. Firstly, they can capture particulate and microbial antigen by phagocytosis (Inaba 
et al, 1993b; Moll et al, 1993; Reis et al, 1993; Svensson et al, 1997). In vitro generated 
immature dendritic cells when pulsed with bacteria can elicit potent immune responses 
both in vitro and in vivo (Svensson et al, 1997). Interestingly, dendritic cells, but not 
macrophages, may acquire antigen from apoptotic cells in vitro and induce MHC class I-
restricted cytotoxic T lymphocytes (CTLs) (Albert et al, 1998). This could be a 
mechanism by which dendritic cells acquire antigens from tumours, transplants, infected 
cells, or even endogenous tissue, for stimulation or tolerization of CTLs. Secondly, 
immature dendritic cells form large pinocytic vesicles in which extracellular fluid and 
solutes are sampled for antigen, in a process termed macropinocytosis (Sallusto et al, 
1995). Contents of a macropinosome may then be delivered to specialized late-endosomal 
structures known as MHC Class II compartments (MIIC) (Pierre et al, 1997). MIIC are 
enriched for MHC class II molecules and other molecules which facilitate antigen 
processing and subsequent loading of peptides generated onto MHC molecules. Although 
immature dendritic cells are active in the biosynthesis of MHC class II molecules and in 
peptide loading, the assembled MHC class II-peptide complexes are mostly targeted to 
endosomal compartments and only transiently to the cell surface (Pierre et al, 1997). 
Thirdly, immature dendritic cells express receptors mediating adsorptive endocytosis. 
These include C-type lectin receptors like macrophage mannose receptor (MMR) 
(Sallusto et al 1995) and DEC-205 (Jiang et al, 1995). Furthermore, immature dendritic 
cells also express Fey and Fe£ receptors (Sallusto and Lanzavecchia, 1994; Maurer et al, 
1995). The combination of macropinocytosis and receptor-mediated antigen uptake 
enable efficient presentation of minute quantities of antigen. Another distinct feature of 
immature dendritic cells is the profile of chemokine receptors they express (Sallusto et al, 
1998; Sallusto et al, 1999). Immature dendritic cells express receptors for chemokines 
secreted at inflammatory sites, namely, CCRl, CCR2, CCR5 and CXCRl. Encounter 
with antigen, however, dramatically alters the fate of an immature dendritic cell. 
20 
1.8.2 Migration and Maturation 
A critical feature of dendritic cells is their capacity to migrate. Migration enables 
dendritic cells to fulfill their normal immunosurveillance of incoming antigens in tissue 
and their subsequent rendezvous with T cells in secondary lymphoid tissue. The rate of 
dendritic cell movement between blood and tissue and tissue and secondary lymphoid 
organs under normal conditions is likely to be low. Insights into the phagocytic activity 
and mobilization of dendritic cells in vivo has been demonstrated in a comprehensive 
study by Matsuno et al (1996). This study tracks particle-laden rat dendritic cells 
following the intravenous administration of particulate tracers. The majority of particle-
laden cells in lymph were identified as dendritic cells on the basis of standard cell surface 
markers and in vitro functional capacity. Particle-laden dendritic cells were first detected 
in the liver and in the spleen 1 hr after injection. Particle-laden cells accumulated in the 
paracortical regions of celiac nodes 18 hr after particle injection. This study implicates 
liver dendritic cells in initiating immune responses to systemic antigen. Furthermore, 
BrDU (5-bromo-2'-deoxyuridine) feeding of the rats revealed that most of the particle-
laden dendritic cells were recently produced by the terminal division of precursor cells. 
The rate of dendritic cell movement is substantially increased during an 
inflammatory response to meet increased need for antigen presentation. Extravasation of 
dendritic cells from the blood stream requires dendritic cells to initially tether to the 
endothelium. Extravasation of leukocytes is mediated by selectins that bind to specific 
carbohydrates on the cell surface (Springer, 1994). Recently it has been demonstrated 
that blood dendritic cells express ligands for P- and E-selectin, which are expressed at 
low levels on endothelial cells and up-regulated during an inflammatory response (Robert 
et al, 1999). Also demonstrated was that dendritic cells preferentially extravasate at sites 
of inflammation. This novel finding suggests that blood dendritic cells are perpetually on 
standby to respond to inflammatory stimuli. 
Although constitutive immigration of blood dendritic cells occurs to replenish 
tissue dendritic cells and for normal immunosurveillance purposes, emigration of 
dendritic cells from tissue may be induced during inflammatory responses . 
Correspondingly, dendritic cells are rapidly mobilized into airway epithelia following 
inhalation of virus or bacteria (Mc William et al, 1994). This was demonstrated in a study 
which aimed to detect dendritic cell response after challenge of the airways with live 
infectious organisms (both viral and bacterial pathogens) to which mice had not 
previously been exposed, and an inert protein antigen (Ovalbumin, OVA) to which mice 
were presensitized by parenteral immunization. The common feature of all these challenge 
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regimes was the transient waves of dendritic cells which were recruited into the 
epithelium during the early phase of cellular inflammatory response. The transient 
recruitment of intraepithelial dendritic cells corresponded to a 2-3-fold increase in 
dendritic cell numbers. Coincident with the inflammatory response was the substantial 
increase in the number of dendritic cells in draining lymph node (Mc William et al, 1996). 
This increase was attributable to the arrival of antigen-loaded dendritic cells from 
inflamed tissue as well as the recruitment of circulating dendritic cell precursors from 
blood (Robert et al, 1999). 
The skin is a favored model to study emigration of dendritic cells from the 
periphery to secondary lymphoid tissue. It is well documented that exposure of skin to 
contact sensitizer (such as fluorescein isothiocyanate, FITC) induces migration of contact 
sensitizer-loaded Langerhans cells to draining lymph node, within 24hr, to become 
interdigitating dendritic cells in the paracortical regions of draining lymph node. A recent 
study has elegantly reiterated previous findings of dendritic cell migration induced by 
contact sensitizers (Knight et al, 1985; Macatonia et al, 1986; Austyn et al, 1988), by 
histological analysis of the localization of FITC-positive Langerhans cells in the T cell 
zone of draining lymph node (Tang and Cyster, 1999). Furthermore, intradermal 
injection of murine IL-1 p or TNFa into mouse skin leads to a reduction in numbers of 
Langerhans cells (Cumberbatch and Kimber, 1992; Roake et al, 1995). Both of these 
cytokines are elicited during exposure to contact allergens. 
The intimate relationship between in vivo migration and maturation of dendritic 
cells has been shown in a study using systemic administration of LPS to mice ( de Smedt 
et al, 1996). LPS treatment of mice induces the migration of most splenic dendritic cells 
from the marginal zone to T cell areas within 4-6 hr. This movement entails a maturation 
process as characterized by the down-regulation of antigen processing capacity and up-
regulation of immunostimulatory properties. Maturation involves increased cell surface 
expression of MHC class II and the costimulatory B7 molecules. The loss of antigen 
processing capacity of LPS-treated dendritic cells was assessed by the inability of freshly 
isolated treated dendritic cells to present protein antigen in vitro. Furthermore, systemic 
administration of LPS causes a massive egress of dendritic cells from non-lymphoid 
tissue such as skin, heart, kidney and intestine (Roake et al, 1995). 
Numerous changes occur during the maturation of dendritic cells. In some 
instances antigenic stimulus may be sufficient to induce maturation of dendritic cells. 
Dendritic cells down-regulate their capacity to acquire and process soluble native antigen. 
In vitro observations have shown that loss of antigen processing capacity correlates with 
loss of acidic organelles involved in antigen processing (Stossel et al, 1990). 
~~ Maturation involves a n1arked up-regulation of receptors for chemokines expressed in 
secondary lymphoid tissue with concon1itant down-regulation of receptors for inflammatory 
cytokines. 
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Furthermore, ceramide, induced during maturation, can limit the ability of dendritic cells 
to capture antigen (Sallusto et al, 1996). Maturation involves the transformation of MIIC 
to non-lysosomal vesicles which discharge their MHC-peptide complexes to the cell 
surface while down-regulating synthesis of new MHC class II molecules (Cella et al , 
1997; Pierre et al, 1997). Maturation also entails a ten-fold increase in the half-life of 
MHC class II molecules on the cell surface of mature dendritic cells . Cell surface 
expression of MHC class II molecules is controlled by the developmental regulation of 
the MHC class II-associated invariant chain (Ii) proteolysis (Pierre and Mellman, 1998). 
Invariant chain cleavage in MIIC is mediated by endosomal proteases called cathepsins. 
In immature dendritic cells, inefficient Ii cleavage due to reduced cathepsin S activity 
leads to MHC class II-Ii complexes being transported to MIIC. In contrast, mature 
dendritic cells possess efficient cathepsin S activity leading to elevated levels MHC class 
II molecules being targeted to the cell surface. This differential trafficking of MHC class 
II molecules is due to the reduced expression of the cathepsin S inhibitor, cystatin c, in 
mature dendritic cells. 
Mature dendritic cells secrete chemokines and up-regulate adhesion molecules to 
recruit, cluster and activate T cells. Mature dendritic cells show increased expression of 
costimulatory molecules including CD40, CD80 (B7.l) and CD86 (B7.2) (Sallusto et al, 
1995; Caux et al, 1994a and Inaba et al, 1994 ). Dendritic cells also undergo a rapid and 
coordinated switch in chemokine receptor expression during maturation. Maturation 
involves a marked up-regulation of receptors for chemokines expressed in secondary 
* lymphoid tissue with concomitant loss of receptors for inflammatory chemokine~. For 
instance, mature dendritic cells up-regulate CCR7 and acquire responsiveness to EBil 
ligand chemokine (ELC) and MIP-3 ~' a chemokine secreted by lymphoid tissue (Dieu et 
al, 1998; Sallusto et al, 1998). The signal transduction pathways that regulate dendritic 
cell maturation, however, remain to be fully elucidated. A recent study has employed 
LPS stimulation of a growth factor-dependent primary dendritic cell-line to illustrate that 
dendritic cell survival and maturation are regulated by distinct signalling pathways 
(Rescigno et al, 1998). It was shown in this study that mitogen activated protein (MAP) 
kinase inhibitors induced apoptosis in the dendritic cell line, but left the NFKB-mediated 
maturation signals unaffected. This evidence suggests that survival and maturation of 
dendritic cells are regulated by the MAP kinase and NFKB signal transduction pathways, 
respectively. 
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1 . 9 Dendritic Cell and T Cell Interaction 
The potent T cell stimulating capacity of mature dendritic cells has been 
documented extensively in early studies. Mature dendritic cells elicit T cell-mediated 
immunity in the presence of antigens, alloantigens and superantigens. Activation of naive 
and unprimed T cells by dendritic cells has been demonstrated in studies carried out both 
in vitro and in vivo (Steinman et al, 1997). Only a few dendritic cells, in comparison to 
macrophages and B cells, are required to evoke potent T cell responses. In mixed 
leukocyte reactions (MLR), the in vitro model for graft rejection, as few as 300-1000 
dendritic cells can double the proliferative capacity of 5x106 allogeneic responder splenic 
cells, while 0.3-1 x 1 o5 dendritic cells can induce maximal stimulation of 30- to 80-fold 
(Steinman and Witmer, 1978). Besides priming T cells in response to mismatched MHC, 
dendritic cells have also been shown to efficiently activate T cells in response to 
superantigens, antigens derived from infectious agents and tumours (Bhardwaj et al, 
1993; Inaba et al, 1993b; Paglia et al, 1996; Mayardomo et al, 1995). Dendritic cells 
pulsed with 1ninute quantities of superantigen are significantly more efficient than 
macrophages or B cells in stimulating naive primary T cells in vitro (Bhardwaj et al, 
1993). This potency in antigen presenting cell function in response to low dose antigen is 
attributable to both the delivery of CD28- and CD4-mediated costimulatory signals during 
antigen presentation. A similar in vitro study using naive transgenic T cells, I-Ek 
-restricted and specific for a peptide of cytochrome c, as responders has also verified the 
efficacy of dendritic cells as antigen presenting cells. Fewer dendritic cells, compared to 
macrophages and activated B cells, were required to stimulate transgenic T cells in the 
presence of a constant amount of cytochrome c peptide antigen (Croft et al, 1992). 
The initial physical interaction between antigen-loaded dendritic cells and specific 
T cells was for the first time directly visualized in vivo by Ingulli et al (1997). Ingulli et al 
(1997) used confocal microscopy to track the in vivo location of fluorescent dye-labelled 
dendritic cells and naive CD4 T cells specific for an OVA-peptide and I-Ad -restricted, 
after adoptive transfer into syngeneic recipients. This study elegantly demonstrates that 
dendritic cells pulsed in vitro with OVA peptide home to the paracortical regions of lymph 
node and form large clusters of specific T cells. 
Chemokines play an important role in dendritic cell-T cell interaction. Two recent 
studies have identified dendritic cell chemokines that preferentially attract naive or mature 
T cells, respectively (Adema et al, 1997; Tang and Cyster, 1999). The first study 
reported the identification and characterization of a C-C chemokine (DC-CKl) that is 
specifically expressed by human dendritic cells at high levels in germinal centres and T 
cell areas of secondary lymphoid tissue. DC-CKl is a potent chemoattractant for naive T 
* TRANCE/RANKL (TNF-related Activation-induced cytokine/receptor activator of NF-KB 
ligand) 
# TRANCE/RANKL 
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cells as shown in in vitro chemotaxis assays. The previously mentioned second study 
uses a murine model to illustrate that FITC-sensitized Langerhans cells upregulate 
macrophage-derived chemokine (MDC) during migration into draining node dendritic 
cells. This study employs a combination of light microscopy and in situ hybridization to 
generate images showing that FITC positive dendritic cells in draining lymph node 
upregulate MDC RNA. Furthermore, this study demonstrates that MDC is preferentially 
chemotactic for activated T cells. 
Recent data on dendritic cell-T cell interaction is strongly suggestive of the nature 
of interaction being mutual. What has become evident is that T cells may further enhance 
the T cell stimulatory capacity of dendritic cells. Evidence supporting this phenomenon is 
provided by the effects of CD40 ligation on dendritic cells. Ligation of CD40 has been 
shown to increase dendritic cell viability (Caux et al, 1994b; Ludewig et al , 1995) and 
maturation (Sallusto and Lanzavecchia, 1994). Furthermore, CD40 ligation is a potent 
inducer of IL-12 secretion by dendritic cells. Dendritic cells secrete high levels of IL-12 
in response to CD40-ligation in vitro (Koch et al, 1996; Cella et al, 1996). The secreted 
IL-12, in turn, would favor the generation of T helper 1 (Th 1) type response (Macatonia 
et al, 1995). Dendritic cell survival is also promoted by the newly described 
TRANCE/RANK (TNF-related Activation-induced cytokine/receptor activator of NF-KB)* 
receptor (Anderson et al, 1997; Wong et al, 1997) on dendritic cells. The 
TRANCE/RANK 1eceptor is ligated by the TNF family of proteins expressed by 
activated and memory T cells. The converse scenario would be the suppression of 
dendritic cells by T cell-secreted factors. Indeed, there are studies which show that IL-10 
induces apoptosis in dendritic cells (Ludewig et al, 1995) and downregulates their 
immunostimulatory capacity ( Caux et al, 1994c) as well as their IL-12 production (Koch 
et al, 1996). 
Most recently, definitive and direct evidence for the influence of T cells on 
dendritic cells has come from a study using T cell-deficient mice (Shreedhar et al , 1999). 
This study employed the induction of contact hypersensitivity (CHS) responses to 
haptens as an integrative model to examine different aspects of dendritic cell function in 
vivo. Results obtained during the course of this study support the concept that acquisition 
of full functional capacity by dendritic cells is a T cell -dependent phenomenon. Evidence 
for this concept is provided by the presence of markedly fewer Langerhans cells and 
draining lymph node dendritic cells in T cell-deficient SCID and RAG mutant mice. This 
dendritic cell deficiency, however, was overcome by reconstitution of mutant mice with 
purified normal T cells. Reconstitution with normal T cells also induced partial maturation 
of mainly immunophenotypically immature dendritic cells seen in T cell deficient mice. 
Furthermore, reconstitution of T cells restored the ability of hapten-bearing dendritic cells 
* In addition to CD40/CD40L interaction for the induction of CTL responses, there is also an 
important role for CD27-CD70 interactions between dendritic cells and CTLs (Stuhler et al, 
1999). Hun1an CTLs, on interaction with dendritic cells, have been shown to upregulate CD70 
molecules for subsequent costi1nulation of Th and dendritic cells. 
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from SCID mice to efficiently initiate a CHS response when adoptively transferred into 
naive, syngeneic immunocompetent recipients. These results suggest that T cells are 
critical for normal dendritic cell maturation and function in vivo. 
Another manifestation of dendritic cell-T cell interaction is the recently proposed 
role of dendritic cells to "license" CTLs to kill virus-infected targets. Data from three 
separate studies suggests a dynamic three cell interaction which incorporates sequential 
interaction of dendritic cells and helper T cells, followed by the interaction between 
dendritic cells and killer T cells (Ridge et al, 1998; Bennett et al, 1998; Schoenberger et 
al, 1998). An initial, CD40-dependent, interaction between dendritic cells and T helper 
cells takes place. The T helper cell, in tum, 'conditons' the dendritic cell to a state where 
it can now directly co-stimulate killer T cells. The initial CD40-dependent can be 
bypassed by viral infection of dendritic cells. * 
1.10 Heterogeneity of Dendritic Cells in Lymphoid Tissue 
Recent advances in the characterization of dendritic cells in lymphoid tissue have 
revealed phenotypic differences among lymphoid tissue dendritic cell subsets (Vremec et 
al, 1992; Vremec and Shortman, 1997; Leenen et al, 1998). This phenotypic difference 
correlates with discrete microanatomical locations occupied by specific subsets of 
dendritic cells in the mouse spleen (Pulendran et al, 1997). Currently there are no reliable 
criteria for delineating dendritic cell subsets. In mouse spleen, however, CD8a (Vremec 
et al, 1992) and DEC-205 (Kraal et al, 1986) have been used to distinguish between 
dendritic cells resident in marginal and T cell zones (Pulendran et al, 1997). 
The expression of the CD8a homodimer on dendritic cells was first demonstrated 
by Vremec et al (1992). Both splenic and thymic dendritic cells were shown to express 
cell surface CD8a and contain CD8a m.RNA. Although thymic dendritic cells express 
both CD8a and~ chains, the a chain is present in relative excess. Splenic dendritic cells 
express only the a chain of CDS. As yet there is no evidence supporting a functional role 
for cell surface CD8a on dendritic cells. 
An important reagent in the study of lymphoid tissue dendritic cells subsets is the 
monoclonal antibody against DEC-205 (formerly known as NLDC-145). The DEC-205 
monoclonal antibody was raised by immunizing rats with mouse lymphoid stromal tissue 
and then selecting for hybridomas that stained T cell areas in tissue sections (Kraal et al, 
1986). The monoclonal antibody stained dendritic profiles in T cell zones and primarily 
stained Dendritic cells and Epithelial Cells in the thymic cortex. Molecular and functional 
* A third subset of splenic dendritic cells expressing CD4 on the cell surface has also been 
recently described (Vren1ec et al, 2000). 
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characterization of the receptor for DEC-205 have shown it to be an intergral membrane 
protein, with molecular weight of 205 kDa, containing multi-lectin domains, homologous 
to the macrophage mannose receptor which are able to bind carbohydrates and mediate 
endocytosis (Jiang et al, 1995). Indeed, it has been shown that DEC-205 is an endocytic 
receptor which can internalize antigen and direct it to specialized antigen processing 
compartments. 
The detection of cell surface CD8cx on dendritic cells and the availability of the 
DEC-205 monoclonal antibody have provided insights into the heterogeneity of dendritic 
cells in lymphoid tissue (Pulendran et al, 1997). In mouse spleen, two subsets of 
dendritic cells have been show in anatomically distinct locations. A minor subset of 
dendritic cells, so-called interdigitating dendritic cells, is situated in the white pulp T cell 
zone (the inner periarteriolar sheath). The majority of dendritic cells in the spleen is found 
at the marginal zone and splenic red pulp. Flow cytometric analyses of splenic dendritic 
cells have shown the presence of two distinct dendritic cell subsets: one of which 
expresses both DEC-205 and CD8cx on the cell surface, and the other expresses neither 
of these molecules. A further difference between these subsets includes the differential 
cell surface expression of the myeloid antigen, CD 11 b, on the subset negative for both 
CD8cx and DEC205. The presence or absence of CDl lb on splenic dendritic cell subsets 
has encouraged the reference of each subset as the putative myeloid-related and 
lymphoid-related dendritic cells, respectively (Vremec and Shortman, 1997). In contrast 
to CD8cx expression, CD 11 b expression is upregulated during culture so both subsets 
acquire equivalent levels of expression between subsets. Similarly, DEC205 is 
upregulated during culture so both subsets become positive, although the difference in 
levels of expression is maintained. Therefore, CD8cx and DEC205 remain as reliable 
markers for the putative lymphoid-related dendritic cell subset in the spleen. 
Immunohistochemical data shows that DEC-205 stains only the interdigitating dendritic 
cells. On the basis of these observations, interdigitating dendritic cells are the most likely 
candidates for being the CD8a+ subset of dendritic cells. * -
Molecular evidence for the presence of CD8cx- and + dendritic cell subsets has 
recently come from a study with the RelB deficient (Rern-1-) mice (Wu et al, 1998). The 
transcription factor RelB is a member of the NFKB/Rel family. Expression of RelB 
mRNA is restricted to lymphoid tissue and in interdigitating dendritic cells (Carrasco et 
al , 1993). Rem-/- mice lack both thymic and splenic dendritic cells and show impaired 
antigen presenting cell function and cellular immunity, despite the presence of normal 
numbers of Langerhans cells (Burkly et al, 1995). These mice have a perturbed thymic 
architecture. Furthermore, these mice exhibited multi-focal inflammation and myeloid 
hyperplasia. It is now apparent that the absence of thymic dendritic cells may be a 
*Similarly, Pulendran et al ( 1997) also den1onstrated that the CDS ex+ dendritic cells were the 
highest producers of IL-12 in response to stimulation with a cocktail of staphylococcus aureus 
enterotoxin, GM-CSF and IFNy. 
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secondary phenomenon underpinned by systemic inflammation and disrupted thymic 
architecture. Wu et al (1998) generated bone marrow chimeric mice by reconstituting 
normal mice with RelB-/- bone marrow. Analysis of chimeric mice showed that similar 
numbers of thymic dendritic cells were produced by the RelB mutant and normal bone 
marrow cells. However, almost all RelB-/- bone marrow-derived splenic dendritic cells 
were CD8a+ and DEC-205+. This represented a 10-fold reduction in CD8a- dendritic 
cells, whereas normal bone marrow-derived splenic dendritic cells constituted almost a 
1: 1 ratio of CD8a+ to CD8a- dendritic cells. Thus, the marked reduction in CD8a-
splenic dendritic cells is a direct consequence of a stem cell-intrinsic effect of the RelB 
mutation. Furthermore, RelB appears to selectively regulate the CD8a- subset of 
dendritic cells. 
1.10 .1 Functional Specialization within Dendritic Cell Subsets? 
Preliminary in vitro data has led to the suggestion that CD8a+ dendritic cells may 
possess regulatory/tolerogenic function while their CD8a- counterparts perform pro-
immunity functions (Stiss and Shortman, 1996; Kronin et al, 1996). It has been 
demonstrated that CD8a+ dendritic cells are less efficient in inducing proliferation of 
purified allogeneic CD4 T cells compared to CD8a- dendritic cells (Stiss and Shortman, 
1996). More dead cells were observed in CD8a+ dendritic cell MLR cultures than in 
CD8a- dendritic cell MLR cultures. The mechanisms for reduced cell viability in CD8a+ 
dendritic cell MLR cultures remain to be elucidated. A similar regulatory role of CDSa+ 
dendritic cells was also observed in MLR cultures containing purified allogeneic CDS T 
cells (Kronin et al, 1996). Again, the proliferative capacity of CDS T cells stimulated with 
CD8cx+ dendritic cells was relatively reduced. This reduced proliferation of CDS T cells 
correlated with relatively reduced IL-2 secretion in the MLR cultures. It was concluded 
from this study that CDSa+ dendritic cells regulate CD8 T cell proliferation by limiting 
their IL-2 production. 
There is also initial in vivo evidence demonstrating differential capacity of the two 
dendritic cell subsets to secrete IL-12 (Sousa et al, 1997). This study shows that in 
response to microbial stimulation in vivo, majority of IL-12 secreting dendritic cells in the 
spleen are CD8a+, as determined by flow cytometry. IL-12 secretion in this model is 
rapid and independent of CD40 ligand. * 
More recently, a number of studies have attempted to demonstrate delineation of 
function between the two dendritic cell subsets both in vitro (Ohteki et al, 1999) and in 
vivo (Pulendran et al, 1999; Maldonado-Lopez et al, 1999, Smith and Fazekas de St. 
Groth, 1999). Results obtained by Ohteki et al (1999) show that IL-12 impacts 
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differentially on the two dendritic cell subsets in vitro. Correspondingly, CD8a+ 
dendritic cells secrete approximately 5-fold higher level of IFNy than do CD8a- dendritic 
cells, when both subsets are sorted and cultured in the presence of IL-12. This results 
suggest that IL-12 secreted by CD8a+ dendritic cells acts in autocrine manner for IFNy 
production and subsequent generation of a Th I-type response. In vivo results reported by 
Pulendran et al (1999), Maldonado-Lopez et al (1999) and Smith and Fazekas de St. 
Groth ( 1999) seem to contradict the regulatory role assigned on the CD8a+ dendritic 
cells on the basis of the previously described in vitro evidence (Si.iss and Shortman, 
1996). Overall, these studies present data which suggest that both dendritic cell subsets 
can prime antigen specific T cells with similar kinetics and magnitude in vivo. However, 
each dendritic cell subset appears to provoke distinct Th responses in vivo (Pulendran et 
al, 1999; Maldonado-Lopez, 1999). While the CD8a+ dendritic cells promote an IL-12-
mediated Th 1 type response, the CD8a- dendritic cells appear to promote a Th2 type of 
response. To date functional specialization within dendritic cell subsets remains 
controversial and obscure. 
1.11 Dendritic Cells as Link between Innate and Adaptive 
Immunity 
Two recent studies have identified dendritic cell precursors in human blood as the 
principal producers of IFNa (Siegal et al, 1999; Cella et al, 1999). IFNa is among the 
key mediators of innate immunity and can be induced in response to various 
inflammatory stimuli, including viral and bacterial infections. IFN a acts by inhibiting 
viral replication, activating NK cells and macrophages, increasing MHC class I 
expression , and providing survival signals to lymphocytes. Both groups isolated a rare 
blood leukocyte on the basis of cell surface HLA-DR and CD4 expression, and absence 
of lineage markers. These cells were found to secrete up to 1000 times more IFN a than 
the same number of bulk blood cells, in response to viral stimulation in vitro. These 
Interferon Producing Cells (IPCs) differentiate to mature dendritic cells when cultured 
with IL-3 and CD40 ligand. IPCs are able to induce IL-4 secretion by T cells, hence 
promoting a Th2 type response. A Th2 type response mediated by IPCs is thought to 
serve as a negative feedback mechanism which downregulates immune responses during 
viral infections (Payvandi et al, 1998). IPCs, detected immunohistochemically on the 
basis of distinct cell surface markers, are undetectable in normal lymph nodes but can be 
detected in close proximity to high endothelial venules (HEVs) in inflamed lymph nodes. 
This location, along with the expression of CD62 (P-selectin) ligand and CXCR3 
(inflammatory chemokine receptor), suggests that IPCs enter lymph nodes from blood 
via HEV s during inflammatory responses. 
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1.12 Dendritic Cells in Autoimmune Diabetes 
Evidence from a number of studies seem to suggest that part of the predisposition 
to autoimmune diabetes may be manifested at the level of hematopoietic precursors which 
give rise to antigen presenting cells. Engraftment NOD bone marrow cells can transfer 
diabetes-susceptibility to disease-resistant strains (Serreze et al, 1988; Wicker et al, 
1988). Thus, bone marrow cells expressing NOD susceptibility genes are essential for 
diabetes induction. In vitro stimulation of hematopoietic precursors derived from both 
human prediabetics and NOD mice show impaired responses to GM-CSF and other 
myeloid growth factors (Jansen et al, 1995; Takahashi et al, 1998; Serreze et al, 1993a 
and b; Langmuir et al, 1993). Furthermore, dendritic cells constitute the initial infiltrate 
into the islets of NOD mice (Jansen et al, 1994). Interestingly, it has recently been shown 
that repeated priming with dendritic cells, bearing an epitope expressed on target tissue, 
can induce the development of secondary lymphoid-like structures in the target tissue, 
ultimately leading to tissue destruction (Ludewig et al, 1998). 
That NOD bone marrow cells were essential for diabetes induction was 
demonstrated in bone marrow chimeric mice. Fl hybrid mice generated by crossing NOD 
with diabetes-resistant strain are resistant to diabetes. However, Fl hybrids become 
susceptible to diabetes when irradiated and reconstituted with NOD bone marrow cells. 
Whether majority of reconstituted Fl hybrids get insulitis or diabetes depends on the 
genotype of the disease-resistant strain. Majority of irradiated (NOD x B lO.H-2g7)Fl 
that are reconstituted with NOD bone marrow cells develop insulitis and some become 
diabetic (Wicker et al, 1988). Majority of (NOD x NON.H-2g7)Fl hybrids similary 
treated develop diabetes (Serreze et al, 1988). Since the NON strain shares more alleles 
with NOD than does the B 10 strain, these results imply that NOD alleles also act within 
the radio-resistant (predominantly non-hematopoietic) cells. 
Defects in dendritic cells generated in vitro from precursors isolated from Type I 
diabetic and prediabetic patients have been reported (Jansen et al, 1995; Takahashi et al, 
1998). Dendritic cells generated from monocyte precursors isolated from the blood of 
diabetics show a reduced ability to cluster and to stimulate autologous and allogeneic T 
cells, compared with dendritic cells from healthy controls. Similarly, monocyte-derived 
- precursors from the blood of prediabetics respond suboptimally in response to 
stimulation with GM-CSF and IL-4. In contrast to controls matched for age, sex and 
MHC genotype, precursors from prediabetics generate fewer dendritic cells which 
appeared to be phenotypically and functionally distinct. Dendritic cells generated from 
prediabetics expressed lower levels of cell surface costimulatory molecules and were 
relatively inefficient in stimulating autologous T cells. 
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As in humans, hematopoietic deficiencies have also been detected in the NOD 
mouse (Serreze et al, 1993a and b; Langmuir et al, 1993). NOD bone marrow cells 
generated fewer colonies than Balb/c bone marrow cells, in response to stimulation with 
myeloid growth factors. The myeloid growth factors used include GM-CSP, IL-3 and 
IL-5 (Langmuir et al, 1993). This phenotype, however, was not replicated in vivo as 
NOD myeloid precursors formed similar number of spleen colonies when injected into 
irradiated syngeneic recipients, compared with precursors from Balb/c mice. In another 
study, it was shown that colony stimulating factor 1 (CSF-1) and IFNy stimulation of 
NOD bone marrow cells resulted in abnormal macrophage development and maturation 
(Serreze et al, 1993a). Macrophages from disease-resistant strains secreted higher levels 
of LPS-stimulated IL-1 compared with macrophages generated from NOD bone marrow 
cells. It was also shown in this study that majority of the disease-resistant 
(NODxNON.H-2g7) Fl hybrid mice when irradiated and reconstituted with NOD bone 
marrow cells developed diabetes. No recipients reconstituted with of a 1: 1 mixture of 
NOD and NON.H-2g7 bone marrow cells developed diabetes, however. Impaired 
maturation of NOD macrophages may therefore be of pathogenic significance in NOD 
rmce. 
Elevated numbers of dendritic cells and macrophages constitute the initial infiltrate 
into the islets of NOD mice. This occurs as early as 3 weeks of age in both male and 
female NOD mice and precedes lymphocytic infiltration into islets (Jansen et al, 1994). It 
has recently been shown that this initial arrival of dendritic cells and macrophages into 
islets coincides with them being the primary producers of the proinflammatory cytokine, 
TNFa, in the islets, as determined by double immunofluorescence analysis (Dahlen et al, 
1998). Thus, early dendritic cell and macrophage infiltration and TNFa secretion in islets 
may be crucial in the initiation and development of diabetes. 
Important evidence for the role of dendritic cells in autoimmune response against 
peripheral tissue came in a study by Ludewig et al (1998). This study employs transgenic 
mice which target the expression of the lymphocytic choriomeningitis virus glycoprotein 
(LCMV-GP) to pancreatic~ cells by using the rat insulin promoter (RIP). RIP-GP mice 
do not spontaneously develop diabetes. However, when infected with LCMV, these mice 
develop an acute form of non-lethal diabetes (Ohashi et al, 1991; Oldstone et al, 1991). 
The study by Ludewig et al (1998) investigates the role of dendritic cells in the initiation 
and maintenance of autoimmune diabetes, by repeatedly priming RIP-GP mice with 
dendritic cells constitutively expressing the immunodominant CTL epitope of LCMV-GP. 
This regime of repeated CTL activation by dendritic cells results in severe and destructive 
mononuclear cell infiltration into islets. A conspicous feature of this process was the 
formation of islet-associated secondary lymphoid-like structures, observed in other 
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autoimmune syndromes, including Hashimoto's thyroiditis (Iwatani et al, 1993) and 
rheumatoid arthritis (Randen et al, 1995). Thus, repeated priming by dendritic cells 
bearing peripheral antigen can induce formation of de novo lymphoid structures in target 
peripheral tissue and provoke tissue autoimmunity. 
1.13 Project Objective 
It is now evident that diabetogenic loci outside the MHC create an overall 
susceptibility to autoimmunity in the NOD mouse (Wicker, 1997). Against the NOD 
autoimmune-prone background, alleles within the MHC determine the target tissue for 
autoimmune destruction. Autoimmune pathology may be directed against salivary or 
thyroid glands or the pancreas depending on the genotype of the MHC on the NOD 
background. 
This thesis analyzes the effects of non-MHC diabetogenic loci on the cell biology 
and function of dendritic cells. There are several key reasons for focusing on this facet of 
immunity. First, bone marrow cells, carrying diabetogenic loci, are essential for diabetes 
induction in NOD mice (Wicker et al, 1988; Serreze et al, 1988), and dendritic cells and 
macrophages constitute the initial infiltrate into islets of young NOD mice (Jansen et al, 
1994). The advent of these antigen presenting cells, prior to lymphocytic infiltration, is 
coincident with the secretion of the proinflammatory cytokine, TNFa, by these antigen 
presenting cells (Dahlen et, 1998). Importantly, it is has been demonstrated that repeated 
priming of mice with dendritic cells bearing islet-expressing epitope leads to severe and 
rapid onset of diabetes (Ludewig et al, 1998). Such an immunization regime transforms 
the pancreas into lymph node-like structures, a phenomenon observed in other 
autoimmune pathologies (Iwatani et al, 1993; Randel et al, 1995). Overall, these data 
suggest that dendritic cells may be of critical importance in the initiation and maintenance 
of autoimmune responses against peripheral tissue. 
The current project utilized BIO.BR and NOD.H-2k congenic mice to investigate 
dendritic cell generation, both in vitro and in vivo, in an attempt to explore cellular 
processes which may be affected by diabetogenic loci outside the MHC. It is conceivable 
that dysregulation of antigen presenting cell function of dendritic cells, mediated by non-
MHC NOD genes, may explain the breach of peripheral tolerance mechanisms in NOD 
rmce. 

Materials and Methods 
2.1 Commonly Used Reagents (Chemicals, Buffers and 
Media) 
Commonly used reagents, along with their sources, are listed in 
Appendix Al. 
2.2 Mice 
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Inbred B 10.BR, NOD.H-2k, Balb/c, mice expressing the 3A9 transgenic T cell 
receptor on the B 1 0.BR background, CBA/H and AKR mice were housed under specific 
pathogen free conditions in microisolator cages in the Medical Genome Centre or the 
Animal Services Unit at the JCSMR. Balb.H-2k mice were purchased from the Animal 
Resources Centre, Perth, Australia. Mice used in this project were 8-16 weeks of age and 
where necessary matched for age and sex. 
2.3 Cell Culture Conditions 
Mammalian cell lines and primary cell cultures were maintained in RPMI 1640 
culture medium (JCSMR; GibcoBRL, Life Technologies, Grand Island, NY, USA) 
supplemented with 10% (v/v) heat inactivated foetal bovine serum (FBS) (Trace 
Biosciences, NSW, Australia), 0.05mM ~-mercaptoethanol (GibcoBRL), 2mM L-
Glutamine (GibcoBRL), l0mM HEPES (Sigma Chemical Co., MO, USA) and 
antibiotics (l00U/mL penicillin, l00µg/mL streptomycin; GibcoBRL). In this thesis, the 
terms 'medium' or 'RPMI' refer to the 10% (v/v) FBS/RPMI described here, unless 
otherwise stated. 
Cell cultures were maintained at 37°C in a 5% carbon dioxide atmosphere in an 
automated incubator (model 3194: Forma Scientific, OH, USA) with humidity provided 
by a solution 0.025% (w/v) benzalkonium chloride in sterile double distilled water. 
Incubators were disinfected routinely with 70% (v/v) ethanol or with a solution of the 
viricidal disinfectant, Virkon (Antee International, Suffolk, UK) prepared according to 
the manufacturer's specifications. 
Centrifugation of cells for the purposes of washing was performed in 
polypropylene, gamma-irradiated Falcon conical tubes (Becton and Dickinson Labware, 
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Franklin Lakes, NJ, USA) at 200g for 4-6 minutes at 4°C. For washing, cells were 
pelleted by centrifugation and resuspended in required volume of fresh medium. Viable 
cell numbers were determined by the exclusion of cells positive for the vital dye, trypan 
blue (0.4% w/v; Sigma Chemicals Co.), as observed on a haemocytometer under a light 
rmcroscope. 
2.4 Cell Lines 
All cell lines used during the course of this project are listed in the table below, 
together with details of their source and functional purpose. 
Table 2.1 
Cell Line 
3D0.54.8 
A20 
HT-2 
GKl.5 
RA3.3Al 
Sf9 
Comments 
I-Ad-restricted, OV A323-339-
specific T cell hybridoma 
EBY-transformed 
B lymphoblastoid cell line 
IL-2 and IL-4-dependent 
T cell line used in bioassays 
B cell hybridoma for 
obtaining anti-CD4 antibody 
B cell hybridoma used for 
obtaining B220 antibody 
Insect cell line used for 
infection with recombinant 
baculovirus encoding growth 
factors 
Source 
Marracl<P 
McDevittb 
McDevitt 
GautamC 
Hodgkind 
Hapele 
Reference 
Shimonkevitz et al (1983) 
Kim et al (1979) 
Watson (1979) 
Dialynas et al (1983) 
Coffman and Weissman 
(1981) 
Gruenwald and Heitz 
(1993) 
a Gift from Prof. P. Marrack, National Jewish Hospital and Research Centre, CO, USA. 
b Supplied by Prof. H.O. McDevitt, Stanford University, CA, USA. 
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c. Supplied by Dr. A.M. Gautam, M&E Biotech, Copenhagen, Denmark 
d. Supplied by Dr. P.D. Hodgkin, Centenary Institute, Sydney, NSW, Australia 
e. Supplied by Dr. A.H. Hapel, John Curtin School of Medical Research, ANU, Canberra. 
The A20 B cell line and the 3DO T cell hybridoma were maintained at 37°C (5% 
CO2) in appropriate sized Nunc tissue culture flasks (Nunc™ Brand Products, Nalge 
Nunc International, Denmark) containing RPMI 1640 medium supplemented with 10% 
FBS. Cultures were fed when medium became acidic, as indicated by a change of 
medium colour to yellow, or when cells in culture became confluent. This was done by 
removing required volume of cultured cells and adding back required amount of fresh 
medium. RA3.3A9 and GKl.5 B cell hyridoma cells were propagated in large Nunc 
tissue culture flasks (800mL volume) until almost all cells underwent apoptosis. Culture 
supernatants were harvested and centrifuged (800g for 10 minute at 4°C) to eliminate 
cellular debris. Supernatants were microfiltered, using a 0.2 micron filter (Millex®-GP, 
Millipore Corporation, MA, USA), and stored at 4°C. HT-2 cells were maintained in 
culture medium including 50 units per mL recombinant murine IL-2 (gift from Prof. 
Christopher Parish, JCSMR). Protocols employed for maintenance of Spodoptera 
frugiperda (Sf9) insect cells are described in section 2.6.4. 
2.5 Monoclonal Antibodies 
All monoclonal antibodies, directed against murine cell surface molecules, used 
during the course of this project are listed in the table below, along with their isotype, 
specificity and source. 
Table 2.2 
Antibody Isotype Specificity Source 
10-3.6.2 mlgG2a I-A~f,k,r,s,u,g7 McDevitt1 
-FITC 
3E2 AHigG CD54 (ICAM-1) Mtillbacher 
l 4-4.4S-FITC mlgG2a 
34-1-2S mlgG2a 
31M rlgM 
I-Ead,k,p,r,u 
anti-H-2 KdDd 
anti-CD8 
McDevitt 
Mtillbacher2 
Finch3 via 
Mtillbacher 
Reference 
Lan dais et al ( 1986) 
Scheynius et al (1993) 
Ozato et al (1980) 
Ozato et al (1982) 
Ceredig et al (1989) 
Table 2.2 - cont 
Antibody Isotype 
B7.1 rigG2a 
B22O rigG2a 
(RA3-6B2) 
-FITC or -PE 
CD69-biotin AHigG 
GKl .5-FITC rigG2a 
or-PE 
Ly5a (AS20.l) migG2a 
-FITC or 
-PE or -Biotin 
Ly5b (104) 
-FITC 
or -Biotin 
mlgG2a 
Macl-FITC rlgG2b 
N418-Biotin AHigG 
or -FITC 
OX6-FITC migGl 
or-PE 
Thy 1.2-FITC rigG2a 
V~8.2-FITC migG2a 
(MRS-2) 
Specificity 
CD80 
CD45 
CD69 
CD4 
CD45a 
CD45b 
CDllb 
CDllc 
I-Af,k,r,s,u,g7 
CD90.2 
V~8.2 T cell 
receptor 
Source 
Mtillbacher 
Goodnow4 
Caltag5 
Pharmingen6 
Caltag 
Goodnow 
Pharmingen 
Caltag 
Townsend8 
Prasad9 
Pharmingen 
Pharmingen 
Pharmingen 
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Reference 
Razi-Wolf et al (1992) 
Coffman and Weissmann 
(1981) 
Yokoyama et al (1988) 
Dialynas et al (1983) 
Shen et al (1986) 
Shen et al (1986) 
Springer et al (1979) 
Metlay et al (1990) 
Fukumoto (1982) 
Gunter et al (1984) 
Kanagawa 0 . (1988) 
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1. Supplied by Prof. H.O. McDevitt, Stanford University, CA, USA. 
2. Supplied by Dr. A. Miillbacher, JCSMR, ANU, Canberra. 
3. Dr. Frank W. Finch, University of Chicago, IL, USA. 
4. Supplied by Prof. C.C. Goodnow, JCSMR, ANU, CanbeITa. 
5. Caltag, Burlingame, CA, USA. 
6. Pharmingen, San Diego, CA, USA. 
7. Gift from Prof. P. Marrack, National Jewish Hospital and Research Centre, CO, USA. 
8. Supplied by Dr. S. Townsend, University of British Columbia, Vancouver, B.C., Canada. 
9. Antibody purified from the N418 hybridoma (supplied by Dr. Hapel, JCSMR) and conjugated to FITC 
during my Honours year (1995) 
Abbreviations in Table 2.2 
AH Armenian Hamster 
FITC Fluorescein Isothiocyante 
lg lmmunoglobulin 
m munne 
PE Phycoerythrin 
r rat 
2.5.1 Secondary Staining Reagents 
Table 2.3 
Reagent 
Goat Anti-mouse lgG-FITC 
Rabbit Anti-Hamster IgG-FITC 
Goat Anti-rat IgG-FITC 
Streptavidin-Phycoerythrin * (SA-PE) 
Streptavidin-Cy Chrome™* (SA-TC) 
Purpose 
2° with 34- l .2S 
2° with 3E2 
2° with B7.l 
* Secondary (2°) reagents used with biotinylated antibodies 
Source 
Pierce, Rockford, IL, USA 
Pierce 
Caltag 
Caltag 
Pharmingen 
2.6 
2.6.1 
In Vitro Culture of Dendritic Cells 
Harvesting Bone Marrow Cells 
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The protocol employed for culturing dendritic cells in vitro was adapted from 
Inaba et al (1992a). Mice providing bone marrow were euthanized by cervical dislocation 
in a tissue culture hood. All subsequent steps were carried out aseptically. The skin from 
each hind leg was peeled from the bottom of the foot to the top. Excess muscle from legs 
were removed by using scissors while holding end of bones with forceps. The legs were 
then severed at the pelvic joints and just above and below the knee. This was followed by 
cutting off the feet. A 3mL syringe (Becton Dickinson Medical (S) Pte Ltd, Singapore) 
with a 25G needle (Terumo Medical Corporation, Elkton, MD, USA) attached was filled 
with 2-5 mL sterile RPMI. The needle was inserted into bone marrow cavity of femur or 
tibia. Bone marrow was flushed out into a petri dish until bone cavity appeared white. 
The bone marrow suspension was passed through a nylon mesh cell strainer (70µm, 
Falcon®, Becton and Dickinson Labware) to remove small pieces of bone and debris. 
The filtered suspension, containing bone marrow cells from one mouse, was collected 
into a sterile 50mL polypropylene Falcon conical tube (Falcon®Blue Max, Becton and 
Dickinson Lab ware) and counted on a heamocytometer under light microscopy. The 
nuclear staining White Blood Cell Counting Dye (see Appendix 2.3h) was used to 
distinguish between leukocytes and erythrocytes during counting. Routinely, there were 
approximately 5xl07 leukocytes from the hind limbs of one mouse. The suspension was 
centrifuged at 200g (Beckman CPKR Centrifuge: Beckman Instruments, Palo Alto, CA , 
USA) for 5 minutes at room temperature and the supernatant was discarded. The pellet 
was resuspended in a 900µL cocktail of monoclonal antibodies to be described below. 
2.6.2 Complement-mediated Lysis of Lymphocytes 
Cedarlane Low-Tox® -M Rabbit complement (Accurate Chemical &Scientific 
Corp, NY, USA) was reconstituted in lmL ice-cold double distilled water. l00µL 
aliquots were frozen at "'."20°c. 1 in 10 dilution of complement was used for lysis. A 
900µL volume antibody cocktail comprising optimal doses of the following monoclonal 
antibodies was made: 1 in 2.5 anti-B220 neat (RA3.3A9 supernatant), 1 in 5 of anti-CD4 
(GKl.5 supernatant) and anti-CDS (3 lM supernatant provided by Dr. Mtillbacher, 
JCSMR). Approximately 5xl07 bone marrow leukocytes were resuspended in the above 
antibody cocktail in 50mL polypropylene Falcon conical tubes and incubated for 30-40 
minutes at 4°C. The antibody-labelled suspension was diluted to 10 mL and washed by 
centrifuging at 200g for 5 minutes at room temperature to remove excess antibody. The 
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pellet was resuspended in lmL medium containing l00µL complement and incubated at 
370c for 30-45 minutes. The lysed sample was washed twice as previously described 
and resuspended in 5mL medium. 
2.6.3 Separation of Mononuclear Cells 
The above 5mL suspension was layered onto 5ml Ficoll gradient (Ficoll-Paque™ 
PLUS, Amersham Pharmacia Biotech, Uppsala, Sweden) in a 15mL Falcon 
polypropylene conical tube (Falcon®Blue Max Jnr). The tube was centrifuged at 500g 
for 20 minutes at room temperature. Interface cells were gently removed with a sterile 
Pasteur pipette. A maximum of 1-2 mL volume of interface cells was harvested. Interface 
cells were diluted in 20mL medium and washed twice by centrifugation at 4°C firstly at 
500g and then at 200g. Cells were then resuspended in growth factor-supplemented 
medium as described next. 
2.6.4 Growth Factors for Dendritic Cell Culture 
Recombinant baculovirus-encoding murine (m) GM-CSF and mIL-4 were 
obtained from Dr A. Hapel and Prof I. Young, respectively. The baculovirus expression 
system for the production of growth factors used baculovirus carrying lethal deletions of 
some essential components of the virus genome (BaculoGold™ system, Pharmingen). 
The lethal deletions were rescued by a complementing polyhedrin-based transfer plasmid 
vector encoding either mGM-CSF or mIL-4 under the polyhedrin promotor. Sf9 insect 
cells were co-transfected with the BaculoGold™ virus (linearized viral DNA) and the 
growth factor-encoding transfer plasmid. After several days, recombinant virus which 
arise as a result of homologous recombination between the plasmid and the viral DNA are 
selected in a plaque assay. Recombinant virus was used to infect Sf9 insect cells. Infected 
insect cells secreted particular growth factor into culture medium. Expression of growth 
factors were analyzed in bioassays to be described below. The process of growth factor 
production is summarized in the schematic illustrated in Figure 2.1. 
Sf9 insect cells at a density of lxl07 cells per mL insect cell medium (Sf-900 II 
SFM GibcoBRL) supplemented with 10% FBS was obtained from Dr. Hapel's 
laboratory and cultured in 30mL culture volume in tightly capped 800mL Nunc tissue 
culture flasks. Cultures were fed every 2-3 days by removing all medium from culture 
flask and adding equal volumes of fresh insect cell medium. Prior to infection with 
recombinant baculovirus semi-confluent monolayer of Sf9 cells in culture were gradually 
adapted to serum free insect cell medium. This was done by initially feeding cultures with 
Figure 2.1. 
Schematic illustrating production of growth factors using 
recombinant baculovirus expression system 
See text for details. 
Baculovirus Transfer Vector 
----mGM-CSF or m.IL-4 cDNA 
Linearized BaculoGold™ 
DNA 
MCS 
Insertion of mGM-CSF or mIL-4 
cDNA 
Co-transfect into Sf9 insect cells 
0 
0 0 
0 
0 
0 
Select recombinant virus by Plaque Assay 
Infect Sf9 insect cells with recombinant virus. 
Use bioassay to analyze expression of growth 
factor 
Key: MCS - Multiple Cloning Site 
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equal volumes of serum and serum free insect cell medium, followed 2-3 days later by 
feeding with only serum free insect cell medium. Serum free insect cell medium enables 
Sf9 cells to form adherent monolayers, making them suitable for infection. 
Sf9 cells adapted to serum free insect cell medium were infected with recombinant 
baculovirus by first removing all culture medium, then adding 30mL virus stock and 
incubating at 27°C for 1 hour. The virus was removed, centrifuged at 800g for 10 
minutes at 4°C and stored in the dark at 4°C. Infected cells were washed twice with 20 
mL serum free insect cell medium. This was done by gently swirling the flask containing 
the insect cell monolayer. After washing the monolayer, 30mL of serum free insect cell 
medium was added to the flask. Infected cells were cultured in tightly capped flasks at 
27°c for 72 and 96 hr for IL-4 and GM-CSF production, respectively. Culture 
supernatants were harvested, dialyzed against PBS and microfiltered using a 0.2 micron 
filter (Millex®-GP). After harvesting growth factor containing supernatants, original 
flasks were used for virus stock collection by adding 30mL serum insect cell medium and 
culturing at 27°C until 90-100% of cells were lysed during later phases of infection. At 
this point, culture supernatant was harvested, centrifuged at 800g for 15 minutes at 4°C 
and stored at 4°C. 
Quantitation of growth factors was perf armed in the fallowing manner. One unit 
of mGM-CSF or mIL-4 was defined as the reciprocal dilution which supports 50% 
maximum growth (ie ED50) of 2xl04 FDC-Pl or HT-2 cells in a proliferation assay 
(Hapel et al, 1984). FDC-Pl is a GM-CSP-dependent myelomonocytic cell line and HT-
2 is an IL-2-dependent T cell line. Bioassays using growth factor responsive cells were 
performed by plating serial two-fold dilutions of growth factor in RPMI with 2x 1 o4 cells 
in triplicate wells of 96 U-shaped well micro-titration plates (Lin bro® /Titertek®, ICN 
Biomedicals, Inc., Ohio, USA). The plate was incubated at 37°C for 12 hr. To assess 
proliferation of HT-2 cells, cells were pulsed with 0.5µCi [3H]Thymidine (Amersham, 
NSW, Australia) and cultured for a further 4-6 hr. Cells were harvested onto glass fibre 
filters (Wallac Oy,Turku, Finland) using a Micro Cell Harvester (Skatron Instruments 
AS, Lier, Norway). The filter radioactivity was counted on a Betaplate liquid scintillation 
counter (model 1205; Wallac Oy, Turku, Finland). [3H]Thymidine incorporation data 
was recorded as counts per minute ( cpm). 
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2.6.5 Culture of Myeloid Precursors 
1x106 lymphocyte-depleted bone marrow leukocytes, resuspended in lmL 
medium suppplemented with 800 U/mL mGM-CSF and 200 U/mL mIL-4 were 
dispensed into individual wells of 24 well Linbro plates (Linbro® /Titertek®), as 
described previously (Inaba et al, 1992a). Cultures were fed on days 2 and 4 by gently 
swirling plate and aspirating 50% of the medium, and adding back equal amount of fresh 
growth factor-supplemented medium. Loosely adherent cell clusters were harvested on 
day 5 and then on day 7, pelleted by centrifugation (200g), resuspended in fresh growth 
factor-supplemented medium, and subcultured onto fresh plates, keeping the number of 
wells constant throughout the culture. The dose of growth factors in culture was halved 
from day 5 onwards. On day 8 of culture, loosely adherent or floating cells were 
harvested, washed twice, and used as required. 
2. 7 Transmission Electron Microscopy (TEM) 
1x106 cells from bone marrow cultures on day 8 were harvested and resuspended 
in lmL RPMI, and supplied to the JCSMR Electron Microscopy Unit for routine TEM. 
For TEM, cells were fixed in 2% glutaraldehyde in 0.lM cacodylate buffer (pH 7.4). 
Cells were post-fixed in 1 % osmium tetroxide in 0.lM cacodylate buffer (pH 7.4), 
dehydrated and dried in a critical point drying apparatus. This was followed by 
embedding cells in Spurr's resin. Thin sections of 80nm were cut on a Reichert Ultracut 
E and stained with lead citrate. Sections were viewed in a Hitachi H7000 electron 
rrucroscope. 
2.8 Fluoresc_ence Activated Cell Sorter (FACS) Analysis -
Cell Staining, Data Acquisition and Analysis 
Flow cytometry experiments were conducted using the standard Argon laser 
FACScan Cytometer (Becton Dickinson, San Jose, CA, USA) with standard filter 
configuration. In all experiments Forward Scatter (FSC) was used as the threshold 
parameter. Data acquisition and analysis were carried using the CELLQuest™ software 
.. package (version 3.1, ©1994-1997 1 Becton Dickinson). The number of cells acquired 
varied from _5x103 to lxlo5 depending on the requirements of the assay. Generally, 0.5-
lxlo4 events were acquired during analysis of red blood cell-depleted blood leukocytes, 
splenocytes and thymocytes. 0.5-lx105 events were acquired during the analysis of 
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cultured or primary dendritic cells. Furthermore, appropriate gating of events during 
acquisition or subsequent analysis will be shown in representative FACS plots. 
2.8.1 Staining Cells for Flow Cytomery 
All reagents used in flow cytometry experiments were diluted in a PBS-based 
FACS buffer (see Appendix A2.la) containing 2% (v/v) FBS and 0.01 % (v/v) sodium 
azide. The FACS buffer was always stored in the dark at 4°C. Prior to staining, red 
blood cells from primary tissue suspensions were depleted by Tris-ammonium chloride 
(see Appendix A2. ld)-mediated lysis, washed twice and resuspended at the required 
concentration in F ACS buffer. Cells resuspended in F ACS buffer were dispensed into 96 
U-shaped microwell plates (Linbro®!Titertek®) at a concentration of 0.5-lxlo6 cells per 
well. Primary and secondary staining reagents used are shown in Tables 2.2 and 2.3, 
respectively. Cells were stained with appropriately diluted primary reagents in 25µL stain 
volume in the dark for 20 minutes at 4°C. This primary incubation was followed by 2 
large volume washes. This was done by first adding l 75µL FACS buffer to each well, 
then centrifuging the plate for 10 seconds at 800g at 4°C in a benchtop centrifuge 
(Labofuge 400R; Heraeus Instruments, N.J.,USA). The plate was flicked with a firm 
wrist to eliminate supernatant. The plate was gently tapped on the sides to resuspend 
pellet in residual supernatant. This preceding wash procedure was then repeated. 
Appropriately diluted secondary reagents where necessary were added and cells incubated 
in the same way as during the primary incubation. Cells were washed twice as after the 
primary incubation and resuspended in 1 00µL F ACS buffer or F ACS fix buffer 
(containing 0.1 % paraformaldehyde, see Appendix A2.lb). 4xlo3 absolute counting 
beads (polystyrene fluorospheres, Flow-Count™, Coulter Corporation, Miami, Florida, 
USA) per l00µL buffer were included in the FACS or FACS fix buffer when absolute 
quantitation of cells was necessary. Resuspended stained cells were transferred to 1.2 mL 
polypropylene cluster tubes (Costar Corporation, Cambridge, MA, USA) and taken for 
acquisition. 
Optimal concentrations of primary and secondary reagents were pre-determined in 
titration assays by staining red blood cell-depleted splenocytes with two-fold serial 
dilutions of reagents. 
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2.9 Whole Blood Stains 
Staining of whole blood for flow cytometry differed from the protocol outlined 
above and, therefore, will be described next. 
2.9.1 Harvesting Blood 
Cages of mice to be bled were placed under a heat lamp for 3-4 minutes to induce 
vasodilation. Individual mice were immobilized in a standard conical restrainer and bled 
by inserting a 26G needle into the lateral tail vein. Then needle was withdrawn and the 
resulting drops of blood collected with a heparinized hematocrit capillary tube 
(Hirschmann Laborgerate, Germany). Blood in the capillary tube was blown out into 
l00µL Alsevers (JCSMR stock, Appendix A2.3a) in a 96 U-shaped microwell plates 
(Linbro® /Titertek®) The capillary tube was swirled in the well to mix blood and 
Alsevers. Alternatively, mice were sacrificed in presence of carbon dioxide and blood 
was collected from the chest cavity using a plastic Pasteur pipette. The blood/ Alsevers 
mixture could be kept at room temperature for up to 2 hours prior to processing to be 
described section 2.9.3. Collected blood was not diluted in Alsevers when staining whole 
blood was necessary. 
2.9.2 Staining Whole Blood 
Required antibody cocktails were prepared by first preincubating primary 
antibodies with appropriate secondary reagents in F ACS buffer at 4°C for time required 
to bleed mice. Where required other directly-conjugated primary antibodies were 
subsequently added to the cocktail. 2µL of whole blood was stained at 4°C for 20 
minutes with appropriate antibodies in a total 25µL stain volume. Each well was then 
diluted with 175µ1 RPMI containing 4x103 counting beads per l00µL RPMI. Stained 
blood samples were then transferred to cluster tubes and taken immediately for 
acquisition. Samples were acquired at a slow flow rate until 400 beads were acquired. 
2.9.3 Processing Blood 
The plate containing the blood/Alsevers solution was centrifuged at 800g for 10 
seconds at room temperature. The supernatant in each well was aspirated using a multi-
channel pipette. 200µL of Tris ammonium chloride was then added to each well and the 
pellet resuspended by pipetting up and down 5 times. The plate was incubated at room 
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temperature for 10 minutes. The plate was centrifuged again and the supernatant aspirated 
as before. The preceding procedure of Tris ammonium chloride addition, pellet 
resuspension, incubation, centrifugation and supernatant aspiration was repeated. Finally 
the cells were resuspended in FACS buffer, washed once and stained as before. 
2.9.4 Absolute Quantitation of Blood Leukocytes 
Whole and processed blood were analyzed in parallel in order to determine the 
frequency of rare blood leukocytes. This was done by comparing the frequency of rare 
leukocytes, monocytes in this study, relative to B cells. B cells, being the most numerous 
in whole blood, are readily detectable and countable on the flow cytometer. As mentioned 
above, counting beads were added to whole blood samples for the quantitation B cells. 
Firstly, the relative proportions of B cells and monocytes in processed (red blood cell-
depleted) blood were determined as fractions of total leukocytes. Absolute numbers of 
monocytes were determined by multiplying the absolute number of B cells in whole 
blood by the ratio of the relative proportions of monocytes to B cells in the same sample 
of processed blood leukocytes. 
2.10 Screening for the Presence of T cell receptor 
Trans gene 
Mice were screened for the presence of T cell receptor (TCR) transgene 
expression by ear punch PCR reactions as described by Chen and Evans (1990). 
2.10.1 Collecting Ear Punches 
Mice were individually ear marked with ear punch using the dominant hand while 
appropriately holding mice with the other hand. The last punch-hole was saved in labelled 
500µL eppendorf tubes (Eppendorf-Netherlor-Hinz-GmbH, Hamburg, Germany) . The 
working area and fingers were kept clean between mice. The punch and forceps used 
were carefully rinsed and dried between mice. This was to minimize carry-over DNA 
from one mouse to another, which can give false positives especially with high copy-
number transgenic mice. 
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2. 1 0. 2 Processing Ear Punches 
Processing of ear punches was carried out in a clean working area using Gilson 
pipettes designated for this purpose. 20µL ear-punch digestion mix was added to each 
tube containing an ear punch. The digestion mix included the following ingredients: 
50 mM Tris pH8.0 
2mMNaCl 
l0mMEDTA 
1 % (v/v)SDS 
1 mg/mL Proteinase K 
The digestion mix was made in advance, autoclaved and store at room 
temperature. All tubes containing ear punches were warmed in a heat block to 55°C for 
20 minutes. This was fallowed by vortexing each tube to dislodge and break up the partly 
digested ear punch. The tubes were warmed again to 55°C for a further 20 minutes. 
180µL of triple distilled water was added to each tube. The tubes were capped tightly and 
placed in a heat block set at 100°C for 5 minutes to inactivate Proteinase Kand to melt 
DNA strands. The tubes were cooled and required volumes of the digest was used in a 
PCR reaction immediately or stored at -20°C for later use. 
2 .10. 3 Polymerase Chain Reaction (PCR) 
The primers used to amplify the 3A9 T cell receptor transgene and for the positive 
control endogenous product (I-Ek a chain) are shown below. 
Primers 
(1) 3A9 T cell receptor transgene 
5' Primer: GCAGTCACCCAAAGCCCAAG 
3' Primer: CCCCAGCTCACCTAACACTG 
(2) I-Ek a chain 
5' Primer: AGTCTTCCCAGCCTTCACACTCAGAGGT AC 
3' Primer: CATAGCCCCAAATGTCTGACCTCTGGAGAG 
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PCR Reaction mix 
Amplification of the transgenic T cell receptor was carried out under conditions 
previously optimized in the laboratory. Amplification of the transgene generates a 371 
base pair long fragment for the transgene versus a 264 base pair product for the 
endogenous V~ 8.2 gene segment. Shown below are the ingredients and volumes used in 
the 50µL PCR reaction mix. 
Reagent 
l0x PCR Buffer 
40mMdNTPs 
Control Primers 
5' 
3' 
TCR Primers 
5' 
3' 
Triton X 100 (10% stock) 
DNA Polymerase 
Template DNA 
Triple distilled water 
Volume (µL) 
5 
1 
1 
1 
1 
1 
0.5 
0.25 
1 
38.25 
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The PCR reaction was conducted using a Corbett Research FTS-960 Thermal 
Cycler. Non-specific amplification was monitored by the inclusion of negative controls 
containing all ingredients except template. PCR efficiency was monitored by the inclusion 
of positive control primers to the I-Ek a chain known amplify a product different in size 
to target product. The program for amplification was outlined below: 
Temperature Time Number of Cycles 
94oc 2 minutes 1 
94°c 
60°C 
72°c 
4°c 
15 seconds 
30 seconds 
45 seconds 
1 minute 
1 
l 
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HOLD 
At the end of the cycle, 5-10% of the reaction was removed and electrophoresed 
on a 1 % agarose gel, containing 0.5µg/mL ethidium bromide. Presence of PCR products 
were visualized by UV transillumination. Standard DNA markers (GibcoBRL) were also 
run in parallel. 
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2.11 CFSE Labelling of Leukocytes 
Whole spleen and lymph node cells or lymphocyte-depleted bone marrow cells 
were labelled with 5-(and 6-) carboxyfluorescein succinimidyl ester (CFSE; Molecular 
Probes, Oregon, USA) in a modified manner to what was described by Lyons and Parish 
(1994). Briefly, cells were washed once by centrifuging at 200g for 4-5 minutes at room 
temperature. Cells at a density of 0.5-lxlo7 cells per mL RPMI containing 1.25µM 
CFSE were incubated for 7 minutes at room temperature. The labelling was stopped by 
adding excess cold RPMI. The cells were washed 3 times in cold RPMI, counted and 
resuspended at required density in RPMI. 
2.12 Antigens 
Protein and peptide antigens used in antigen presentation assays are listed below. 
Chicken Egg Albumin (Ovalbumin, OVA) - Sigma Chemical Co. 
OV A323-339 peptide - synthesized at the Biomolecular Resources Facility, JCSMR. 
Hen Eggwhite Lysozyme (HEL) - Sigma Chemical Co. 
HEL46-61 peptide - synthesized at the Protein and Nucleic Acid Facility, Stanford 
University, Palo Alto, CA, USA 
Antigen stocks were made by dissolving each antigen in sterile RPMI. Suspensions were 
microfiltered and stored at -20°C. 
2.13 Antigen Presentation Assay using a T Cell Hybridoma 
Two different T cell assays were employed during the course of this project. The 
first has been previously described (Shimonkevitz, 1983) and was used as part of the 
functional analyses of dendritic cells generated in vitro from myeloid precursors isolated 
from Balb/c mice. The ability of day 8 Balb/c bone marrow-derived dendritic cells to 
present protein (Ovalbumin) and peptide antigen (OV A323-339) was compared against an 
EBY-transformed, Balb/c-derived B cell line (A20). Essentially, antigen presentation to 
the T cell hybridoma, 3DO, (I-Ad-resricted and OVA323-339-specific) was assessed 
using an IL-2 bioassay. The 3DO T cell hybridoma has previously been shown to secrete 
IL-2 in response to ovalbumin presented by the I-Ad-expressing A20 cells (Shimonkevitz 
et al, 1983). The assay was performed in a polystyrene 96 well flat-bottom microtitre 
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plate (Nunc, Roskilde, Denmark). Antigen presenting cells and T cell hybridoma cells 
were washed twice and resuspended in RPMI at required densities. 5x103 dendritic cells 
or 2.5xlo4 A20 cells (unfixed) were cocultured in triplicate wells with 2.5xl04 T cell 
hybridoma cells, in the presence of two-fold serial dilutions of OVA or OVA 323-339. 
The total culture volume in each well was 200µL. Negative control wells contained no 
antigen. Plates were incubated at 37°C for 18-24 hr. 150µL supernatant was harvested 
into fresh 96 well plates and frozen for 30 minutes at -70°C to lyse all viable cells. 
T cell response was measured by assaying culture supernatant for IL-2 activity. 
This was done by using a secondary culture of the IL-2-dependent cell line, HT-2 
(Watson, 1979), in 96 well flat-bottom plates. HT-2 cells were washed 3-4 times to 
remove residual IL-2 from culture and resuspended in RPMI at 1 o5 cells per mL. 50µL 
of this suspension was added to an equal volume of the primary culture supernatant. 
Positive control wells included RPMI (10% FBS) supplemented with 50U/mL 
recombinant murine IL-2. The plate was incubated at 37°C for 12 hr. As before, 
proliferation of HT-2 cells was assessed by pulsing cells with 0.5µCi [3H]Thymidine 
and cultured for a further 4-6 hr. Cells were harvested onto glass fibre filters using a 
Micro Cell Harvester. The filter radioactivity was counted on a Betaplate liquid 
scintillation counter. [3H]Thymidine incorporation data was recorded as cpm. 
2.14 Antigen Presentation Assay using Transgenic T Cells 
A second in vitro T cell assay, to be described below, was specifically designed to 
allow the frequency of responding T cells to be visualized and quantitated. The assay was 
designed to determine any functional difference between control B 10.BR-derived 
dendritic cells and test NOD.H-2k-derived dendritic cells to activate specific T cells and 
induce their proliferation. Cultured day 8 bone marrow cells, derived from either strain, 
were harvested and transferred to 15mL polypropylene Falcon conical tubes. Cells were 
washed twice in RPMI by centrifugation and used as source of dendritic cells. To 
synchronize T cell activation and limit antigen delivery, cultured dendritic cells were 
pulsed with required doses of antigen. For this purpose, 1-5 x 106 cultured bone marrow 
cells were resuspended in almost 15mL RPMI, containing appropriate doses of HEL or 
HEL46-6 l, and incubated at 37°C for 2hr. The cells were washed twice in RPMI to 
eliminate unbound antigen. Two-fold serial dilutions of pulsed antigen presenting cells 
were co-cultured in triplicate wells with 3xlo5 spleen and lymph node leukocytes from 
the 3A9 T cell receptor transgenic mice on the B 1 0.BR background, as source of 
transgenic CD4 T cells (Ho et al, 1994 ). Each well contained a total volume of 200µL 
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RPMI, consisting of spleen and lymph node cells prelabelled with CFSE as previously 
described (2.11). Negative control wells contained the highest number of unpulsed 
antigen presenting cells. The plates were incubated at 37°C from 14hr to 5 days. Prior to 
plating, the presence of the 3A9 T cell receptor transgene was reconfirmed by flow 
cytometry using the anti-clonotypic monoclonal antibody, V~8.2. 
After 15 hr of incubation, CD4 T cell activation was analyzed by flow cytometry 
using the early activation marker, CD69. Proliferation of CD4 T cells on days 3 and 5 
was also analyzed by flow cytometry using CFSE dilution. Following cell staining, cells 
were resuspended in FACS or FACS fix buffer containing 4x103 absolute counting 
beads per l00µL buffer. The presence of known concentration of counting beads in each 
sample enabled the absolute quantitation of responding CD4 T cells. 
2.15 In Vitro Proliferation and Apoptosis Assay 
A flow cytometry-based proliferation and apoptosis assay was designed to gain 
insight into the nature of the response of myeloid precursors, following growth factor 
stimulation, early in culture. Bone marrow cells were harvested from BIO.BR and 
NOD.H-2k mice and processed as previously described. Prior to culturing in the 
presence of growth factors, lymphocyte-depleted bone marrow cells were labelled with 
CFSE. The levels of proliferation and apoptosis on Days 1, 2 and 3 of culture were 
analyzed by flow cytometry. Apoptotic cells were detected by staining with merocyanin 
540 (MC540; Sig1na Chemical Co.), a lipophilic dye, which intercalates loosely-packed 
lipids (McEvoy et al, 1988; Mower, Jnr. et al, 1994; Frey, 1997) exposed on the 
membrane of apoptotic cells. Staining of cells with the appropriate concentration of 
MC540 was like the usual antibody staining of cells except cells were incubated at 4°C in 
the dark for a duration of 4 minutes. As with staining using other reagents, MC540 
stained cells were washed twice, resuspended in 1 00µL F ACS buffer and taken for 
acquisition on the flow cytometer. Again, addition of beads in the F ACS buffer allowed 
quantitation of cell populations of interest. 
2<>16 Enrichment for Splenic and Thymic Dendritic Cells 
The protocol to enrich for splenic and thymic dendritic cells was adapted from 
Vremec and Shortman (1997). One spleen or thymus from relevant mice was cut into 
small fragments and suspended in l0mL RPMI containing lmg/mL Collagenase A 
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(Boehringer Mannheim GmBH, Mannheim, Germany) and 0.02mg/mL DNase 
(Boehringer Mannheim). The mixture was digested with intermittent agitation for 25 
minutes at 22°c. Dendritic cell-T cell complexes were disrupted by the addition of 200µL 
of 0.5M EDTA (pH 7.2) and the digest agitated for a further 5 minutes. The digest was 
passed through a cell strainer to remove undigested stromal material. Cells were 
recovered from the digest by centrifugation at 200g for 5 minutes at room temperature. 
Cells were resuspended in 5mL RPMI. The cell suspension was layered onto 14.5% 
(w/v) metrizamide (Nycomed Pharma, Oslo, Norway) gradient (See Appendix A2.3f), 
contained in a 15mL Falcon conical polypropylene tube, and centrifuged at 800g for 10 
minutes at room temperature. Low density interface cells were harvested and washed 
twice. The dendritic cell-enriched low density cells were stained with appropriate 
antibodies and analyzed by flow cytometry. 
2.17 Bone Marrow Reconstitution Assays 
2 .1 7 .1 Irradiation of Recipients 
Three 8-12 week old BIO.BR or NOD.H-2k male or female mice were placed in a 
sterile cylindrical canister 10cm diameter x 20cm long containing tissue paper for nestling 
into and absorbing urine. These canisters are made of opaque PVC and have two screw-
capped ends. The ends are mesh-filtered and provide good ventilation and protect 
contained mice from external infection. The canisters were secured horizontally inside a 
Taconic shipping box and taken by car to the CSIRO Division of Entomology Cesium 
source irradiator. Each canister was placed in the irradiator and a programmable timer 
was used to deliver precisely 5 Gray. The mice were held in the canisters for 3 hr in a 
quiet and cool place before a second dose of 5 Gray was delivered. The mice were then 
returned to microisolator cages in the Medical Genome Centre. 
2 .1 7. 2 Reconstitution 
Total bone marrow cells from donor female B 10.BR and NOD.H-2k mice (8-12 
weeks of age) were aseptically harvested as described before (2.6.1). Bone marrow cells 
were washed twice and resuspended at lxl07 leukocytes per mL RPMI. 200µL of this 
inoculum (2x106 leukocytes) was injected via the lateral tail vein into each irradiated 
mouse immobilized in standard conical restraint. Control groups of recipient mice 
received either B 10.BR or NOD.H-2k bone marrow cells alone while the test group of 
mice received an inoculum comprising a 1:1 mixture of BIO.BR and NOD.H-2k bone 
marrow cells. Reconstituted mice were given drinking containing Polymyxin B (8.5x105 
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U/mL; Sigma Chemicals Co.) and Neomycin (1.1 mg/mL; Sigma Chemicals Co) ad 
libitum for the duration of reconstitution. 
2 .1 7. 3 Assessment of Reconstitution 
Recipient mice were screened for the level of chimerism 5 weeks post-
reconstitution. This was done by flow cytometric analysis of peripheral blood leukocytes. 
Mice were micro-bled through the lateral tail vein as described previously (2.9.1) . 
Distinguishing BIO.BR-derived cells from NOD.H-2k -derived cells in recipient mice 
was made possible by the allelic variants of CD45 (Ly5) expressed between the strains 
(McClive et al, 1994). NOD.H-2k-derived cells express Lysa while BIO.BR-derived 
cells express Ly5b. Antibodies against B cells, T cells and monocytes, in combination 
with anti-Ly5a monoclonal antibody were used to assess the level of reconstitution in 
blood of recipient mice. Further analysis of recipient mice was performed 10-12 weeks 
post-reconstitution by flow cytometric determination of the origin of splenic and thymic 
dendritic cells. Enrichment for splenic and thymic dendritic cells was achieved as 
previously described (2.16). 
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Generation and Characterization of Bone Marrow-
Derived Dendritic Cells 
3 .1 Introduction 
Paucity of dendritic cells in tissue and tedious protocols for their isolation have 
until recently limited the comprehensive cellular, biochemical and molecular analyses of 
dendritic cells. However, the discovery that specific growth factor stimulation of 
hematopoietic precursors in liquid culture systems resulted in the generation of sizeable 
numbers of dendritic cells has facilitated these analyses (Witmer-Pack et al, 1987; Heufler 
et al, 1988; Scheicher et al, 1992; Inaba et al, 1992a and b; Caux et al, 1992; Sallusto and 
Lanzavecchia, 1994). The first liquid culture system developed to generate substantial 
numbers of dendritic cells involved the use of precursors from mouse blood in cultures 
supplemented with GM-CSF (Inaba et al, 1992b). Typical dendritic cells were released 
from loosely-attached, proliferating cell aggregates during the course of culture. Dendritic 
cells from such cultures were readily identified on the · basis of their distinct shape, 
ultrastructure and repertoire of cell surface markers. Dendritic cells generated in liquid 
cultures, in response to GM-CSF stimulation, expressed high levels of cell surface MHC 
class II molecules and were potent stimulants of mixed leukocyte reactions. Dendritic 
cells thus generated enabled analyses of their distinct morphology, phenotype and 
function. This liquid culture system was extended to the culture of MHC class II negative 
precursors from the bone marrow (Inaba et al, 1992a). As with precursors from blood, 
myeloid precursors were stimulated with GM-CSF. GM-CSF stimulation of myeloid 
precursors resulted in three distinct types of myeloid cells: granulocytes, macrophages 
and dendritic cells. Enrichment of dendritic cells in culture was carried out by removing 
non-adherent granulocytes during feeding of cultures, while macrophages remained 
firmly adherent. 
A similar culture system was subsequently established for precursors isolated 
from human blood (Sallusto and Lanzavecchia, 1994). Besides GM-CSF, the culture was 
supplemented with IL-4. The presence of IL-4 in culture is thought to enhance viability of 
precursors during culture and also favors the development of precursors towards 
dendritic cells over that of macrophages (Strunk et al, 1996). In contrast to the murine 
culture system of generating dendritic cells, cultured human dendritic cells could be 
induced to mature by addition into culture of TNFa (Sallusto and Lanzavecchia, 1994 ). 
The establishment of liquid cultures of hematopoietic precursors, supplemented 
with GM-CSF and IL-4, provides an efficient source of dendritic cells and facilitates 
investigation of these critical antigen presenting cells. 
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3 .2 Objective: 
The initial objective of this project was to establish an in vitro bone marrow 
culture system to generate dendritic cells, to be used for morphological, 
immunophenotypic and functional analyses. As reported in the literature, bone marrow 
cultures were supplemented with GM-CSF and IL-4. The availability of recombinant 
baculovirus encoding murine GM-CSF and murine IL-4 within the JCSMR ensured 
sufficient supplies of critical growth factors required during the course of this study. A 
further objective for this part of the study was to use the in vitro generated dendritic cells 
to develop a flow cytometric-based functional assay. Specifically, it was aimed that the 
assay would allow the frequency of responding T cells to be visualized and quantitated 
when antigen is presented by dendritic cells . 
3. 3 Morphological Analysis of In Vitro Generated 
Dendritic Cells 
Bone marrow cells from the hind limbs of Balb/c mice were aseptically harvested 
and depleted of lymphocytes by complement-mediated lysis as previously described 
(Inaba et al, 1992a). The monoclonal antibodies used to delplete B and T lymphocytes 
included: RA3.3A9 (anti-B220), GKl.5 (anti-CD4) and 3 lM (anti-CDS). Further 
information regarding isotype and source of the monoclonal antibodies used and detailed 
protocols for lymphocyte depletion are described in sections 2.5 and 2.6.2 of the 
Methods Chapter, respectively. Viable mononuclear cells were enriched on a Ficoll 
gradient, washed in RPMI twice by centrifugation, and the pellet resuspended in RPMI 
supplemented with 800U/mL GM-CSF and 200U/mL IL-4. Cells were plated at a density 
of 1x106 cells per mL growth factor supplemented medium per well in 24 well Lin bro 
tissue culture plates. Details of how the growth factors were derived and quantitated are 
described in section 2.6.4. Cultures were fed on days 2 and 4 by gently swirling plates 
and removing half the medium in each well and adding fresh growth factor-supplemented 
medium. Feeding served the additional purpose of removing non-adherent granulocytes 
that are also generated during culture. 
Observation by inverted light microscopy during the course of culture revealed the 
presence of numerous clusters of proliferating cells attached to a monolayer of adherent 
cells as of day 3 of culture (Figure 3.la). The size and number of these clusters expanded 
between days 3 and 5 of culture. The loosely-adherent clusters were dislodged by gentle 
pipetting and replated onto fresh plates, in the presence of medium supplemented with 
Figure 3.1 
Phase contrast micrographs depicting the development of dendritic cells in 
liquid cultures of lymphocyte-depleted murine bone marrow cells 
supplemented with GM-CSF and IL-4. 
(a) High-power view of proliferating cell clusters attached to a monolayer of adherent 
cells on day 3 of culture (250x magnification). Cells with dendrites can be seen at the 
periphery of clusters. 
(b) High-power view (250x magnification) of individual cells with dendrites as seen on 
day 8 of culture when clusters were harvested and subcultured onto fresh plates. 

Figure 3.2 
Transmission electron micrograph of dendritic cells on day 8 of culture 
Numerous cytoplasmic processes or dendrites are seen. The absence of 
numerous electron dense granules in the cytoplasm suggests the absence of 
lysosomal or phagocytic structures. 
Scale bar represents 5µm. 7500x magnification. 
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reduced concentrations of growth factors. Cultured cells were subcultured in this manner 
on days 5 and 7. This process of subculturing enriched for dendritic cells by eliminating 
adherent macrophages. Optimal yields of dendritic cells were obtained on day 8, as 
individual cells with typical dendritic cell morphology were released from the clusters 
(Fig.3.lb). Numerous large cells with cytoplasmic processes, or dendrites, were 
observed floating in culture on day 8. Ultrastructural analysis by Transmission Electron 
Microscopy (see section 2.7 for details) of day 8 dendritic cells clearly revealed the 
presence of dendrites and a large irregularly-shaped nucleus (Figure 3.2). The cells were 
generally 10-20 µmin diameter, excluding dendrites. The cytoplasm contained many 
mitochondria but few electron dense granules representing lysosomal compartments 
involved in antigen processing. 
3.4 Immunophenotypic Analysis of Day 8 Dendritic Cells 
Cells on day 8 of culture were harvested and analyzed for the cell surface 
expression of a panel of standard dendritic cell markers by single-colour flow cytometry. 
Cells were stained (as described in section 2.8) with fluorescent-tagged or unconjugated 
primary monoclonal antibodies (section 2.5) specific for CDl lc (N418), MHC class I 
(34-1-2S) and class II (10.3.6) molecules, B7-1 and ICAM-1 (3E2). Appropriate 
fluorescent secondary reagents (section 2.5.1) were used where required. Unlabelled 
cells or cells incubated with appropriate secondary reagents were used as controls for 
directly conjugated or unconjugated antibodies, respectively. The N418 monoclonal 
antibody is used as a specific marker for murine dendritic cells (Metlay et al, 1990). In a 
typical culture, >80% of cells on day 8 displayed classic dendritic cell morphology. Flow 
cytometric analysis of these cells for standard dendritic cell surface markers confirmed the 
morphological observations described earlier. As shown in Figure 3.3, most of the cells 
on day 8 of culture stained positive for N418. Correspondingly, these cells expressed 
high levels of MHC class I and class II molecules. Furthermore, most of these cells were 
found to express the costimulatory molecule, B7 .1, and the adhesion molecule, ICAM-1. 
Inspite of the lack of isotype specific controls for staining antibodies, the above cell 
surface marker expression pattern mirrors that previously reported for both murine and 
human dendritic cells (Inaba et al, 1992a; Sallusto and Lanzavecchia, 1994). 
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Cells harvested on day 8 of a typical culture were stained for a selected panel of 
monoclonal antibodies specific for markers on mature dendritic cells and analyzed 
by single-colour flow cytometry. Shaded histograms represent the relative 
fluorescence of the marker shown. Unshaded histograms represent either unstained 
controls or appropriate secondary antibody control. Dead cells were eliminated 
from analysis by propidium iodide exclusion. Bars over histograms indicate 
percentage of viable cells positive for the particular marker shown. 
* It appears that dendritic cells are 5-fold n1ore efficient in presenting OV A323-339 to T cell 
hybridon1a cells than unfixed A20 cells since 5 times as n1any A20 cells were required to induce 
con1parable levels of IL-2 secretion (Figure 3 .4a). However, this conclusion needs to be 
validated by titrating the dose of antigen presenting cells with a fixed dose of peptide. 
3.5 
3.5.1 
Functional Analyses of Dendritic Cells 
Dendritic Cells Efficiently Present Peptide Antigen to a T cell 
Hybridoma 
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A key feature of dendritic cells is their ability to efficiently initiate T cell-mediated 
primary immune responses (Steinman, 1991). Immature dendritic cells actively acquire, 
process and present antigen to T cells. On maturation, however, dendritic cells down-
regulate their ability to acquire and process complex antigens but acquire a potent 
immunostimulatory capacity. The capacity of dendritic cells to present peptide and protein 
antigens (section 2.12) to T cells was compared with a murine (Balb/c-derived) Epstein 
Barr virus (EBV)-transformed B lymphoblastoid cell line, A20. Cultured Balb/c-derived 
bone marrow cells on day 8 were used as the source of dendritic cells. The antigens used 
were whole ovalbumin (OVA) and OV A323-339 peptide. The I-Ad restricted, OV A323-
339-specific T cell hybridoma, 3DO, was used as the responder population 
(Shimonkevitz et al, 1983). IL-2 secretion by the T cell hybridoma was used as a measure 
of T cell activation. The antigen presentation assay is described in detail in section 2.13. 
A description of the cell lines used in this assay and how they were maintained is 
provided in sections 2.3-2.4. Briefly, the assay was set up by co-culturing 2.5xl04 
unfixed A20 cells or 5x103 dendritic cells in triplicate wells with 3x1Q4 3DO T cell 
hybridoma cells, in presence of graded doses (two-fold serial dilutions) of protein or 
peptide antigen. Optimal numbers of dendritic cells and A20 cells required to present 
OVA and OV A323-339 were determined elsewhere (Prasad S., Honours Thesis, 1995). 
Both dendritic cells and A20 cells stimulated the 3DO T cell hybridoma cells in an 
antigen dose-dependent manner. It is evident from Figure 3 .4a that dendritic cells are 5-
fold more efficient in presenting OVA323-339 to T cell hybridoma cells than unfixed A20 
cells since 5 times as many A20 cells were required to induce comparable levels of IL-2 
* 
secretion. In contrast, dendritic cells appeared relatively less efficient in presenting whole 
ovalbumin (Fig.3.4b ). Whereas A20 cells presented both OVA and OV A323-339 equally 
well, the capacity of dendritic cells to present OVA was markedly reduced in response to 
the entire range of OVA concentrations where T cell response was detectable. This is 
consistent with the conclusion that mature dendritic cells are inefficient at acquiring native 
proteins and processing them into peptides (Sallusto and Lanzavecchia, 1994). 
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Cultured dendritic cells efficiently present peptide antigen to a T cell 
hybridoma. 
Five thousand Balb/c -derived dendritic cells or 2.5xl04 unfixed A20 cells were 
co-cultured in triplicate wells with 3xlo4 I-Ad-restricted, OV A323-339-specific 
3DO T cell hybridoma cells, in the presence of shown concentrations of OV A323-
339 (a) or OVA (b). IL-2 secretion by activated T cells was measured in culture 
supematants by the proliferation of the IL-2-dependent cell line, HT-2 (y-axis of 
both plots). Data is presented as mean of triplicate wells+- SE. 
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3. 6 Dendritic Cells Pulsed with Antigen Activate Primary 
Transgenic CD4 T Cells and Induce their Prolif era ti on 
For further functional characterization of the in vitro generated dendritic cells and 
for the purposes of subsequent analyses in this study, a flow cytometric-based functional 
assay was developed. This functional assay was developed to allow the frequency of 
responding T cells to be visualized and quantitated when antigen was presented by 
dendritic cells. The assay was performed using primary resting CD4 T cells from a T cell 
receptor transgenic mouse with the 3A9 T cell receptor. The 3A9 T cell receptor 
recognizes Hen Eggwhite Lysozyme (HEL)46-61 in the context of I-Ak (Ho et al, 1994). 
The assay is described in detail in section 2.14. Briefly, to synchronize T cell activation 
and limit antigen delivery, cultured dendritic cells were pulsed with antigen by incubating 
with 0.lµM HEL or 20µM HEL46-61 for 2 hours at 37°C. Two-fold serial dilutions of 
pulsed dendritic cells were co-cultured in triplicate wells with 3x 1 o5 total spleen and 
lymph node leukocytes, prelabelled with CFSE (section 2.11), from the 3A9 T cell 
receptor transgenic mice on the B 10.H-2k background, as source of transgenic CD4 T 
cells (Ho et al, 1994 ). The presence of the 3A9 T cell receptor trans gene was determined 
in advance by PCR (section 2.10) and reconfirmed by flow cytometry using the V~8.2 
monoclonal antibody (and co-staining with CD4) prior to setting up the assay. Negative 
control wells contained T cells with highest number of unpulsed dendritic cells. 
Activation of CD4 T cells was determined using flow cytometry by measuring the 
induction of the early activation marker, CD69, after 15 hr of culture. B cells were 
excluded from this analysis by negatively gating on B220+ cells. Representative flow 
cytometry data illustrating CD4 T cell response as a result of stimulation with dendritic 
cells pulsed with 20µM HEL46-61 is depicted in Figure 3 .Sa. In the absence of antigen, 
no induction of CD69 was observed on CD4 T cells (Fig.3.5a, left panel). In contrast, 
dendritic cells pulsed with 20µM HEL46-61 induced the expression of CD69 on >80% of 
CD4 T cells (Fig. 3.5a, right panel). Graphical representation of the results obtained 
during this functional assay is shown in Fig.3.5b. A clear titration curve of CD69 
induction is seen in response to graded doses of dendritic cells pulsed with HEL46-61 , 
with > 1 x 1 o3 dendritic cells per well inducing maximal CD69 expression. Dendritic cells 
pulsed with HEL, however, exhibited a reduced capacity to induce CD69 on CD4 T cells. 
Just over 25% of T cells express CD69 in response to the highest dose of dendritic cells 
pulsed with HEL. This reduced capacity of dendritic cells to present whole protein 
antigens mirrors the pattern already observed iri the previous assay in which dendritic 
cells inefficiently presented OVA to 3DO T cell hybridoma cells. This reduced capacity of 
dendritic cells to present native HEL protein may be attributable to either their inability to 
process complex protein antigens or to the suboptimal (non-saturating) concentration of 
HEL used in the assay. 
* Fig. 3.5 
Note: A role for B cells, present in culture, in antigen presentation would require HEL46-61 
loaded onto dendritic cells to be shed or transferred to the B cells. Dendritic cells pulsed with 
HEL46-61 and cocultured with transgenic B cells specific for HEL were unable to induce CD69 
expression on the B cells (Townsend and Goodnow, 1998). 
# HEL used in this assay was purchased from Sigma and prepared by 3x crystallization, 
followed by dialysis and lyophilization ( ~95 % purity). High concentration stock solutions were 
prepared, aliquoted and stored at -20°C. Stock solutions were thawed for single use only. 
Figure 3.5 
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Day 8 dendritic cells were initially pulsed with 20mM HEL46-61 or 0. lmM HEL 
by incubating dendritic cells with relevant antigen for 2 hr at 37°C. Pulsed dendritic cells were washed, serially diluted and cocultured in triplicate wells of 96 
microwell plates in the presence of 3x105 total spleen and lymph node leukocytes 
from mice carrying the 3A9 T cell receptor transgene on the B 10.H-2k background. Spleen and lymph node leukocytes were pre-labelled with CFSE. T 
cell activation was measured by flow cytometry using the early activation marker, CD69, after 15 hr of incubation. Specific activation of CD4 T cells was determined by co-staining cells with anti-CD4 monoclonal antibody (GKl.5). The level of CD4 T cell proliferation was similarly determined by measuring CFSE dilution 
after 72 hr of culture. 
(a) Representative FACS data illustrating CD4 T cell activation in response to 
stimulation with unpulsed dendritic cells (left panel) or dendritic cells pulsed with 20mM HEL46-61 (right panel). B cells were excluded from this analysis by 
negatively gating on B220+ cells. 
(b) Dose ·response of CD4 T cell activation in response to stimulation with HEL46-61 or HEL pulsed dendritic cells. 
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Figure 3.6 
pulsed with HEL46-61 
--0-- HEL46-61 
...... ,0.,, ...... HEL 
Cultured dendritic cells induce proliferation of a primary transgenic CD4 T 
cell. 
(a) Representative FACS plots illustrating CD4 T cell proliferation in response to 
stimulation with unpulsed dendritic cells or dendritic cells pulsed with 20µM 
HEL46-61. The inclusion of counting beads enabled absolute quantitation of 
responding CD4 T cells (rectangular region in top panel). Numbers in quadrants 
represent percent CD4 T cells in that quadrant. 
(b) Dose response of CD4 T cell proliferation in response to stimulation with 
HEL46-61 or HEL pulsed dendritic cells. Dose response data is presented as mean 
of triplicate wells +- SE. Note: CD69 induction and CFSE dilution are also 
observed in CD4 negative cells. These are mainly CD4 and CDS double negative T 
cells, arising from transgene induced anomaly in thymic selection, that are 
exported to the periphery. 
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The level of CD4 T cell proliferation induced by antigen-pulsed dendritic cells was 
determined by flow cytometry by measuring CFSE dilution (Lyons and Parish, 1994) 
after 72 hr of culture. Prior to acquisition on the flow cytometer, stained cell samples 
were resuspended in medium containing a known concentration of polystyrene 
fluorospheres (counting beads). The inclusion of counting beads in each sample enabled 
quantitation of the absolute number of proliferating CD4 T cells. Representative flow 
cytometry plots depicting how CD4 T cell proliferation was quantitated is illustrated in 
Figure 3.6a. The proliferation pattern observed on day 3 essentially mirrored the pattern 
of CD69 expression described previously (Fig.3.5). As in the case of CD69 induction, a 
clear titration curve of CD4 T cell proliferation was observed in response to graded doses 
of dendritic cells pulsed with HEL46-61, with >lxlo3 dendritic cells per well inducing 
maximal CD4 T cell proliferation (Fig.3.6b). CD4 T cell proliferation induced by 
dendritic cells pulsed with HEL was markedly lower than that induced by dendritic cells 
pulsed with HEL46-61 across the whole range of dendritic cell doses used. 
The primary CD4 T cell activation and proliferation assay described above 
provides two significant advantages in assaying antigen presenting cell function in vitro. 
Firstly, the assay employs resting primary CD4 T cells instead of T cell clones or T 
hybridoma cells. The use of primary CD4 T cells in vitro provides a closer picture of CD4 
T cell function under physiological conditions. Secondly, the above flow cytometric-
based assay allows single cell resolution of activation and proliferative efficiencies of 
CD4 T cells. 
3. 7 Discussion 
The liquid culture system of generating dendritic cells, pioneered by Inaba et al 
(1992a), was adapted and successfully established and utilized during the course of this 
study. The availability of such culture systems has facilitated extensive characterization of 
dendritic cells by bypassing the use of tedious purification protocols required to isolate 
this trace cell type residing in most tissue. The discovery that GM-CSF stimulation of 
hematopoietic precursors in vitro resulted in the generation of dendritic cells has been a 
major advance in the study of dendritic cell biology. In vitro generated dendritic cells have 
enabled extensive cellular, biochemical and molecular characterization of this unique cell 
type. 
The liquid culture system employed lymphocyte-depleted bone marrow cells as 
precursors of dendritic cells. Myeloid precursors stimulated with GM-CSF and IL-4 
followed a course of development as described previously (Inaba et al, 1992a, Sallusto 
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and Lanzavecchia, 1994 ). This culture system consistently generated approximately 1.5-
2x 106 dendritic cells per 2 donor mice, with >80% purity, after 8 days of culture. This 
yield of dendritic cells is low compared to that reported by Inaba et al ( 1992a) who 
generated 5x106 dendritic cells per mouse at 60% purity. Most recently, an advanced 
method for generating large quantities of highly pure dendritic cells from mouse bone 
marrow cells has been described (Lutz et al, 1999). The advanced method incorporates a 
number of modifications in the protocol established by Inaba et al ( 1992a). These 
modifications include: (i) avoidance of antibody-mediated depletion of lineage positive 
cells in the bone marrow to circumvent precursor loss, (ii) reduction in the density of cells 
plated, (iii) lengthening the culture period to 10-12 days, and (iv) reduction of the GM-
CSF dose from day 8 or 10 onwards to minimize granulocyte contamination. 
Microscopic analysis showed that individual dendritic cells were released from 
loosely-adherent, proliferating clusters. Ultrastructural analysis of these cells suggested 
the presence of primarily mature dendritic cells. This was indicated by the absence of 
numerous cytoplasmic electron dense granules representing lysosomal compartments 
involved in the generation of peptide epitopes by processing of complex protein antigens. 
Analysis of a panel of cell surface markers characteristic of dendritic cells substantiated 
this observation as almost all of day 8 cells uniformly expressed high levels of MHC 
class I and class II molecules. Furthermore, most of these cells expressed the 
costimulatory molecule, B7.1, and the adhesion molecule, ICAM-1. Thus, as known for 
mature dendritic cells in vivo, cultured dendritic cells were appropriately-equipped to 
efficiently activate T cells (Banchereau and Steinman, 1998). The expression of high 
levels of MHC molecules allows presentation of more T cell determinants, while adhesion 
molecules serve to cluster T cells. Costimulatory molecules expressed on dendritic cells 
may reduce the threshold for T cell activation or qualitatively regulate the nature of a T cell 
response. 
Functional analysis of day 8 dendritic cells provided further evidence supporting 
the presence of mainly mature dendritic cells. These cells efficiently presented peptide 
antigens to T cells but were found to be relatively inefficient in presenting whole protein 
antigens. Two antigen presentation assays with distinct antigens and responder T cells 
were employed in this study. Firstly, dendritic cells were less efficient in inducing IL-2 
secretion by the 3DO T cell hybridoma in response to OVA, compared with control A20 
cell lines. However, dendritic cells presented the already processed OVA323-339 more 
efficiently than A20 cells. Secondly, dendritic cells pulsed with HEL appeared less 
efficient in inducing CD69 expression on primary, transgenic CD4 T cells. In contrast, 
equivalent numbers of dendritic cells pulsed with HEL46-61 were able to induce maximal 
CD69 expression. The apparent inability of dendritic cells to present HEL could be due to 
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the suboptimal (non-saturating) concentration of HEL used and not solely due to the 
down-regulated antigen processing capacity of mature dendritic cells. Coincident with 
their ability to induce maximal CD69 expression, dendritic cells pulsed with HEL46-61 
efficiently induced proliferation of antigen specific primary CD4 T cells. Taken together, 
these results indicated that dendritic cells generated in the liquid culture system utilized in 
this study, produced mainly mature dendritic cells. This state of maturation was reflected 
in morphological, phenotypic and functional analyses. The failure to efficiently process 
and present protein antigens suggested that these dendritic cells had down-regulated their 
antigen processing capacity. Unlike in the human dendritic cell culture system, the trigger 
for maturation in the murine dendritic cell culture system remains to be identified. It is 
possible that factors derived from foetal calf serum or baculovirus-derived growth factors 
may be responsible for dendritic cell maturation in this culture system. Furthermore, the 
physical stress involved in subculturing cells is also thought to contribute towards 
dendritic cell maturation. 
Biochemical events underlying the process of dendritic cell maturation have 
recently been studied in both cultured human and murine dendritic cells (Cella et al, 1997; 
Pierre et al, 1997). Key findings in both systems include the demonstration that immature 
dendritic cells are active in the biosynthesis of MHC class II molecules and peptide 
loading. Newly synthesized MHC class II molecules are mainly targeted to lysosomal 
compartments and MHC class II-peptide complexes are only transiently expressed on the 
cell surface as they are rapidly removed and degraded. The process of maturation entails a 
10-fold increase in cell surface half life of MHC class II molecules, with newly 
synthesized MHC class II molecules mainly targeted to the cell membrane. The increased 
half life of cell surface MHC class II molecules is critical as it allows sufficient time for 
the antigenic cargo of dendritic cells to be scanned by T cells. 
As previously mentioned, factors inducing maturation in cultured human dendritic 
cells are known and include TNFa and CD40 ligand (Sallusto and Lanzavecchia, 1994 ). 
Remarkably, stimulation of human dendritic cells for 24 hour with TNFa or CD40L 
results in two- to three-fold increase in cell surface MHC class II, ICAM-1, LFA-3, 
CD40 and B7. The functional consequences of these changes entailed enhanced T cell 
stimulatory capacity and a reduced ability to present protein antigen. These observations 
suggest that under physiological conditions dendritic cell maturation may be induced by 
inflammatory stimuli or interaction with T cells. Consistent with this, it has also been 
shown that systemic administration of LPS into mice induces the maturation and 
redistribution of marginal zone dendritic cells in the spleen to the T cell zone (De Smedt et 
al, 1996). 
* However, GM-CSF transduced tun1or cells have been shown to elevate dendritic cell nun1bers 
in vivo (Hanada et al, 1996). 
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Although substantial numbers of dendritic cells can be generated in in vitro 
cultures by stimulating myeloid precursors in the presence of GM-CSF, it is unlikely that 
a similar sequence of developmental events occur in the bone marrow or blood, both of 
which have been the source of precursors for culture (Inaba et al, 1992a and b ). Mature 
dendritic cells are detectable neither in bone marrow nor in blood. Inaba et al ( 1992a) 
suggest that immature dendritic cell progeny are exported from the bone marrow into the 
circulation from where the progeny are able to populate tissue. In contrast to the in vitro 
capacity of GM-CSF to generate dendritic cells, GM-CSF or GM-CSF and IL-4 treatment 
of mice did not result in significant increase in dendritic cell numbers in vivo 
* (Maraskovsky et al, 1996J. ·r o date only the hematopoietic growth factor Flt-3 ligand 
(Lyman et al, 1993) is known to stimulate excess dendritic cell production in vivo. It had 
been previously shown that in vivo administration of Flt-3 ligand dramatically increased 
the number of hematopoietic progenitors in the bone marrow, blood and spleen, resulting 
in elevated levels of myelopoiesis and lymphopoiesis (Brasel et al, 1995; Brasel et al, 
1996). Maraskovsky et al (1996) have demonstrated that treatment of mice with Flt-3 
ligand results in substantial increase in the number of functionally mature dendritic cells in 
vivo. In Flt-3 ligand-treated mice, absolute number of MHC class rr+ and CDl lc+ cells 
was increased 17-f old in the spleen, 4-fold in the inguinal and axillary nodes and 6-f old 
in the peripheral blood. These results, however, must be interpreted taking into account 
that Flt-3 ligand treated spleens are 2-3 fold larger than control spleens, and splenic 
architecture appears disrupted (Pulendran et al, 1997). 
Dendritic cells generated in vitro provide a source of potential vehicles for cellular-
based immunotherapy. The availability of substantial number of dendritic cells has made 
it possible to test dendritic cell-based immunization regimes, especially with the intention 
of eliciting CTL responses against tumor antigens (Young and Inaba, 1996). Numerous 
studies in experimental animal models have demonstrated the feasibility of such an 
approach. Immunization of mice with dendritic cells pulsed with synthetic peptides 
(Mayordomo et al, 1995; Celluzzi et al, 1996), eluted peptides from tumor cell lines 
(Zitvogel et al, 1996) and intact soluble proteins (Paglia et al, 1996) induce protective 
CTL responses against tumors. In vitro generated dendritic cells pulsed with tumor 
antigens and injected into animal tumor models have been shown to elicit anti-tumor 
immune responses, resulting in protection against tumors and reduction of established 
tumors (Specht et al, 1997; Song et al, 1997; Schuler and Steinman, 1997). Various 
modes of using dendritic cells as vehicles for tumor antigens are possible and are curently 
being investigated. Viral vectors, naked and plasmid DNA, RNA, liposomes with nucleic 
acids of proteins, tumor lysates, apoptotic cells and peptides could also be delivered via 
dendritic cells. 

Functional and Developmental 
Dendritic Cells Generated from 
NOD.H-2k Congenic Strains 
4 .1 Introduction 
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Analyses of 
B10.BR and 
Autoimmune diabetes is a complex polygenic disease. Genetic susceptibility to 
autoimmune diabetes is conferred by susceptibility loci within and outside the MHC in the 
NOD mouse model. It has now become clear that non-MHC diabetogenic loci create an 
overall susceptibility to autoimmunity in the NOD mouse (Wicker, 1997). Against the 
autoimmune prone NOD background, alleles within the MHC appear to determine the 
target tissue for autoimmune destruction. Autoimmune pathology may be directed against 
the pancreas, thyroid or salivary glands, depending on the genotype of the MHC on the 
NOD background. A simplified summary of NOD genetics and how target tissues for 
autoimmune destruction may be altered, depending on the genotype of the MHC, is 
illustrated in Figure 4.1. 
Several lines of evidence suggest that part of the genetic predisposition to 
autoimmune diabetes resides in hematopoietic stem cells which give rise to antigen 
presenting cells. In radiation chimeric mice, bone marrow-derived cells from NOD mice 
can reconstitute diabetes susceptibility in disease-resistant strains (Serreze et al, 1988; 
Wicker et al, 1988). It is not known whether this susceptibility resides in lymphocytes or 
antigen presenting cells. Myeloid-derived dendritic cells and macrophages have been 
shown to constitute the initial infiltrate into pancreatic islets of prediabetic young NOD 
mice, prior to infiltration by lymphocytes (Jansen et al, 1994). Furthermore, dendritic 
cells and macrophages have been demonstrated to be the initial and principal producers of 
TNFa in pancreatic islets (Dahlen et al, 1998). TNFa has been shown to have a critical 
role in the initial stages of islet autoimmunity (Green et al, 1998; Yang et al, 1994). Given 
that dendritic cells have a well established role in promoting T cell responses in processes 
like rejection of tissue grafts in vivo (Lafferty et al, 1983) and generation of T helper 1 
type responses in vitro (O'Garra and Murphy, 1994 ), a role for dendritic cells in 
mediating tissue-specific autoimmunity is possible. Interestingly, a recent study has 
demonstrated that repeated priming with dendritic cells, bearing a self antigen that is 
transgenically expressed in the pancreatic islets, results in severe and rapid onset of 
diabetes. A striking feature of the pathology induced by the repeated priming with 
dendritic cells is the formation of secondary lymphoid-like structures in the islets, 
ultimately leading to tissue destruction (Ludewig et al, 1998). 
Figure 4.1 
The genotype of the MHC, on the NOD background, determines target 
tissue for autoimmune destruction while non-MHC NOD genes confer 
overall susceptibility to tissue-specific autoimmunity. 
Studies in NOD.H-2 congenic strains underscore the differential roles of MHC and non-
MHC genes in tissue autoimmunity. Firstly, the NOD MHC (H-2g7) is essential but 
insufficient to induce diabetes. This is demonstrated by the absence of diabetes in the 
NOD.H-2k and converse B lO.H-2g7 congenic strains. Secondly, the genotype of the 
MHC, on the autoimmune-prone NOD background, determines target tissue for 
autoimmune destruction. This is demonstrated by the presence of tissue autoimmunity 
against altered targets in NOD.H-2h4 or k and NOD.H-2b congenic strains. The presence 
of H-2h4 or k or H-2b on the NOD background renders NOD mice susceptible to 
autoimmune thyroiditis or sialitis, respectively. Altogether, these observations implicate 
non-MHC NOD genes in creating an overall susceptibility to tissue-specific 
autoimmunity. 
Figure 4.1. Simplified Summary of NOD Mouse Genetics 
Strain H-2 Genes 
NOD 
+ 
NOD 
NOD.H-2k + 
B10.H-2k 
NOD.H-2h4 + 
BlO.H-2h4 
NOD.H-2b + 
B10.H-2b 
Bl0.H-2g7 
+ 
NOD 
B10.H-2k + 
B10.H-2k 
Non-H-2 Genes 
NOD 
NOD 
NOD 
NOD 
B10.H-2k 
B10.H-2k 
---•• Diabetes 
---•• Little Insulitis 
No diabetes 
Low incidence 
thyroiditis 
---•• Thyroiditis 
---•• Sialitis 
---•• No Diabetes 
No Insulitis 
No Sialitis 
No Thyroiditis 
---•• No Diabetes 
No Insulitis 
No Sialitis 
No Thyroiditis 
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4.2 Objective: 
The preceding evidence is suggestive of a potential role of dendritic cells in the 
initiation and maintenance of peripheral tissue-specific autoimmunity. This study, 
therefore, attempted to explore functional and developmental differences in dendritic cells 
generated from bone marrow cells derived from the autoimmune prone NOD.H-2k and 
autoimmune-resistant B 10.BR congenic mice strains. The B 10.BR congenic strain 
(hereafter referred to as 'B 10.H-2k') was developed by first outcrossing C57BL/10 strain 
to the C57BR strain (donor of the H-2k haplotype), followed by 8 generations of 
backcrossing (N9) to the C57BL/10 strain (Genetic Variants and Strains of the 
Laboratory Mouse, edited by Lyon and Searle, 1990). The NOD.H-~k strain was 
similarly developed by outcrossing NOD mice with the B 10.H-2k congenic strain 
(Podolin et al, 1993), followed by 5 generations of backcrossing (N6) to NOD mice. A 
proportion of NOD.H-2k congenic mice have been shown to develop spontaneous 
autoimmune thyroiditis (Damotte et al, 1997). The earliest sign of disease onset occurred 
in mice > 15 weeks old. The annual cumulative incidence of autoimmune thyroiditis in 
NOD.H-2k was approximately 20%. The NOD.H-2k congenic strain, however, gets 
neither insulitis nor diabetes but does display a mild leukocytic infiltration in the 
periductal or perivascular regions of the pancreas (Podolin et al, 1993). 
The B 10.H-2k and NOD.H-2k congenic strains provide excellent models for the 
study of autoimmune-resistant and autoimmune-prone genotypes. Specifically, by being 
identical for MHC genes of the 'k' haplotype, these strains allow the investigation of the 
role of non-MHC NOD genes in autoimmune pathology. As mentioned previously, non-
MHC diabetogenic loci create an overall susceptibility to autoimmunity in NOD mice 
(Wicker, 1997). At least part of this susceptibility is due to non-MHC genes in 
hematopoietic cells beacause bone marrow grafts from NOD mice can reconstitute 
diabetes in MHC-congenic disease-resistant strains such as (NODxB l0.H-2g7)Fl 
hybrids (Serreze et al, 1988; Wicker et al, 1988). Importantly, there is evidence to 
suggest that dendritic cells are critical in the initiation and maintenance of autoimmune 
responses against peripheral tissue. In light of the preceding evidence, it is possible that 
non-MHC NOD genes alter dendritic cell function, thus making the NOD mouse prone to 
tissue autoimmunity. The current study employs experience in dendritic cell production 
and functional assays developed in the previous Chapter to explore what effect, if any, 
non-MHC NOD genes have on dendritic cell function. 
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4. 3 Functional Analyses of Cultured Bone Marrow Cells 
Bone marrow cell cultures to generate dendritic cells and antigen presentation-T cell 
activation assays developed in the previous Chapter were used to test the hypothesis that 
non-MHC diabetes susceptibility genes from NOD mice act by altering dendritic cell 
function. An in vitro flow cytometric-based functional assay, developed in the previous 
Chapter and described in detail in section 2.14, was used to determine the ability of 
cultured bone marrow cells, derived from B 10.H-2k and NOD.H-2k mice, to activate 
CD4 T cells and induce their prolif era ti on. The design of this assay enables single cell 
resolution of activation and proliferation efficiencies of responding T cells. The assay was 
performed by harvesting cells, cultured in the presence of GM-CSF and IL-4, on day 8 of 
culture and using them as antigen presenting cells. These antigen presenting cells were 
pulsed with 0.2µM or 2µM or 20µM HEL46-61 or 0.lµM HEL, washed by 
centrifugation, serially diluted and co-cultured in triplicate wells with CFSE-labelled 
lymph node and spleen leukocytes (3xlo5 per well) from mice carrying the 3A9 T cell 
receptor transgene on the B 10.H-2k background. The 3A9 T cell receptor transgenic CD4 
T cells are I-A k -restricted and specific for HEL46-61 (Ho et al, 1994). Activation of 
responder CD4 T cells was determined using flow cytometry by measuring the induction 
of the early activation marker, CD69, after 15 hr of culture. Proliferation of CD4 T cells 
was determined by measuring the level of CFSE dilution on days 3 and 5 of culture. 
Absolute cell numbers of proliferating CD4 T cells were determined by the inclusion of 
counting beads to each sample prior to acquisition on the flow cytometer. 
The activation of CD4 T cells was determined by flow cytometry by measuring the 
induction of the early activation marker, CD69 (Figure 4.2). Representative FACS plots 
illustrating the induction of CD69 expression on CD4 T cells by B 10.H-2k or NOD.H-2k 
myeloid antigen presenting cells is shown in Fig.4.2a. It was evident from Fig.4.2b that 
there was no apparent difference in the ability of antigen presenting cells, derived from 
B 10.H-2k or NOD.H-2k strains, to induce CD69 expression on CD4 T cells, under the 
various conditions employed during the course of this analysis. Maximal CD69 induction 
was observed when antigen presenting cells (6x103 per well) were pulsed with 20µM 
HEL46-61. In this instance, the highest number of antigen presenting cells induced CD69 
expression on 80% of CD4 T cells. 
The level of CD4 T cell proliferation on days 3 and 5 of culture, as measured by 
CFSE dilution, is shown in Figure 4.3. Graphical representations of the level of CD4 T 
cell proliferation on days 3 and 5 of culture are depicted in Fig.4.3a-b. A reproducible 
difference in the proliferation responses of CD4 T cells, induced by B 10.H-2k or 
Figure 4.2 
T cell activation by B10.H-2k versus NOD.H-2k myeloid cells. 
Bone n1arrow cells obtained fron1 B 10.H-2k and NOD.H-2k mice, depleted of 
lymphocytes and cultured in the presence of GM-CSF and IL-4 to generate dendritic 
cells. Cultured cells were harvested after 8 days, washed by centrifugation and pulsed 
with shown doses of HEL46-61 peptide or native HEL protein. Antigen pulsed cells were 
washed again to eliminate unbound antigen. Shown numbers of pulsed, viable bone 
marrow cells were added to triplicate wells and co-cultured with 3x105 CFSE-labelled 
spleen and lymph node leukocytes from mice expressing the 3A9 T cell receptor 
trans gene on the B 10.H-2k background. Expression of the early activation marker, 
CD69, on CD4 T cells was measured by flow cytometry after 15 hr of culture. 
(a) Representative FACS plots showing CD4 T cell activation in response to stimulation 
with antigen-pulsed or unpulsed 6x103 myeloid cells. Numbers in quadrants represent 
percentage CD4 T cells expressing CD69. 
(b) Mean percent CD69 positive CD4 T cells +/- SE in triplicate wells is shown as a 
function of the input number of viable antigen-pulsed myeloid cells. Data is representative 
of three independent experiments. 
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Proliferation of CD4 T cells measured by CFSE dilution 
10000 
10000 
Bone marrow cells from B10.H2k or NOD-H2k cultures were harvested on day 8, 
pulsed with antigen and co-cultured in triplicate wells with CFSE-labelled lymph 
node and spleen leukocytes from the 3A9 T cell receptor transgenic mice as 
described in Fig.4.2. Proliferation of CD4 T cells on days 3 ( 4.3a) and 5 ( 4.3b) was 
analyzed by measuring CFSE dilution using flow cytometry. Quantitation of the 
absolute number of CFSE-positive CD4 T cells was carried out by including 
known concentration of Coulter Counting beads in samples prior to acquisition. 
Mean number proliferated (CFSE-low) CD4 T cells +/- SE in triplicate wells is 
shown as a function of the input number of viable antigen-pulsed cells. Data 
presented is representative of three independent experiments. 
Fi~. 4.3 
Note : Total vi::1ble cells were not non11alized for dendritic cell number. 
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Figure 4.4 
Bone marrow cells from NOD.H-2k mice generate fewer dendritic cells in 
culture. 
The yield of viable dendritic cells from B10.H-2k and NOD.H-2k bone marrow 
cultures on days 5 and 8 was determined by flow cytometry using anti-MHC class 
II (10.3.6) or anti-CDl lc (N418) monoclonal antibody. Dead cells and cellular 
debris were eliminated from analysis by propidium iodide (PI) exclusion and 
appropriate forward and side scatter gating. 
(a) Representative FACS plots illustrating low yield of dendritic cells from 
NOD.H-2k cultures on days 5 and 8. Numbers near elliptical regions represent 
percentage total cells in that region. Numbers near quadrants represent percentage 
viable cells in that quadrant. MHC class II profiles represent viable cells only, 
using gates shown. 
(b) The yield of viable dendritic cells from individual mice is shown by circles, 
and columns represent mean values. Data is representative of 5 separate 
experiments. 
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NOD.H-2k myeloid-derived antigen presenting cells, was observed on day 3 when 
antigen presenting cells were pulsed with either 0.2µM HEL46-61 or 0. lµM HEL. The 
absolute number of proliferating CD4 T cells was markedly lower in response to NOD.H-
2k-derived antigen presenting cells pulsed with either 0.2µM HEL46-61 or 0.lµM HEL. 
On day 5, however, the proliferation curves appeared to converge presumably due to the 
logarithmic nature of proliferation. The day 3 results suggested a relative inefficiency of 
NOD.H-2k-derived antigen presenting cells to induce proliferation of CD4 T cells. 
However, these results became difficult to interpret as will become evident from data 
presented in Figure 4.4. 
4.4 Reduced Dendritic Cell Yield from NOD.H-2k Bone 
Marrow Cultures 
During the course of the preceding functional analyses, the yield of dendritic cells 
from the NOD.H-2k bone marrow cultures was found to be much lower than from 
B 10.H-2k cultures (Fig.4.4a-b). Flow cytometric analyses of viable B 10.H-2k- and 
NOD.H-2k-derived bone marrow cells on day 5 of culture for the cell surface expression 
of the N418 marker (CDl lc) or MHC class II molecules revealed that dendritic cells 
constituted 75% of the cells in B10.H-2k cultures, compared with 30% in NOD.H-2k 
cultures. Similary, dendritic cells constituted >80% cells in B 10.H-2k cultures on day 8, 
compared to only 15% in the NOD.H-2k cultures. Concomitant with the reduced number 
of dendritic cells, NOD.H-2k cultures contained a greater proportion of dead cells, as 
measured by propidium iodide staining. B 10.H-2k cultures contained 9.8% and 11.4% 
dead cells on days 5 and 8, respectively. In contrast, NOD.H-2k cultures contained 40% 
and 62.1 % dead cells on days 5 and 8, respectively.The previously observed inefficiency 
of NOD.H-2k-derived antigen presenting cells to induce proliferation of CD4 T cells may 
thus be accounted for by a relative deficiency in dendritic cell numbers in NOD.H-2k-
derived antigen presenting cell population. 
4.5 Reduced Dendritic Cell Yield is a Cell-Intrinsic 
Feature of NOD.H-2k Myeloid Precursors 
The reduced yield of dendritic cells from NOD.H-2k cultures prompted the question 
of whether or not this phenotype was cell-intrinsic to NOD.H-2k myeloid precursors. It 
was conceivable that NOD.H-2k myeloid cells in culture secreted factors which could 
inhibit the survival, proliferation and differentiation of NOD.H-2k myeloid precursors in 
an autocrine manner in vitro. If this were the case, paracrine effects on B 10.H-2k 
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myeloid precursors in co-culture would be likely. Alternatively, NOD.H-2k myeloid 
precursors may possess a genetic predisposition, underpinned by non-MHC NOD genes, 
to generate fewer dendritic cells in vitro. To resolve this issue, B 10.H-2k and NOD.H-2k 
bone marrow cells were co-cultured at a 1: 1 ratio and the cells generated from this culture 
analyzed by flow cytometry on days 5 and 8 of culture. The experimental design of this 
assay is illustrated in Figure 4.5. The allelic variants of the cell surface marker Ly5 
(CD45 or Leukocyte Common Antigen) expressed between B10.H-2k and NOD.H-2k 
mice (McClive et al, 1994) enabled flow cytometric analysis of strain specific cells in co-
culture. Cell surface Ly5 is expressed by all nucleated hematopoietic cells and readily 
detectable by flow cytometry using Ly5 monoclonal antibodies. Cells from the B 10.H-2k 
strain express the 'b' allotype of Ly5 whereas cells from the NOD.H-2k strain express 
the 'a' allotype. 
On day 5 of co-culture, MHC class II positive and negative cells were gated (Figure 
4.6a) and analyzed for Ly5 allotype expression. The majority (> 70%) of MHC class II 
expressing cells present on day 5 of culture were B 10.H-2k-derived ie. Ly5b positive 
(Fig.4.6b ). By contrast, MHC class II negative cells in the same co-culture were equally 
derived from either strain (Fig.4.6c ). On day 8 of culture, the bias of MHC class II 
positive cells towards B 10.H-2k origin was more extreme than observed on day 5 
(Fig.4.6d). As on day 5 of culture, MHC class II negative cells in the same culture on 
day 8 were equally derived from either strain (Fig.4.6e). Since B 10.H-2k myeloid 
precursors appeared to develop in co-culture like they would alone, it was concluded that 
the reduced capacity of NOD.H-2k myeloid precursors to generate dendritic cells in in 
vitro cultures was a cell-intrinsic feature of NOD.H-2k myeloid precursors. This data is 
the first demonstration of a cell-intrinsic phenotype of NOD.H-2k myeloid precursors 
which affects dendritic cell generation in vitro. 
4. 6 Heterogeneous Proliferation and Elevated Levels of 
Apoptosis in NOD.H-2k Bone Marrow Cultures 
A number of possibilities could account for the reduced yield of dendritic cells from 
NOD.H-2k bone marrow cultures. These include reduced proliferation, increased levels 
of apoptosis, inability to differentiate, or a combination of these factors attributable to 
NOD.H-2k myeloid precursors. In order to distinguish between these possibilities and to 
unravel the mechanisms contributing towards the reduced dendritic cell yield from 
NOD.H-2k bone marrow cultures, a flow cytometric-based in vitro proliferation and 
apoptosis assay ( described in detail in section 2.15) was designed to monitor the fate of 
bone marrow cells during the early days of culture. Bone marrow cells from either strain 
B 10.H2k (Ly5b) NOD.H-2k (Ly5a) 
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Ly5b e e Bone Marrow Cells 00 Ly5a 
Figure 4.5 
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Experimental design for mixed bone marrow cell cultures. 
In order to determine whether or not the reduced yield of dendritic cells from 
NOD.H-2k bone marrow cells was a cell-intrinsic feature of NOD.H-2k myeloid 
precursors, bone marrow cells from B 10.H-2k and NOD.H-2k were admixed and 
cultured in the presence of GM-CSF and IL-4. Bone marrow cells were aseptically 
harvested from the hind limbs of B 10.H-2k or NOD.H-2k mice and depleted of 
lymphocytes by complement-mediated lysis. A 1:1 mixture (lx106 leukocytes in 
total) of lymphocyte-depleted bone marrow leukocytes from both strains were 
cultured in lmL growth factor-supplemented RPMI. The relative production of 
dendritic cells in culture from each precursor pool was determined on days 5 and 8 
by flow cytometry using the cell surface-expressed allelic variants of Ly5 to 
distinguish between dendritic cells derived from the two strains. All nucleated 
hematopoietic cells from the B 10.H-2k strain express the'b' allotype of Ly5, while 
NOD.H-2k cells express the 'a' allotype. 
Figure 4.6 
Restricted ability of NOD.H-2k myeloid precursors to generate dendritic 
cells in vitro is a cell-intrinsic phenotype. 
Bone marrow cultures to generate dendritic cells were established as before, except input 
cells comprised a 1: 1 mixture of lx106 total lymphocyte-depleted bone marrow 
leukocytes from B 10.H-2k and NOD.H-2k mice. The relative production of dendritic 
cells from each precursor pool was determined on days 5 and 8 by flow cytometry using 
allelic variants of Ly5 to distinguish between dendritic cells derived from the two strains. 
(a) Dendritic cells (I-Ak -positive) and other cells (I-Ak -negative) were gated and 
analyzed for Lysa (NOD.H-2k -specific) and Ly5b (B 10.H-2k -specific) expression. 
(b) Relative proportions of dendritic cells from Lysa (NOD.H-2k) and Lysb (B 10.H-2k) 
origin at day 5. 
(c) Relative proportions of other cells from Lysa (NOD.H-2k) and Lysb (B 10.H-2k) 
origin at day 5. 
(d) and (e). Comparable analysis of the relative proportions ofLysa and Lysb cells at day 
8 of culture. Numbers in rectangular regions or quadrants represent percentage of total or 
MHC class II+ or - cells in that region or quadrant, respectively. Data is representative of 
three independent experiments. 
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were prelabelled with CFSE and cultured in the presence of GM-CSF and IL-4. 
Proliferation and apoptosis in the two cultures were analyzed by flow cytometry on days 
1-3. As before, the level of proliferation was measured by CFSE dilution and absolute 
numbers of dividing cells quantitated by the inclusion of counting beads in the assay. 
Apoptotic cells were detected by flow cytometry on the basis of their staining with 
the fluorescent, lipophilic dye, merocyanin 540 (MC540; Frey T., 1997; Mower Jr et al, 
1994; McEvoy et al, 1988). MC540 preferentially binds to cell membranes with loosely 
packed lipids. One of the earliest events in cells undergoing apoptosis is the loss of cell 
membrane integrity (Cohen et al, 1992). This occurs as a result of the translocation of 
phospholipid phosphatidylserines from the inner to the outer leaflet of the cell membrane. 
The externalization of phospholipid phosphatidylserines causes membranes to become 
loosely packed, thereby allowing lipid-intercalating reagents like MC540 to bind. In this 
respect, MC540 is like Annexin V which binds externalized phospholipid 
phosphatidylserines with high affinity (Vermes et al, 1995). Loss of membrane integrity 
during apoptosis precedes DNA fragmentation and permeability of membranes to DNA 
fluorophores like propidium iodide. Membrane permeability is also a feature of necrotic 
cells so propidium iodide staining does not distinguish between apoptotic and necrotic 
cells. MC540 was the reagent of choice for the flow cytometric detection of cells in early 
stages of apoptosis for the following reasons. Firstly, MC540 fluoresces in the FL-2 
channel on the flow cytometer and is ideal in combination with the FL-1 dye, CFSE, for 
simultaneous analyses of apoptosis and proliferation. Secondly, unlike Annexin V, 
MC540, being a dye, does not require conjugation to appropriate fluorochromes for such 
multiparameter analysis. Furthermore, MC540 is relatively inexpensive to purchase. 
Results from the above assay are presented in Figure 4.7. Representative flow 
cytometry data depicting how cell proliferation was determined are shown in histogram 
plots (Fig.4.7a). Myeloid precursors in B 10.H-2k cultures proliferated uniformly and 
generated a discrete population of cells that had undergone similar numbers of cell 
division (indicated by unimodal CFSE-low peak) on day 3 (Left panel). By contrast, 
NOD.H-2k myeloid precursors proliferated heterogeneously (Right panel). Aberrant 
proliferation in NOD.H-2k cultures was characterized by the presence of cells that had 
undergone variable numbers of cell division (indicated by the presence of sequential 
CFSE-low peaks), absent from B 10.H-2k cultures. Quantitation of the absolute number 
of proliferating cells is shown in Fig.4.7b. The absolute number of viable cells that had 
divided in the B 10.H-2k bone marrow culture doubled between days 2 and 3, but 
remained relatively stable in the NOD.H-2k culture during this period. 
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Figure 4.7 
Heterogeneous prolif era ti on and elevated levels of apoptosis and in 
NOD.H-2k bone marrow cultures. 
Bone marrow cultures to generate dendritic cells were established as before, except 
input cells were labelled with CFSE. 
(a) Cultures were analyzed on day 3 for proliferating (CFSE-low) and apoptotic cells 
(MC540+) by 2-colour flow cytometry. 
(b) Proliferation on days 1-3 as revealed by CFSE dilution in each of the cultures. 
(c) Apoptotic cells on days 1-3 were detected by MC540 positivity. Both relative 
and absolute numbers of MC54Q+ cells are shown. Data presented in (b) and ( c) is 
representative of three independent experiments. Circles represent actual value 
from bone marrow cultures derived from single mouse, and columns depict mean 
values. 
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* Alternatively, NOD-H.2k myeloid precursors may have an inherent inability to make multiple 
successive divisions, in addition to or independent of any tendency towards apoptosis. 
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The aberrant proliferation observed in NOD.H-2k bone marrow cultures may be 
attributable to either the variable rates of entry into successive divisions by NOD.H-2k 
myeloid precursors, increased cell loss between cycles, or both. To distinguish between 
these possibilities, cultures were further screened for the presence of apoptosis. 
Representative flow cytometry data depicting how apoptosis, on day 3 of culture, was 
determined is illustrated in the density plots in Fig.4.7a. It is evident from these plots that 
NOD.H-2k cells (Right panel) in culture exhibit a relatively higher incidence of apoptosis 
than B 10.H-2k cells (Left panel) in culture. Apoptotic cells, as represented by cells 
positive for MC540, are shown in the polygonal region. The small rectangular region on 
the same plots depicts co"unting beads added for the determination of absolute cell 
numbers. Approximately 10% of cells in B 10.H-2k bone marrow cultures underwent 
apoptosis on each of the first 3 days of culture (Fig.4.7c). By contrast, the level of 
apoptosis in the NOD.H-2k cultures was 13% on day 1 and increased to >25% on day 3. 
Furthermore, the absolute number of apoptotic cells in NOD.H-2k cultures was higher 
than in B 10.H-2k cultures on days 2 and 3. A high and comparable absolute number of 
apoptotic cells is detected in both cultures on day 1 as a result of cells unresponsive to 
growth factors undergoing apoptosis. These results indicate that heterogeneous 
proliferation of NOD.H-2k myeloid cells is accompanied by markedly elevated levels of 
apoptosis in culture. 
The preceding results clearly demonstrate that NOD.H-2k bone marrow cells in 
culture exhibit proliferative and apoptotic trends distinct from that exhibited by B 10.H-2k 
cells in culture. Taken together, the above results indicate that heterogeneous proliferati~n 
and elevated levels of apoptosis underpin the reduced dendritic cell yield generated from 
NOD.H-2k bone marrow cultures. The simplest interpretation of this data is that NOD.H-
2k cells have a much higher probability of undergoing apoptosis at each cell division, 
resulting in fewer cells making multiple divisions and a rising fraction of apoptotic cells. * 
4. 7 Heterogeneous Proliferation is Unique to NOD.H-2k 
Bone Marrow Cells in Culture 
It was concluded from the preceding data that non-MHC NOD genes confer on 
NOD.H-2k myeloid precursors an aberrant growth phenotype that was cell-intrinsic and 
manifested in the form of heterogeneous proliferation ( as indicated by cells undergoing 
variable numbers of cell division) and elevated levels of apoptosis in vitro. To examine 
whether this trait was uniquely conferred by non-MHC NOD genes, three other H-2k 
congenic strains, CBA/H, AKR and Balb.H-2k, were tested by the same in vitro 
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Bone marrow from the H-2k congenic strains, CBA/H, AKR and Balb.H-2k, were 
tested by the in vitro proliferation and apoptosis assay described in Fig.4.7. Bone 
marrow cultures from each of these strains were compared with parallel cultures 
from the B 10.H-2k strain. 
(a) Proliferation on days 2-3 as revealed by CFSE dilution in each of the cultures. 
(b) Representative proliferation profiles of selected strains. 
(c) Apoptotic cells on days 2-3 were detected by MC540 positivity. Circles 
represent value from bone marrow cultures derived from single mice, and columns 
depict mean values. 
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proliferation and apoptosis assay. Bone marrow cultures from each of these H-2k strains 
was compared with parallel cultures from the B 10.H-2k strain. 
Analysis of the levels of proliferation in the other H-2k strains revealed a trend 
that mirrored results obtained in the B 10.H-2k cultures (Figure 4.8a). Firstly, bone 
marrow cells from these strains proliferated uniformly and generated a discrete population 
of cells that had undergone similar number of cell divisions by day 3 of culture. This 
homogeneous nature of proliferation was indicated by the presence of a unimodal CFS E-
low population of cells on day 3, as illustrated in representative CFSE histograms 
(Fig.4.8b). Secondly, the absolute number of cells that underwent cell division (CFSE-
low cells), inspite of being variable between strains, doubled between days 2 and 3 in 
these cultures, as previously noted in the B 10.H-2k cultures. 
Concomitant with the homogeneous nature of proliferation, CBA/H, AKR and 
Balb.H-2k cultures exhibited variable but relatively stable levels of apoptosis on days 2 
and 3 of culture (Fig.4.8c ). The highest level of apoptosis, corresponding to 
approximately 30%, was detected in CBA/H cultures. The level of apoptosis in AKR 
cultures was approximately 10% and comparable to that observed in B 10.H-2k cultures. 
The level of apoptosis in Balb.H-2k cultures was approximately 20% and a slight 
increase was observed on day 3. 
4. 8 Discussion 
The results presented here illuminate for the first time cell-intrinsic effects of non-
MHC NOD genes on NOD.H-2k myeloid precursors, which alter dendritic cell 
generation in vitro. NOD.H-2k myeloid precursors, cultured in the presence of GM-CSF 
and IL-4, generated a very reduced yield of dendritic cells compared to precursors from 
the B 10.H-2k strain. This reduced yield was accounted for by precursor cells undergoing 
variable numbers of proliferative cycles and progressively increased levels of apoptosis in 
NOD.H-2k cultures. These phenotypes were unique to the NOD.H-2k background as 
other H-2k strains tested exhibited phenotypes comparable to the B 10.H-2k strain. 
Altogether, these results support the conclusion that non-MHC NOD genes confer on 
NOD.H-2k myeloid precursors unique and cell-intrinsic features which contribute 
towards the reduced yield of dendritic cells in vitro. 
Previous studies of culturing hematopoietic precursors, isolated from NOD mice 
have documented the reduced capacity of these precursors to form clusters and generate 
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antigen presenting cells, including dendritic cells (Serreze et al, 1993a and b; Langmuir et 
al, 1993; Morel et al, 1999). NOD bone marrow cells generated fewer colonies in vitro 
than Balb/c bone marrow cells, in response to stimulation with myeloid growth factors 
including GM-CSF, IL-3 and IL-5 (Langmuir et al, 1993). This phenotype, however, 
could not be replicated in vivo as NOD myeloid precursors generated comparable number 
of colonies in the spleen when injected into irradiated syngeneic recipients, compared 
with precursors from control Balb/c mice. In a related study, it was shown that CSF-1 
and IFNy stimulation of NOD bone marrow cells resulted in abnormal macrophage 
development and maturation (Sen·eze et al, 1993a and b ). Macrophages generated in vitro 
from disease-resistant strains secreted higher levels of LPS-stimulated IL-1 compared 
with macrophages generated from NOD bone marrow cells. Most recently, Morel et al 
(1999) have demonstrated that NOD-derived bone marrow cells, cultured in the presence 
of GM-CSF and IL-4, generate a lower yield of dendritic cells than diabetes-resistant 
B 10.H-2k bone marrow cells. Data generated in this study from the culture of B 10.H-2k-
and NOD.H-2k-derived bone marrow cells confirm the evidence provided by the 
preceding reports. Furthermore, the proliferation and apoptosis assay employed to 
analyze B10.H-2k and NOD.H-2k bone marrow cultures provide an important extension 
of previous findings by revealing mechanisms responsible for the reduced yield of 
dendritic cells from NOD.H-2k bone marrow cultures. Significantly, results described 
here demonstrate for the first time that the reduced yield of dendritic cells from NOD.H-
2k cultures is a phenotype cell-intrinsic to NOD.H-2k myeloid precursors. 
One mechanistic hypothesis to explain the observed outcomes during the culture of 
NOD.H-2k myeloid precursors would be impaired signalling transduced by GM-CSF. 
Since GM-CSF, IL-3 and IL-5 share a common P chain of the GM-CSF receptor 
(Miyajima et al, 1993), it is possible that the p common chain itself, and components 
proximally and/or distally involved, may be responsible for the in vitro phenotypes of 
NOD.H-2k myeloid precursors. Thus, the P common chain signal transduction pathway 
merits investigation in the context of autoimmune diabetes in NOD mice. It is conceivable 
that NOD.H-2k hematopoietic precursors transduce an exaggerated initial proliferative 
signal which in vitro is not matched by complementary survival/differentiation signal/s . 
This issue will be discussed in detail in the General Discussion (Chapter 6). 
As mentioned previously, several possibilities could explain the reduced yield of 
dendritic cells from NOD.H-2k bone marrow cultures. These possibilities include 
reduced proliferation, increased levels of apoptosis, inability to differentiate, or a 
combination of these factors attributable to NOD.H-2k myeloid precursors. The in vitro 
proliferation and apoptosis assay utilized in the analysis of bone marrow cultures 
69 
facilitated the resolution between the various possibilities. It was evident from bone 
marrow cultures that NOD.H-2k myeloid precursors underwent variable number of cell 
divisions (heterogeneous proliferation). In addition to the heterogeneous nature of 
proliferation, NOD.H-2k bone marrow cultures exhibited a progressive increase in the 
fraction of apoptotic cells during the course of culture. This reduces the number of 
NOD.H-2k precursors entering successive proliferative cycles. By contrast, myeloid 
precursors in B 10.H-2k cultures divided uniformly and underwent similar number of 
proliferative cycles. B 10.H-2k bone marrow cultures also exhibited a constant, relatively 
low fraction of apoptotic cells during the course of culture. Taken together, the simplest 
interpretation of these results is that heterogeneous proliferation is due to a much higher 
fraction of cells dying during each cell division, thus dramatically reducing the yield of 
dendritic cells from NOD.H-2k bone marrow cultures. 
The proliferation and apoptosis response of NOD.H-2k myeloid precursors, 
stimulated with GM-CSF and IL-4, was found to be uniquely conferred by non-MHC 
NOD genes. This finding potentially implicates myeloid-derived antigen presenting cells, 
especially dendritic cells, in the pathology of autoimmune diabetes. Consistent with the 
findings from this study of NOD.H-2k mice and studies conducted using the NOD 
mouse, in vitro hematopoietic growth defects have also been reported in human diabetics 
and prediabetics (Jansen et al, 1995; Takahashi et al, 1998). Dendritic cells generated 
from monocyte precursors isolated from blood of diabetics showed a reduced ability to 
cluster and to stimulate autologous and allogeneic T cells, compared to dendritic cells 
generated from healthy controls. Similarly, monocyte-derived precursors from the blood 
of prediabetics responded suboptimally in response to stimulation with GM-CSF and IL-
4 (Takahashi et al, 1998). In contrast to controls matched for age, sex and MHC 
genotype, precursors from prediabetics generated fewer dendritic cells which appeared 
phenotypically and functionally compromised. These dendritic cells expressed lower 
levels of costimulatory molecules on the cell surface and were relatively inefficient in 
stimulating autologous T cells. Overall, findings from the current study and studies in 
NOD mice and in human diabetics or prediabetics, suggest a potential dysregulation in the 
antigen presenting cell population, especially in dendritic cell function, which coexist with 
the onset and maintenance of autoimmune diabetes. 
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In Vivo Analysis of NOD.H-2k-derived Dendritic 
Cells 
5 .1 Introduction 
In vitro results described in the previous Results Chapter clearly demonstrated 
unique and cell-intrinsic effects of non-MHC NOD genes on NOD.H-2k myeloid 
precursors. These effects were manifested in the form of elevated levels of a pop to sis and 
fewer cells entering successive divisions and variable rates of division (heterogeneous 
proliferation), and consequent reduced dendritic cell yield, when NOD.H-2k myeloid 
precursors were cultured in the presence of GM-CSF and IL-4. By contrast, control 
B 10.H-2k myeloid precursors exhibited a basal level of apoptosis and proliferated 
homogeneously: growth factor responsive cells underwent a relatively uniform number of 
divisions and at a uniform rate, generating a greater yield of dendritic cells. 
Given the reduced capacity of NOD.H-2k myeloid precursors to generate dendritic 
cells in vitro, an expected in vivo correlate would be a deficiency in dendritic cell numbers 
in the NOD.H-2k mouse. However, since both GM-CSF and the~ common chain of the 
GM-CSF receptor are dispensable for dendritic cell production in vivo (Vremec et al, 
1997), the possibility of alternate physiological phenotypes, besides numerical deficiency 
of dendritic cells in NOD.H-2k mice, could not be discounted. There are precedents for 
growth factor redundancy in the development of lymphoid and myeloid cells under 
physiological conditions. These have been demonstrated in specific ligand and/or receptor 
deficient mice. For example, in vitro studies show that stem cell factor (SCF) synergizes 
with IL-7 to induce the proliferation and differentiation of B cell precursors (McNiece et 
al, 1991; Hirayama et al, 1992; Yasunaga et al, 1995). However, c-kit (receptor for SCF) 
is dispensable for the in vivo production of B cells since foetal liver cells from c-kit-
deficient mice can reconstitute immature and mature B cells in B and T cell-deficient 
RAG2-deficient mice (Takeda et al, 1997). Similarly, it has previously been reported that 
IL-3 can augment SCP-dependent mast cell development in vitro (Tsuji et al, 1991). In 
vivo results from IL-3-deficient mice again contradict in vitro findings by showing that 
IL-3 is not essential for the generation of mast ~ells or basophils under physiological 
conditions (Lantz et al, 1998). 
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The overall objective for this part of the study was, therefore, to extend the study 
of dendritic cells to a physiological context. Given the reduced capacity of NOD.H-2k 
n1yeloid precursors to generate dendritic cells in vitro, the initial objective of this part of 
the study was to quantitate the absolute numbers of primary splenic and thymic dendritic 
cells in B 10.H-2k and NOD.H-2k mice. The second objective for this part of the study 
was to determine the relative physiological capacity of B10.H-2k and NOD.H-2k myeloid 
precursors to reconstitute an irradiated host and generate dendritic cells in vivo. 
5.2 Presence of a Putative 'Immature' Dendritic Cell 
Population in Spleen and Thymus of NOD.H-2k Mice 
A possible in vivo correlate of the reduced capacity of NOD.H-2k myeloid 
precursors to generate dendritic cells in vitro was a numerical deficiency of dendritic cells 
in the NOD.H-2k mouse. In order to investigate this possibility, enumeration of B l0.H-
2k or NOD.H-2k splenic and thymic dendritic cells in vivo was performed by flow 
cytometric analyses of dendritic cells enriched from tissue. Since dendritic cells constitute 
only a trace population in tissue and are firmly attached to tissue stroma, splenic and 
thymic dendritic cells were released into single cell suspension by collagenase digestion 
of tissue and subsequently enriched by collecting low density cells after centrifugation on 
a metrizamide gradient (Vremec and Shortman, 1997). Dendritic cell-enriched low density 
cells were stained with N418 (anti-CDl lc) and anti-MHC class II monoclonal antibodies 
and analyzed by flow cytometry. As before, inclusion of counting beads in the assay 
enabled absolute quantitation of tissue-derived dendritic cells. Each dendritic cell 
quantitation experiment was performed by pair-wise analysis of B 10.H-2k and NOD.H-
2k spleen and thymus. Mice were matched for age and sex for this analysis. 
What became obvious during the initial attempts to quantitate dendritic cells in 
vivo, was a consistent difference in the cell surface expression of MHC class II molecules 
on both splenic and thymic dendritic cells from the B 10.H-2k and NOD.H-2k strains. 
Most splenic dendritic cells from B 1 O.H-2k mice expressed high levels of MHC class II 
molecules (Figure 5. la). Splenic dendritic cells from B 10.H-2k mice were represented 
mainly by a subset expressing high levels of cell surface MHC class II molecules. In 
contrast, dendritic cells from the spleen of NOD.H-2k mice were also represented by a 
sizeable population of MHC class II-low expressing dendritic cells. Furthermore, thymic 
dendritic cells from NOD.H-2k mice comprised predominantly dendritic cells expressing 
low levels of MHC class II molecules. The presence of dendritic cells expressing 
intermediate and low levels of MHC class II molecules in the spleen and thymus, 
respectively, of NOD.H-2k mice becomes clearer when the relative proportions of 
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Heterogeneity in cell surface MHC class II expression on splenic and thymic 
dendritic cells from NOD.H-2k mice. 
Dendritic cells from B 10.H-2k or NOD.H-2k spleen and thymus were obtained by 
collagenase digestion, followed by enrichment of dendritic cell-containing low 
density cells on metrizamide gradients. Low density cells were stained with anti-
MHC class II (10.3.6) and anti-CDl lc (N418) monoclonal antibodies and 
analyzed by 2-colour flow cytometry. Dendritic cells were gated on the basis of 
high forward scatter (relative size), CDl lc and MHC class II expression and 
quantitated against known concentration of counting beads included in the assay. 
(a) Representative FACS plots of spleen cells (top panels) or thymic cells (bottom 
panels) are shown. Numbers beside regions represent percentage of large, low 
density cells in that region. 
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Figure 5.1 
Heterogeneity in cell surface MHC class II expression on splenic and thymic 
dendritic cells from NOD.H-2k mice. 
(b) The ratio of MHC class II-high to MHC class II-intermediate dendritic cells in 
the spleen and thymus of B10.H-2k and NOD.H-2k mice. Columns show mean 
ratios, circles represent ratio from individual mice. Data is compiled from three 
separate experiments involving pair-wise analysis of B 10.H-2k and NOD.H-2k 
mice. The difference in splenic or thymic ratios between strains were tested for 
statistical significance using the Student's t test (paired). 
* p = 0.016, # p = 0.002 
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dendritic cells expressing high and intermediate/low levels of MHC class II molecules in 
each strain are considered. The ratio of MHC class II-high to intermediate expressing 
dendritic cells in the spleen of B 10.H-2k mice is approximately 2.5 (Fig.5.1 b ). In 
contrast, the ratio is significantly lower at approximately 1.0 (Student's t test (paired), p 
<0.02) in the spleen of NOD.H-2k mice. The ratio in the B 10.H-2k and NOD.H-2k 
thymus is approximately 1 and 0.25, respectively. Again, the ratio in the NOD.H-2k 
thymus is significantly lower (p = 0.002). The prevalence of dendritic cells expressing 
intermediate/low levels of MHC class II molecules in the spleen and thymus of NOD.H-
2k mouse indicates the presence of a putative immature dendritic cell subset. 
5.2.2 Comparable Absolute Numbers of Splenic and Thymic 
Dendritic Cells in Bl0.H-2k and NOD.H-2k Mice 
Quantitation of the absolute number of dendritic cells in vivo demonstrated that 
absolute counts were comparable between B 10.H-2k and NOD.H-2k strains in each 
experiment but showed substantial variation between experiments (Figure 5.2a,b). This 
variation between experiments may be attributed to the intervening manipulations required 
before the eventual dendritic cell count. Due to this variation, absolute count data is also 
presented as a ratio of the absolute number of B10.H-2k splenic or thymic dendritic cells 
to the absolute number of NOD.H-2k splenic or thymic dendritic cells from each 
experiment. It is clear from this analysis that the ratio is approximately 1 in both the 
spleen and the thymus, indicating that similar absolute numbers of splenic or thymic 
dendritic cells are present in B 10.H-2k and NOD.H-2k mice. Since the absolute number 
of splenic and thymic dendritic cells are comparable in both strains, this data suggests that 
NOD.H-2k mice contain a larger pool of immature dendritic cells, or a smaller pool of 
mature dendritic cells. 
5. 3 Skewing of the Myeloid Lineage of Cells towards 
NOD.H-2k Origin in Mixed Bone Marrow Chimeric 
Mice 
To determine the in vivo potential of NOD.H-2k hematopoietic stem cells and their 
progenitors, bone marrow reconstitution studies ·were performed. Mixed bone marrow 
chimeric mice were constructed by transferring into irradiated B 10.H-2k recipients an 
inoculum of total bone marro,v cells from B 10.H-2k and/or NOD.H-2k mice. There are 
important advantages with this experimental approach. Significantly, mixed bone 
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Figure 5.2 
Comparable numbers of splenic and thymic dendritic cells in B10.H-2k and 
NOD.H-2k mice. 
Dendritic cells from B 10.H-2k and NOD.H-2k spleen and thymus were obtained, 
stained and analyzed as described in Fig.5 .1. 
a) and b) Absolute numbers of splenic and thymic dendritic cells in B10.H-2k or 
NOD.H-2k mice as quantitated in 5 separate experiments. Columns represent 
absolute number from individual mice analyzed pair-wise during 5 separate 
experiments. 
c) Data is presented as ratio of the absolute number of splenic or thymic dendritic 
cells from B 10.H-2k mice to the absolute number of splenic or thymic dendritic 
cells from NOD.H-2k mice. Columns represent mean ratio from 5 separate 
experiments involving pair-wise analysis of B 10.H-2k and NOD.H-2k mice. 
Circles represent ratio from individual experiments. 
Figure 5.3 
The majority of blood monocytes in B/N->B chimeric mice are of 
NOD.H-2k origin. 
Irradiated B 10.H-2k recipients were reconstituted with B 10.H-2k bone marrow cells (B-
>B), NOD.H-2k bone marrow cells (N->B), or with a 1: 1 mixture of B 10.H-2k and 
NOD.H-2k cells (B/N->B). Recipient mice were analyzed by 3-colour flow cytometry for 
donor-derived leukocytes in blood 8-12 weeks post-reconstitution. B cells, T cells and 
monocytes in blood were analyzed by using B220, Thy 1 and Mac 1 monoclonal 
antibodies, respectively. As before, Ly5a was used to distinguish between NOD.H-2k-
and B 10.H-2k-derived cells. Representative FACS plots illustrate the relative 
reconstitution of myeloid and lymphoid lineages in red blood cell-depleted blood 
leukocytes in recipient nuce. Numbers in quadrants represent percentage of leukocytes in 
that quadrant. 
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marrow reconstitution studies should elucidate in vivo correlates of the cell-autonomous 
traits of NOD.H-2k myeloid precursors observed in vitro. Quantitative differences in 
myelopoiesis that may be masked when all cells are equivalent should become much more 
apparent under competitive reconstitution in mixed chimeric animals. Furthermore, flow 
cytometric analysis of reconstitution provides the sensitivity required to detect subtle 
quantitative differences in the reconstitution capacity of donor cells from either strain. As 
in the in vitro bone marrow co-culture experiment, allelic variants of Ly5, expressed on 
the cell surface by all nucleated hematopoietic cells, allows the resolution of strain-
specific cells. A further advantage is that progeny from B 10.H-2k precursors serve as an 
internal control such that differences in the relative proportions of progeny would reflect 
differences in absolute terms. Previous studies have employed mixed bone marrow 
chimeric mice to illuminate quantitative differences in B cell lymphopoiesis between non-
transgenic and immunoglobulin transgenic B cells (Cyster et al, 1994). Furthermore, 
mixed bone marrow chimeric mice have been utilized to demonstrate that the 
lymphoproliferation (lpr) mutation confers cell intrinsic over-proliferation of B and T 
cells (Sobel et al, 1991; Katagiri et al, 1988). 
For the construction of bone marrow chimeric mice, 2x106 total bone marrow 
leukocytes from B 10.H-2k or NOD.H-2k mice, or a mixture of the two, were used to 
reconstitute irradiated B 10.H-2k recipients. Four groups of bone marrow chimeric mice 
were generated. The first group comprised B 10.H-2k recipients reconstituted with 2x106 
B10.H-2k bone marrow cells alone (B->B), the second group comprised B10.H-2k 
recipients reconstituted with 2xlo6 NOD.H-2k bone marrow cells alone (N->B), the 
third group comprised NOD.H-2k recipients reconstituted with 2xlo6 B 10.H-2k bone 
marrow cells alone (B->N), and the fourth group comprised B 10.H-2k recipients 
reconstituted with a mixed inoculum comprising bone marrow cells from both B 10.H-2k 
and NOD.H-2k mice (total 2x106 cells) at a ratio of 1:1 (B/N->B). Recipient mice were 
analyzed by flow cytometry for donor-derived leukocytes 8-12 weeks post-reconstitution. 
As in the in vitro co-culture assays, the allelic variants of Ly5 were used to distinguish 
between B 10.H-2k (Ly5b) and NOD.H-2k-derived (Ly5a) cells. Co-staining with 
monoclonal antibodies against B cells (B220), T cells (Thyl) and myeloid cells (Macl) 
was used to monitor the relative reconstitution of myeloid and lymphoid lineages of red 
blood cell-depleted leukocytes in blood of recipient mice (Figure 5.3). 
In control N->B chimeric mice, almost all B cells and monocytes were NOD.H-
2k-derived(Lysa+), confirming efficient ablation of endogenous hematopoietic cells by 
the radiation regime employed, and efficient reconstitution with NOD.H-2k bone marrow 
cells (Fig.5.3b ). However, a proportion of host-derived, radio-resistant T cells still 
persist (Fig.5.3b, middle panel). Memory T cells are well established to be radio-resistant 
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(Sado et al, 1980). In contrast to B 10.H-2k recipients, efficient ablation of endogenous 
cells and reconstitution by donor bone marrow cells did not occur in the reciprocal control 
B->N chimeric mice (Figure 5.4). Almost all cells in this group of chimeric mice were 
host-derived. Similar resistance of NOD mice to bone marrow engraftment has been 
described (Kaufman et al, 1997). The B->B control group served as specificity controls 
for antibody staining for the Ly5 allotypes (Fig.5.3a). 
In B/N->B mice receiving the mixed bone marrow inoculum, Band T cells were 
derived in approximately equal proportions from the two donors (Fig.5.3c). In contrast, 
the majority of blood monocytes (Macl +) were of NOD.H-2k origin (Fig.5.3c, right 
panel). Like monocytes in blood, splenic and thymic dendritic cells in BIN->B group of 
mice were disproportionately of NOD.H-2k origin, with NOD.H-2k-derived dendritic 
cells constituting 87% total splenic dendritic cells and 82% thymic dendritic cells, 
respectively (Figure 5.5a-b). As in blood, B and T cells in the spleen and T cells in the 
thymus of B/N->B were practically even between the two donors (Figure 5.6). Analysis 
of multiple mixed bone marrow chimeric mice, from two separate experiments, is 
depicted in Figure 5.7. The mean ratio of NOD.H-2k to B10.H-2k leukocytes is 
approximately 1 for B and T cells in blbod and spleen, and for T cells in the thymus. In 
stark contrast, the ratios for monocytes, thymic dendritic cells and splenic dendritic cells 
are approximately 4, 3 and 6, respectively. While lymphocytes in blood, spleen and 
thymus of mixed bone marrow chimeric mice were almost evenly derived from both 
donors, the myeloid lineage of cells were disproportionately derived from the NOD.H-2k 
strain. 
The above skewing of the myeloid lineage of cells in mixed bone marrow chimeric 
mice prompted the question whether this skewing occurred in relative or absolute terms. 
It was possible that the relative skewing observed was underpinned by an increase in 
absolute cellularity in the myeloid compartment or reduced cellularity in the lymphoid 
compartment, or both. To pursue this question, whole blood and red blood cell-depleted 
(processed) blood leukocytes from bone marrow chimeric mice were stained for B cells, 
T cells, monocytes and Ly5a, and apalyzed by 3-colour flow cytometry. Coulter counting 
beads were added to whole blood samples for quantitation of target cell populations. 
Erythrocytes and platelets were excluded from whole blood analysis by gating on 
leukocytes on the basis of their forward scatter (relative size) and side scatter (relative 
granularity, log scale: left panel in top row of Figure 5.8a). Counting beads were 
similarly gated on the basis of their distinct scatter profiles. Parallel analysis of whole and 
processed blood enabled absolute quantitation of monocytes which are too infrequent to 
detect in 2µL whole blood using the flow cytometer. B cells are the most numerous 
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Figure 5.4 
NOD.H-2k recipients are resistant to engraftment. 
Bone marrow chimeric mice, using NOD.H-2k recipients, were constructed and 
analyzed for B cell reconstitution in blood as described in Fig.5 .3. Each panel 
represents individual NOD.H-2k recipient. 
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Specificity of Ly53 staining. 
(a) Splenic and thymic dendritic cells were obtained from B 10.H-2k mice, stained 
and analyzed as described in Fig.5.1 except cells were also stained with anti-Ly5a 
monoclonal antibody to demonstrate specificity of Ly5a staining. Splenic and 
thymic dendritic cells were gated on the basis of high forward scatter (relative 
size), MHC class II and CDl lc expression. Histograms demonstrate control Lysa 
staining of B 10.H-2k dendritic cells. Numbers next to rectangular regions 
represent percentage dendritic cells in low density, large cells. 
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The majority of splenic and thymic dendritic cells in BIN-> B mixed 
bone marrow chimeric mice are of NOD.H-zk origin. 
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(b) Splenic and thymic dendritic cells in B/N->B mixed bone marrow chimeric 
mice were analyzed as described in (a). Numbers in histograms represent 
percentage of dendritic cells that are NOD.H-2k-derived. 
Fig. 5.5 
Note: It appears that cells bearing the unique NOD.H-2k Fe receptor bind SA-TC. Hence, a 
subset of NOD.H-2k splenic cells exhibit intermediate fluorescence in the CDl lc channel. 
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Figure 5.6 
B cells and T cells in spleen and T cells in thymus of B/N-> B chimeric mice 
are derived in approximately equal proportions from both donors. 
Spleen and thymus harvested from BIN->B chimeric mice 8-12 weeks post-
reconstitution were digested with collagenase to obtain single cell suspensions. 
Cells were stained for B and T cell markers and analyzed by 3-colour flow 
cytometry. Numbers in quadrants represent the percentage of leukocytes in that 
quadrant. 
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Preferential generation of NOD.H-2k-derived myeloid lineage of cells in 
B/N->B chimeric mice. 
Summary data pooled from two separate bone marrow chimeric experiments 
showing the Lysa+ to Lysa- ratio of each of the shown leukocyte population in 
blood, spleen and thymus of B/N->B mixed bone marrow chimeric mice. Columns 
represent mean ratios, and circles represent ratio from individual mixed bone 
marrow chimeric mice. 
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leukocyte in whole blood and readily detectable and countable with the flow cytometer. 
The relative proportions of B cells and monocytes was determined by parallel analysis of 
processed blood leukocytes (after lysis of erythrocytes). The absolute number of 
monocytes could then be determined by multiplying the absolute number of B cells in 
whole blood by the ratio of monocytes to B cells in the same leukocyte fraction of the 
same blood sample. 
The previously described groups of bone marrow chimeric mice were used during 
this analysis. These groups included B10.H-2k recipients reconstituted with B10.H-2k 
bone marrow cells alone (B->B), or reconstituted with NOD.H-2k bone marrow cells 
alone (N->B), or reconstituted with a mixed inoculum comprising bone marrow cells 
from both B 10.H-2k and NOD.H-2k mice at a ratio of 1: 1 (BIN->B). Chimeric mice 
were micro-bled via the lateral tail vein 8 weeks post-reconstitution. As previously 
mentioned, nearly all B cells in whole blood of N->B chimeras were NOD.H-2k-derived 
(Fig.5.8c). Similarly, B cells in whole blood of B/N->B were equally derived from both 
B10.H-2k and NOD.H-2k donors. Graphical representation of the absolute numbers ofB 
cells in whole blood is illustrated in Fig.5.8d. Both B->B and B/N->B groups contained 
similar numbers of B cells at ~5xl04 B cells/µL of blood. In contrast, the total number of 
B cells in N->B, at ~3xl04 cells/µL blood, was significantly lower than the number of B 
cells in B->B (p = 0.008, Student's t test). As described above, whole blood and blood 
leukocytes were analyzed in parallel so that the frequency of more rare leukocytes could 
be determined by comparing their frequency relative to B cells. Absolute quantitation of 
monocytes in processed blood leukocytes of the three chimeric mice groups is shown in 
Fig.5.7e. It is clear that the skewing towards NOD.H-2k-derived monocytes in mixed 
bone marrow chimeric mice (B/N->B) occurs in absolute terms, with 2.5xl04 
monocytes/µL blood being NOD.H-2k-derived compared with only 5xl03 monocytes/µL 
that were B 10.H-2k-derived. Thus, the skewing towards NOD.H-2k-derived monocytes 
in B/N->B mixed chimeric mice is due to both the presence of a higher absolute number 
of NOD.H-2k-derived monocytes, and a lower absolute number of B 10.H-2k-derived 
monocytes. The results obtained from the above analysis are indicative of a preferential 
generation of NOD.H-2k-derived monocytes, and by inference the entire myeloid 
lineage of cells. Furthermore, these results suggest a possible predisposition of NOD.H-
2k myeloid precursors to over-produce myeloid cells at the expense of B cells. 
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Figure 5.8 
Skewing towards NOD.H-2k-derived monocytes in mixed chimeric mice 
occurs in absolute terms. 
The absolute number of B cells in whole blood of B->B, N->B and BIN->B 
chimeric mice was determined by staining whole blood in a one-step stain with a 
25µL monoclonal antibody cocktail containing antibodies against B cells (B220-
PE), T cells (Thyl.2-FITC) and Ly5a-Biotin (preincubated with SA-TC). Samples 
were not washed after incubation with stains but were diluted in RPMI containing 
counting beads and immediately taken for acquisition on the flow cytometer. 
(a) Counting beads were enumerated by gating on beads on the basis of their 
distinct forward and side scatter. 
(b) Absolute number of B cells were enumerated on the basis of B220 staining on 
gated leukocytes. 
( c) B cell reconstitution in bone marrow chimeric mice. 
Numbers next to regions or in quadrants represent the number of events in that 
region or quadrant. 
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Figure 5.8 
( d) The absolute number of B cells in whole blood of chimeric mice as determined 
in (a). * p = 0.008 (Student's t test) 
( e) The absolute number of monocytes was quantitated by multiplying the ratio of 
monocytes to B cells in red blood cell-depleted blood leukocytes with absolute 
number of B cells in the same sample of whole blood. Hatched columns show 
mean number B 10.H-2k derived leukocytes, while white columns show 
NOD.H-2k-derived leukocytes. Circles and squares represent values from blood of 
individual mice. 
5.4 CD8a· Splenic Dendritic Cells Account for the 
Skewing towards NOD.H-2k Origin in Mixed Bone 
Marrow Chimeric Mice 
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As previously mentioned, splenic dendritic cells in mixed chimeric mice were 
primarily of NOD.H-2k origin. Splenic and thymic dendritic cells in the mouse comprise 
two subsets, distinguished by differential cell surface CD8a expression (Vremec et al, 
1992; Pulendran et al, 1997). Each subset appears to occupy distinct microanatomic 
environments in the spleen. The CDSa- dendritic cells seem to be resident in the marginal 
zone of the spleen while the CDSa+ subset seem to reside in the T cell zone of the spleen. 
As yet there is no definitive evidence to assign functional specialization between subsets 
or to establish a precursor-progeny relationship between the two subsets. Interestingly, it 
has recently been reported that RelB selectively regulates the CDSa- dendritic cell subset 
in the spleen (Wu et al, 1998). It was, therefore, intriguing to ask which splenic dendritic 
cell subset in mixed bone marrow chimeric mice accounted for the pronounced skewing 
of splenic dendritic cells towards NOD.H-2k origin. Splenic dendritic cells from mixed 
bone marrow chimeric mice were prepared by collagenase digestion and enrichment on 
metrizamide gradient as previously described (Fig.5.1). Enriched splenic low density 
cells were stained with monoclonal antibodies against CDl lc, Ly5a and CD8a, and 
analyzed by flow cytometry. Large cells positive for CDl lc expression were gated and 
analyzed for Ly5a and CD8a expression (Figure 5.9a). The over-representation of 
NOD.H-2k-derived dendritic cells was primarily within the CDSa- subset, as the mean 
ratio of Ly5a+ to Ly5a- CDSa+ dendritic cells in mixed bone marrow chimeric mice was 
2.6, whereas it was 5.3 in the CDSa- subset (Fig.5.9b). Thus, the CDSa- dendritic cell 
subset in mixed bone marrow chimeric mice was primarily responsible for the over-
representation of splenic dendritic cells from the NOD.H-2k donor. The high ratio of 
CDSa- to CDSa+ splenic dendritic cells appeared to be a cell-intrinsic characteristic of the 
NOD.H-2k strain since dendritic cells from unmanipulated NOD.H-2k were 6.5: 1 in 
favor of CDSa- dendritic cells, whereas dendritic cells from unmanipulated B 10.H-2k 
mice were more evenly balanced at 1.5: 1 (Figure 5.10). The difference between the 
CDS a- to CDSa+ splenic dendritic cell ratios from unmanipulated B 10.H-2k and 
NOD.H-2k mice is statistically significant ( p = 0.0003, Student's t test). 
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Skewing towards NOD.H-2k-derived splenic dendritic cells in B/N->B is 
accounted for predominantly by the CD8a- dendritic cell subset. 
Splenic dendritic cells from mixed chimeric mice were obtained, stained and 
analyzed as described in Fig.5 .5. 
(a) Representative FACS plots illustrating relative proportions of splenic dendritic 
cell subsets in BIN->B chimeric mice. Numbers in quadrants represent percentage 
dendritic cells in that quadrant. 
(b) Data is presented as the mean ratio of Lysa+ to Lysa- dendritic cells (y-axis), 
against CD8a expression (x-axis). Columns represent mean ratios, and circles 
represent ratios from individual mice. 
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The bias towards the CDSa· dendritic cell subset is also observed in 
unmanipulated NOD.H-2k mice. 
Dendritic cells from spleen of unmanipulated B 1 O.H-2k and NOD.H-2k mice were 
prepared and analyzed for CD 1 lc, Ly5a and CD8a expression. 
(a) Representative FACS plots gated on N418 (CDl lc+) cells, illustrating relative 
proportions of splenic dendritic cell subsets in B 10.H-2k or NOD.H-2k mice. 
(b) Data is presented as the mean ratio of Lysa+ to Lysa- dendritic cells (y-axis), 
against CD8a expression (x-axis). For comparison, results from the same analysis 
using BIN->B mixed bone marrow chimeric mice is shown in the right panel. 
Columns represent mean ratios, and circles represent ratios from individual mice. 
* p = 0.0003, Student's t test. 
5. 5 Skewing towards CDSa · Dendritic Cell Subset in the 
Spleen is a Unique Feature of NOD.H-2k Mice 
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The intrinsic bias towards the production of CDSa- dendritic cell subset in the 
spleen appeared unique to the NOD.H-2k strain background. Other H-2k congenic 
strains, including CBA/H, AKR, Balb.H-2k and (B 10.H-2kxNOD.H-2k)Fl hybrids, 
showed CDSa- : CD8a+ dendritic cell mean ratios ranging from 1.6 to 3.5, in contrast to 
7 observed in the NOD.H-2k spleen (Figure 5.11). AKR mice had a ratio (1.6) 
comparable to that seen in the B 10.H-2k mice. CBA/H, AKR, Balb.H-2k and (B l0.H-
2kxNOD.H-2k)Fl hybrids had an intermediate ratio (3.5) relative to that seen in NOD.H-
2k mice. It was concluded from the preceding observations that the selective bias in 
mixed bone marrow chimeric mice towards NOD.H-2k-derived CDSa- dendritic cells 
was not only a cell-intrinsic but also a unique feature of NOD.H-2k hematopoietic stem 
cells as a similar bias is observed in the spleen of unmanipulated NOD.H-2k mice and not 
in other H-2k strains screened. It is interesting that Fl hybrids between B 10.H-2k and 
NOD.H-2k have an intermediate CDSa- to CD8a+ dendritic cell ratio. 
A further question arising from these observations was which splenic dendritic 
cell subset in NOD.H-2k mice accounted for the heterogeneity in cell surface MHC class 
II expression noted earlier (Figure 5.1), and whether this feature was peculiar to the 
NOD.H-2k background. Splenic dendritic cells from NOD.H-2k, B 10.H-2k, AKR, 
CBA/H, Balb.H-2k and (B 10.H-2k x NOD.H-2k)Fl hybrid mice were prepared by 
collagenase digestion and enrichment on metrizamide gradient as previously described. 
Enriched splenic low density cells were stained with monoclonal antibodies against 
CDl lc, MHC class II and CD8a, and analyzed by flow cytometry. Large cells positive 
for CDl lc expression were gated and analyzed for MHC class II and CD8a expression 
(Figure 5.12a). In all the H-2k congenic strains tested, heterogeneity in cell surface MHC 
class II expression was only evident in the CDSa- dendritic cell subset (lower left 
quadrants in all panels). In contrast, the CD8a+ dendritic cell subset uniformly expressed 
high levels of MHC class II molecules in all strains (Upper right quadrant in all panels). 
The heterogeneity in cell surface MHC class II expression resulted from the presence of 
CDSa- dendritic cells expressing both high and intermediate/low levels of MHC class II 
molecules. The largest proportion of dendritic cells expressing intermediate/low levels of 
MHC class II molecules was observed in the NOD.H-2k spleen where it constituted 35% 
of all splenic dendritic cells (Fig.5.12b ). The proportion of this subpopulation within the 
CDSa- dendritic cell subset did not exceed 12.1 % in all other H-2k strains tested. The 
mean proportions in the other H-2k strains were 12.1 % in B 10.H-2k, 3.5% in AKR, 
9.8% in CBNH, 4.3% in Balb.H-2k and 8.9% in (B10.H-2kxNOD.H-2k)Fl hybrids. 
The fact that Fl hybrids were like the B 10.H-2k parent implies that the NOD.H-2k trait is 
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Skewing towards the CDSa· dendritic cell subset in the spleen is unique to the 
NOD.H-2k background. 
Dendritic cells from the spleens of shown H-2k strains were prepared and analyzed 
as described in Fig.5.1. except cells were also stained with anti-CD8a monoclonal 
antibody. Dendritic cells were gated on the basis of high forward scatter (relative 
size), CD 1 lc and MHC class II positivity and analyzed for CD8a expression. 
Data is presented as the ratio of CDsa- to CDSa+ dendritic cells in the various 
strains. Columns represent mean ratios, and circles represent ratios from individual 
nnce. 
Figure 5.12 
Cell surface MHC class II heterogeneity is restricted to the CD8a -
dendritic cell subset and is unique to the NOD.H-2k background. 
Dendritic cells from spleens of shown H-2k congenic strains were prepared and analyzed 
as previously described. 
(a) Representative FACS plots illustrating the presence of CD8a- dendritic cells 
expressing intern1ediate and low levels of cell surface MHC class II molecules. Numbers 
in quadrants represent percentage dendritic cells in that quadrant. 
(b) Relative proportions of a putative immature dendritic cell subpopulation within the 
CD8a- subset in the various H-2k congenic strains. Columns represent 1nean 
proportions, and circles represent propo1iions from individual mice. 
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recessive. Thus, there is a relative over-representation in the NOD.H-2k spleen of a 
putative immature subpopulation of dendritic cells within the CD8a- dendritic cell subset. 
Furthermore, this feature appeared unique to the NOD.H-2k strain background. 
5. 6 Discussion 
In vitro results described in Chapter 4 revealed cell-intrinsic effects of non-MHC 
NOD genes on dendritic cell production. To explore in vivo correlates, experiments 
described in this Chapter examined the effects of non-MHC NOD genes on dendritic cell 
formation in vivo. Given the impaired ability of NOD.H-2k myeloid precursors to 
generate dendritic cells in vitro, the initial objective of this part of the study was to 
compare the formation of splenic and thymic dendritic cells in NOD.H-2k mice with 
B 10.H-2k controls. Quantitation of the absolute numbers of dendritic cells in NOD.H-2k 
and B 10.H-2k mice indicated the presence of comparable frequencies of dendritic cells in 
the two strains. Furthermore, an immature population of dendritic cells, peculiar to the 
NOD.H-2k background, was detected in the NOD.H-2k spleen and thymus. A further 
objective was to determine the relative capacity of NOD.H-2k and B 10.H-2k 
hematopoietic stem cells to reconstitute irradiated B 10.H-2k hosts and generate dendritic 
cells by constructing mixed bone marrow chimeric mice. Contrary to what was expected 
on the basis of results from in vitro cultures, the myeloid lineage of cells in mixed bone 
marrow chimeric mice were disproportionately derived from the NOD.H-2k donor. 
Interestingly, the skewing towards NOD.H-2k-derived splenic dendritic cells was 
accounted for primarily by the CD8a- dendritic cell subset, reflecting a similar bias 
observed in the spleen of unmanipulated NOD.H-2k mice and not in other H-2k congenic 
strains screened. Thus, the cell intrinsic bias towards the production of CD8a- dendritic 
cells appeared unique to the NOD.H-2k background. Furthermore, the production of an 
immature subpopulation of CD8a- dendritic cells, in relative excess, appeared unique to 
the NOD.H-2k background. 
It was postulated that a deficiency in dendritic cell numbers in vivo could be a 
correlate of the reduced capacity of NOD.H-2k myeloid precursors to generate dendritic 
cells in vitro. Contrary to what was postulated, B 10.H-2k and NOD.H-2k mice consisted 
comparable numbers of splenic and thymic dendritic cells. The presence of normal 
numbers of dendritic cells in NOD.H-2k mice may be attributed to the presence of other 
growth/survival factors provided by physiological microenvironments which in vitro 
cultures cannot mimic. Furthermore, normal dendritic cell numbers in vivo may also be 
reflecting the fact that GM-CSF is dispensable for dendritic cell production in vivo 
(Vremec et al, 1997). Consistent with the finding in this study, a previous report has 
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demonstrated that NOD bone marrow hematopoietic precursors when transferred into 
irradiated syngeneic recipients form similar number of spleen colonies in vivo as control 
Balb/c precursors, despite responding suboptimally to in vitro stimulation with GM-CSP, 
IL-3 and IL-5 (Langmuir et al, 1993). 
An expanded population of putatively immature dendritic cells appeared unique to 
the lymphoid organs of NOD.H-2k mice, particularly in the thymus. The immature 
dendritic cell population was characterized by a lower level of cell surface MHC class II 
expression. These immature dendritic cells were 4-fold more frequent than MHC class II-
high expressing dendritic cells in the NOD.H-2k thymus. In contrast, MHC class II-low 
and MHC class II-high dendritic cell populations were equally represented in the B l0.H-
2k thymus. Evidence suggesting that thymic dendritic cells expressing low levels of cell 
surface MHC class II molecules were immature came from thymic reconstitution studies 
(Ardavin et al, 1993). Intrathymic transfer of dendritic cell precursors demonstrated that 
MHC class II -low and MHC class II-high dendritic cells appeared sequentially, with the 
former preceding the latter. This observation suggests that the MHC class II-low dendritic 
cells represents an immature stage in thymic dendritic cell differentiation. Thymic 
dendritic cells are mainly located in the cortico-medullary border and medulla of the 
thymus where they are thought to play a key role in negative selection of thymocytes 
(Ardavin, 1997; Sprent and Webb, 1995). The relative prevalence of MHC class II-
intermediate dendritic cells in the NOD.H-2k thymus could potentially influence a key 
variable in central (thymic) selection of T cells: MHC-peptide ligand density. 
To determine the in vivo differentiation potential of NOD.H-2k hematopoietic 
stem cells and their progenitors, mixed bone marrow chimeric mice were constructed by 
injecting a mixed inoculum of B 10.H-2k and NOD.H-2k bone marrow cells into 
irradiated B 10.H-2k recipients. B 10.H-2k mice were chosen as recipients since, as 
reported for NOD mice (Kaufman et al, 1997), NOD.H-2k mice were found to be highly 
resistant to bone marrow engraftment. Results obtained from mixed bone marrow 
chimeric mice were contrary to that expected on the basis of results from in vitro cultures. 
The myeloid lineage of cells in mixed bone marrow chimeric mice were predominantly of 
NOD.H-2k origin while the lymphoid compartment was even between the two donors. 
Such a skewing could be explained by the inherent competitive advantage of NOD.H-2k 
hematopoietic precursors over B 10.H-2k precursors to generate myeloid cells during 
reconstitution. Furthermore, NOD.H-2k hematopoietic precursors may be predisposed to 
making more myeloid cells at the expense of lymphocytes, as suggested by significantly 
fewer absolute number of NOD.H-2k-derived B cells in whole blood of N->B bone 
marrow chimeric mice. Furthermore, results from bone marrow chimeric mice also 
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indicated over-production of NOD.H-2k-derived monocytes in both N->B and B/N->B 
chimeric mice. 
The previously described cell surface MHC class II heterogeneity in splenic and 
thymic dendritic cells of unmanipulated NOD.H-2k mice was not detectable in bone 
marrow chimeric mice. This observation suggests that the cell surface MHC class II 
heterogeneity in splenic and thymic dendritic cells of NOD.H-2k mice may be a 
consequence of microenvironmental influences rather than a cell-intrinsic feature NOD.H-
2k hematopoietic stem cells. Such a possibility can be tested by constructing B->N 
chimeric mice, provided efficient engraftment occurs in the NOD.H-2k recipients. 
The skewing towards NOD.H-2k-derived dendritic cells in mixed bone marrow 
chimeric was most pronounced in the spleen. There were 6-fold more NOD.H-2k-derived 
dendritic cells than B 10.H-2k-derived dendritic cells in the spleen of mixed chimeric 
mice. Interestingly, this skewing towards NOD.H-2k-derived dendritic cells was 
accounted for mainly by the CD8a- subset, reflecting a similar bias observed in 
unmanipulated NOD-H-2k mice and not in other H-2k congenic strains screened. It is 
worth noting that the (B 10.H-2kxNOD.H-2k)Fl hybrids showed an intermediate CD8a-
: CD8a+ dendritic cell ratio, suggesting that the balance between CD8a+ and CD8a-
subsets in the spleen is a quantitative trait. The presence of the putative immature dendritic 
cell subpopulation in the NOD.H-2k spleen was exclusively derived from the CD8a-
dendritic cell subset. The CD8a+ dendritic cell subset, on the other hand, uniformly 
expressed high levels of MHC class II molecules in all strains. Taken together, these 
_observations may suggest a potential precursor-progeny relationship between CD8a- and 
CD8a+ dendritic cell subsets. As previously mentioned, the presence of immature splenic 
dendritic cells was not evident in B/N->B chimeric mice and therefore not a cell-intrinsic 
feature of NOD.H-2k hematopoietic stem cells. However, the relative over-representation 
of immature dendritic cells in NOD.H-2k spleen appeared unique to the NOD.H-2k 
background as immature dendritic cells in the spleen of other H-2k congenic strains were 
relatively scarce. 
Although the relationship, in terms of origin and function, between the two 
splenic dendritic cell subsets remains controversial and unresolved, the relative bias 
towards CD8a- dendritic cell in the NOD.H-2k spleen is an interesting cell-intrinsic and 
unique feature of NOD.H-2k hematopoietic stem cells. Overall, data from mixed bone 
marrow chimeric mice demonstrate that non-MHC MHC NOD genes confer on NOD.H-
2k hematopoietic stem cells a cell-intrinsic phenotype which in vivo is manifested by 
skewing towards the myeloid lineage of cells and the CD8a- splenic dendritic cell subset. 
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Summary and General Discussion 
6 .1 Introduction 
While the NOD MHC is critical in the determination of target tissue for 
autoimmune destruction, diabetogenic loci outside the MHC confer a general 
susceptibility to autoimmunity in the NOD mouse. There is sufficient evidence to suggest 
a role for myeloid-derived antigen presenting cells, especially dendritic cells, in the 
initiation and maintenance of autoimmune pathology (Jansen et al, 1994; Serreze et al, 
1993a and b; Langmuir et al, 1993; Jansen et al, 1995; Takahashi et al, 1998; Ludewig et 
al, 1998). This study has, therefore, utilized NOD.H-2k and control B 10.H-2k congenic 
mice to study dendritic cell generation, both in vitro and in vivo, in an attempt to explore 
cellular processes which may be affected by non-MHC NOD genes. The results obtained 
during the course of this study demonstrated for the first time that non-MHC NOD genes 
conferred on myeloid precursors a cell-intrinsic phenotype which was manifested by: 
i) elevated levels of apoptosis and heterogeneous proliferation, resulting in reduced 
dendritic cell yield during in vitro cultures; 
ii) skewing towards the myeloid lineage of cells in vivo; and 
iii) selective bias of splenic dendritic cells towards the CD8a- subset in vivo. 
Furthermore, results from the current study demonstrated the prevalence of putatively 
immature MHC class II-low dendritic cells in NOD.H-2k mice. The presence of immature 
dendritic cells was not cell-intrinsic to NOD.H-2k hematopoietic stem cells but a unique 
feature of the NOD.H-2k background. Three key questions arise from the overall results 
obtained during the course of this study: 
A) Why do NOD.H-2k myeloid precursors respond differently to GM-CSF 
stimulation in vitro? 
B) What is the relationship between the apparently contradictory in vitro and in vivo 
results? 
C) What is the relevance of the overall findings from this study to autoimmune 
diabetes? 
These questions form the basis of the fallowing discussion. 
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PART A: The Response of NOD.H-2k Myeloid Precursors In 
Vitro 
6.2 The Uniquely Different Response of NOD.H-2k 
Myeloid Precursors to GM-CSF Stimulation In Vitro 
Preliminary attempts to generate dendritic cells by culturing myeloid precursors, in 
the presence of GM-CSF and IL-4, revealed that the yield of dendritic cells from NOD.H-
2k-derived myeloid precursors was dramatically lower than that obtained from precursors 
isolated from control B 10.H-2k mice. The inability of NOD.H-2k myeloid precursors to 
generate control levels of dendritic cells was concluded to be a cell-intrinsic feature of 
NOD.H-2k myeloid precursors as B10.H-2k-derived myeloid precursors developed in 
co-culture similar to the way they develop in single cultures. 
Previous studies have documented hematopoietic deficiencies in in vitro cultures 
of precursors, isolated from NOD mice and human prediabetic or diabetic patients 
(Serreze et al, 1993 a and b; Langmuir et al, 1993; Jansen et al, 1995; Takahashi et al, 
1998; Morel et al, 1999). Findings from the current study confirm results from previous 
reports and have been discussed in the context of these reports in the 'Discussion Section' 
of Chapter 4. Significantly, results from this study provide important extensions of 
previous findings by demonstrating for the first time that the reduced yield of dendritic 
cells from NOD.H-2k cultures is a phenotype cell-intrinsic to NOD.H-2k myeloid 
precursors. Furthermore, attempts at dissecting the reduced dendritic cell yield phenotype 
of NOD.H-2k-derived myeloid precursors revealed the cellular basis for fewer dendritic 
cells generated in NOD.H-2k cultures. While B 10.H-2k cultures exhibited a basal level of 
apoptosis and homogeneous proliferation, NOD.H-2k cultures exhibited elevated levels 
of apoptosis and heterogeneous proliferation during the initial days of culture. Elevated 
levels of apoptosis and heterogeneous proliferation appeared to be unique features of the 
NOD.H-2k background since similarly screened precursors from other H-2k congenic 
strains, including CBA/H, AKR and Balb-H-2k, behaved like precursors from control 
B 10.H-2k mice. Altogether, these results suggest that non-MHC NOD genes confer on 
NOD.H-2k-derived myeloid precursors a cell-intrinsic phenotype which is responsible 
for the elevated levels of apoptosis and heterogeneous proliferation observed in NOD.H-
2k cultures. 
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A key question arising from the preceding observations is: what is the molecular 
basis for the uniquely different mitotic and apoptotic responses of NOD.H-2k myeloid 
precursors to GM-CSF stimulation in vitro? A number of potential scenarios could 
explain the elevated levels of apoptosis and heterogeneous proliferation accounting for the 
reduced dendritic cell yield from NOD.H-2k bone marrow cultures. These include 
proximal, distal or parallel components of signal transduction pathways which determine 
the fate of a cell by balancing survival and apoptotic cues. 
6.2.1 Candidate Molecular Signalling Pathways 
GM-CSF, IL-3 and IL-5 are hematopoietic growth factors that are secreted by 
activated T cells and mast cells (Arai et al, 1990). These cytokines are actively involved in 
hematopoiesis by modulating proliferation, differentiation, survival and effector functions 
of cells of the hematopoietic lineages and their progenitors. GM-CSF and IL-3 act on 
various lineages such as macrophages, granulocytes, erythrocytes, megakaryocytes and 
hematopoietic progenitors (Metcalf and Nicola, 1992; Gasson, 1991 ), while IL-5 plays a 
major role in the development of eosinophils both in humans and in mice (Takatsu, 
1988). In both humans and mice the GM-CSF, IL-3 and IL-5 receptor is a heterodimeric 
complex comprising a cytokine-specific a chain and a shared ~ common (~c) chain 
(Miyajima et al, 1993). In addition to the ~c chain, a unique IL-3-specific ~ chain is also 
present in the mouse (Hara et al, 1992). The a chains can bind their ligands with low 
affinity but the ~c chain does not bind ligand by itself. However, the ~c chain when 
complexed with an a chain forms a high affinity signalling-competent receptor. It has 
been previously reported that NOD bone marrow cells display a reduced response to IL-
3, IL-5 and GM-CSF (Langmuir et al, 1993). Given this observation, a mechanistic 
hypothesis to explain the observed elevated levels of apoptosis and heterogeneous 
proliferation in NOD.H-2k cultures during this study is a potential defect in the signal 
transduction mediated by the ~c chain of the GM-CSF receptor. 
The role of the human Pc chain in signal transduction has been studied by using a 
series of cytoplasmic tail truncation mutants (Miyajima et al, 1993). Functional analyses 
of the deletion mutants was carried out by co-expression of the mutant ~c chain with 
human GM-CSF receptor a chain in a murine IL-3-dependent cell line, BaF3 (Sakamaki 
et al, 1992). The cytoplasmic region of the ~c can be subdivided into at least two 
functionally distinct domains, responsible for transducing mitogenic, survival or negative 
regulatory signals (Sato et al, 1993). The first and membrane proximal region transduces 
mitogenic and survival signals by the induction of the proto-oncogene c-myc and 
activation of DNA replication. The second domain leads to the activation of ras and MAP 
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(Mitogen-Activated Protein) kinases, with consequent induction of c-fos and c-jun, 
transcription factors which are involved in cell differentiation. Elimination of amino acid 
544 from the membrane proximal region results in a mutant which proliferates in 
response to GM-CSF stimulation. However, stimulation with GM-CSF is unable to 
maintain cell viability, causing cells to die by apoptosis while receiving mitogenic signals 
(Kinoshita et al, 1995). Apoptosis in the mutants was prevented by the ectopic expression 
of an activated form of ras. Taken together, these results indicate that cell proliferation 
combines both mitogenic and anti-apoptotic signals. Furthermore, ras plays an important 
role in the suppression of apoptosis in hematopoietic cells. It is likely that similar 
mechanisms are operating in the NOD.H-2k mouse during signal transduction mediated 
by the ~c chain of the GM-CSF receptor. Such mechanisms could account for the 
elevated levels of apoptosis and heterogeneous proliferation observed in NOD.H-2k bone 
marrow cultures. 
An similar scenario has been described in the IL-2-mediated regulation of T cells. 
IL-2 plays a critical role in the proliferation and survival of T cells (Nelson et al, 1998). 
In addition, IL-2 plays an opposite role in sensitizing T cells to activation-induced 
apoptosis (Lenardo, 1991). How IL-2 mediates these opposing outcomes has been 
recently demonstrated in a study using mutant forms of the IL-2 receptor (Van Parijs et al, 
1999b). The IL-2 receptor is a heterotrimeric complex comprising a cytokine binding a 
chain, and two obligate signalling subunits. The signalling subunits comprise a ~ chain 
and a common y chain which is shared with the IL-4, IL-7, IL-9 and IL-15 receptors 
(Leonard et al, 1995). Van Parijs et al ( 1999b) unravelled the molecular basis of the 
opposing effects of IL-2 by introducing wild type and two mutant forms of the human IL-
2 receptor ~ chain into receptor-deficient murine T cells by retroviral gene transfer. The 
two mutant forms of the ~ chain were individually defective in either the Stat-5 (signal 
transducer and activator of transcription-5) or Akt activation because these molecules 
were previously implicated in T cell proliferation and survival (Freidmann et al, 1996; 
Ahmed et al, 1997; Brennan et al, 1997; Fujii et al, 1998; Moriggl et al, 1999). Co-
transfection with green fluorescent protein (GFP) enabled detection of transfected cells. 
Results obtained during this study are discussed below. 
T cells reconstituted with wild type receptor or receptor deficient in Akt signalling 
were sensitive to activation-induced death (AICD) when stimulated with anti-CD3 
monoclonal antibody. In contrast, T cells reconstituted with receptor deficient in Stat5 
signalling were largely resistant to AICD when stimulated with anti-CD3 monoclonal 
antibody. This reduction in AICD was attributed to reduced Fas (CD95, death receptor 
belonging to the TNF receptor superfamily) ligand expression in T cells lacking Stat5 
activation. The requirement of the two signalling modules was altered in T cell survival. 
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When stimulated with IL-2, transfectants expressing wild type receptor or receptor 
deficient in Stat5 signalling remained viable and continued to proliferate. In contrast, 
transfectants deficient in Akt signalling proliferated for three days then underwent 
apoptosis. It has previously been shown that IL-2 signalling results in the induction of the 
anti-apoptotic molecule, Bcl-2 (Adams and Cory , 1998; Chao and Korsmeyer, 1998; 
Lord et al, 1998). Consistent with this observation, co-transfection of T cells with human 
Bcl-2 compensated for the lack of Akt signalling. Taken together, these findings support 
the model that distinct signalling modules within the IL-2 P chain regulate T cell fate by 
stimulating proliferation or by promoting apoptosis. It is possible that NOD.H-2k 
myeloid precursors receive normal mitogenic signals mediated by GM-CSF but are 
defective in generating sufficient levels of complementary survival signals. 
Apoptosis must be averted by inhibiting the function of pro-apoptotic molecules. 
Such a phenomenon is evident in the cell survival promoted by signalling through 
phosphatidylinositide-3'-0H kinase (PI-3 kinase) and its downstream target, the serine-
threonine kinase Akt (Datta et al, 1999). PI-3 kinase has been shown to be involved in the 
survival of a number of cell types in response to growth factor stimulation (Datta et al, 
1999). Correspondingly, its target Akt has also been shown to be a general mediator of 
growth factor induced survival in various cell types. Thus, the sequential activation of PI-
3 kinase and Akt has become a paradigm for growth factor induced cell survival. In order 
to elucidate the mechanism by which the PI-3 kinase/Akt pathway promotes cell survival, 
Datta et al ( 1997) employed the well-established insulin-like growth factor (IGF)-1 
supplemented neuronal culture system. It was previously shown that IGF-1 stimulation 
specifically activated the PI-3 kinase/Akt pathway in cultured neurons (Dudek et al, 
1997). Furthermore, it was shown that IGF-1-mediated induction of the PI-3 kinase/Akt 
pathway was necessary and sufficient for the survival of neurons in culture. Clues 
towards the mechanism of Akt action came from the in vitro and in vivo observations that 
Akt activation triggers the phosphorylation of the pro-apoptotic Bcl-2 family member 
BAD (Gajewski and Thompson, 1996; Wang et al, 1996; Zha et al, 1996). To test the 
hypothesis that the IGF-1 induced PI-3 kinase/Akt survival pathway suppressed BAD-
mediated apoptosis, neurons were transfected with various derivatives of BAD (Datta et 
al, 1997). In contrast to neurons transfected with control constructs, the majority of the 
wild type BAD-transfected neurons underwent apoptosis. Apoptosis in the wild BAD-
transfectants was substantially suppressed by treatment with the survival factor, IGF-1. 
Indeed, by using neurons transfected with mutant forms of BAD, it was demonstrated 
that IGF-1 promoted PI-3 kinase/ Akt-mediated cell survival by site-specific 
phosphorylation of BAD. This finding was a confirmation of a previous report which 
demonstrated that IL-3 -mediated survival of a hematopoietic cell line was underpinned by 
BAD phosphorylation (Zha et al, 1996). Furthermore, it was shown that phosphorylation 
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of BAD resulted in it being sequestered in the cytosol. This promotes survival by 
precluding heterodimerization of phosphorylated BAD with anti-apoptotic members of the 
Bcl-2 family (Adams and Cory, 1998; Chao and Korsmeyer, 1998). Unphosphorylated 
BAD heterodimerizes with certain anti-apoptotic members of the Bcl-2 family and 
neutralizes their protective effect. Thus, proximal survival signals may modulate 
apoptosis by inactivating distal pro-apoptotic molecules. 
It is interesting to note that the PI-3 kinase/ Akt survival pathway was not required 
for the survival of a murine mast cell line stimulated with GM-CSF (Scheid et al, 1995). 
Inhibitors of PI-3 kinase rapidly induced apoptosis in cells incubated in the presence of 
IL-4 or IL-3. In contrast, cells incubated in the presence of GM-CSF, or to a lesser extent 
IL-5, could bypass the effects of the inhibitors. These results suggest that alternative 
survival pathways are activated as a result of GM-CSF stimulation of myeloid cells. 
Signals transduced in parallel with growth factor receptor signalling is another 
possible mechanism by which apoptosis may be induced. Parallel signals may be 
involved in the downregulation of anti-apoptotic molecules. It has recently been 
demonstrated that mature lymphocytes express a novel anti-apoptotic protein called cFLIP 
(Thome et al, 1997). Naive B and T cells express high levels of cFLIP which is 
downregulated when B and T cells are given a mitogenic or activation stimulus (Irmler et 
al, 1997; Refaeli et al, 1998). The downregulation of cFLIP in activated lymphocytes 
co1related with their heightened sensitivity to death receptor-mediated apoptosis. The role 
of cFLIP in apoptosis was illuminated by expressing cFLIP in primary lymphocytes 
using a retroviral transfection system (Van Parijs et al, 1999a). It was demonstrated that 
retrovirus-mediated expression of cFLIP inhibited death receptor induced apoptosis in 
activated lymphocytes. Interestingly, mice reconstituted with cFLIP expressing bone 
marrow cells developed B cell-mediated autoimmunity. The autoimmune response was 
characterized by the presence of anti-DNA autoantibodies and elevated levels of serum 
immunoglobulins of various isotypes, reminiscent of the autoimmune syndromes 
observed in lpr mice deficient in the death receptor Fas (Cohen and Eisenberg, 1991 ). 
Altogether, these results suggest that cFLIP down-regulation renders lymphocytes 
susceptible to apoptosis and is required to maintain tolerance. Dysregulated 
downregulation of a survival molecule may be a mechanism that contributes towards 
elevated levels of apoptosis observed when NOD.H-2k myeloid precursor are stimulated 
with GM-CSF in vitro. 
Dysregulated mitogenic signals in cultured NOD.H-2k myeloid precursors could 
be yet another mechanism which induces apoptosis. The proto-oncogene c-myc has been 
implicated in the regulation of cell proliferation in several studies (Schmidt, 1999). It is 
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rapidly induced in quiescent cells given a mitogenic stimulus and is continuously present 
at an appreciable level throughout the cell cycle in proliferating cells. This suggests that c-
myc plays a role in the transition from quiescence to cell proliferation and in the 
maintenance of proliferation. Conversely, mi to gen withdrawal is accompanied by the 
down-regulation in cells of both c-myc mRNA and protein levels (Dean et al, 1986; 
Waters et al, 1991), and the entry of cells into growth arrest. The latter observation 
suggests that c-myc down-regulation is required for cells to enter growth arrest (Waters et 
al, 1991). Furthermore, c-myc can be a potent inducer of apoptosis when combined with 
a block in proliferation. Rat-1 fibroblasts constitutively expressing human c-myc, by 
retroviral gene transfer, undergo apoptosis when deprived of growth factor (Evan et al, 
1992). Comparable results were also reported using an IL-3-dependent myeloid cell line 
(Askew et al, 1991). 
PART B: The Link between In Vivo and In Vitro Results 
6. 3 Skewing of the Myeloid Lineage of cells towards 
NOD.H-2k Origin in Mixed Bone Marrow Chimeric 
Mice (B/N->B) 
A potential correlate of the reduced yield of dendritic cells in vitro would be fewer 
dendritic cells arising from NOD.H-2k hematopoietic stem cells in vivo. To test the in 
vivo capacity of NOD.H-2k hematopoietic stem cells to generate dendritic cells, mixed 
bone marrow chimeric mice were constructed using irradiated B 10.H-2k recipients. 
Recipients were reconstituted with an inoculum comprising a 1: 1 mixture of bone marrow 
cells. Again, the allelic variants of Ly5 were used during flow cytometric analysis of 
donor-derived leukocytes in recipient mice 8-12 weeks post-reconstitution. Contrary to 
expectation, the myeloid lineage of cells in recipient mice were skewed towards NOD.H-
2k origin, while the lymphoid lineage was practically even between the two donors. 
Monocytes, thymic dendritic cells and splenic dendritic cells in mixed bone marrow 
chimeric mice were predominantly NOD.H-2k-derived. In contrast, total Band T cells in 
blood and spleen, and total T cells in thymus were derived equally from both donors. The 
number of monocytes in peripheral whole blood of control N->B chimeric mice appeared 
to be higher than in the control B->B chimeric mice (p = 0.084). Similarly, the number of 
NOD.H-2k -derived monocytes in mixed bone marrow chimeric B/N->B mice was 
significantly higher than the number of monocytes in control B->B chimeric mice (p = 
0.03). In contrast, the number of B cells in peripheral whole blood of the former group of 
mice was significantly lower than in the latter group (p = 0.008). These results suggest 
that NOD.H-2k hematopoietic stems cells may be preferentially generating myeloid cells 
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over lymphoid cells. Interestingly, a recent study has demonstrated that tissue monocytes, 
in response to a phagocytic stimulus, migrate to draining lymph node and differentiate 
into T cell zone dendritic cells in vivo (Randolph et al, 1999). This observation indicates 
that monocytes can serve as a dendritic cell precursor pool from which lymphoid and 
peripheral tissue maybe seeded. 
6.3.1 Predominance of CDSa· Dendritic Cells in Mixed 
Bone Marrow Chimeric Mice (B/N->B) and in 
Unmanipulated NOD.H-2k Mice 
The most pronounced skewing of myeloid cells in B/N->B mixed bone marrow 
chimeric mice towards NOD.H-2k origin was seen in the splenic dendritic cell 
population. Since two dendritic cell subsets (CD8a- and +) form the splenic dendritic cell 
population, it was interesting to determine which subset was responsible for the skewing 
towards NOD.H-2k origin. Interestingly, the skewing towards NOD.H-2k-derived 
splenic dendritic cells was accounted for mainly by the CD8a- subset, reflecting a similar 
bias observed in unmanipulated NOD.H-2k mice. The CD8a- to CD8a+ ratio of splenic 
dendritic cells in control B 10.H-2k mice was 1.5. In contrast, the same ratio was 6.5 in 
NOD.H-2k mice. This bias towards CD8a- dendritic cells in NOD.H-2k mice appeared 
unique since other H-2k strains similarly screened either had an intermediate or Bl0.H-
2k-like low ratio. Taken together, in vivo results reveal that the cell-intrinsic effects of 
non-MHC NOD genes on NOD.H-2k myeloid precursors results in the preferential 
generation of myeloid cells. Furthermore, non-MHC NOD genes appear to selectively 
bias splenic dendritic cell population in favor of the CD8a- subset. 
6.3.2 Roles of GM-CSF in Myeloid and Dendritic Cell 
Differentiation 
Interestingly, inspite of numerous in vitro studies indicating that GM-CSF is a key 
cytokine for dendritic cell development, normal numbers of dendritic cells are detected in 
the lymphoid organs of mice with a null mutation for GM-CSF (Stanley et al, 1994; 
Dranoff et al, 1994) or ~c chain of the GM-CSF receptor (Robb et al, 1995; 
Nishinakamura et al, 1995; Vremec et al, 1997). Overall, no hematopoietic defects were 
observed in these mice. Both these mutants suffer from a lung disease characteristic of the 
human disease pulmonary alveolar proteinosis (PAP). Mutant mice show markedly 
reduced alveolar clearance and catabolism of lung surfactant protein, resulting in clogged 
* These in1mature dendritic cells were not detected in B/N->B mixed bone marrow chimeric 
mice, suggesting that the presence of in11nature dendritic cells was not a cell-intrinsic feature of 
NOD.H-2k hen1atopoietic stem cells. 
# It is in1portant to note, however, that the large nun1bers of CD8cc mature dendritic cells 
(MHC class nhi) were produced from NOD.H-2k precursors in B/N->B chimeras. 
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air spaces. This pulmonary lesion is thought to be partly due to impaired alveolar 
macrophage function (Scott et al, 1998). The myeloid growth factor GM-CSF and 
signalling through the ~c are therefore dispensable for dendritic cell generation and 
compensatory mechanisms exist in vivo. 
The apparent contradiction between in vitro and in vivo results obtained during the 
course of this finding may be reconciled by taking into account that GM-CSF is 
redundant for basal level hematopoiesis in vivo but required for hematopoiesis during an 
immune response. GM-CSP-deficient mice when infected with the facultative intracellular 
bacterium Listeria monocytogenes harbored 50-fold more organisms in their spleen and 
liver than similarly infected wild-type mice (Zhan et al, 1998). The high bacterium load 
correlated with a severe depletion of bone marrow hematopoietic cells and a reduced 
inflammatory response in the peritoneal cavity of GM-CSP-deficient mice. A comparable 
finding has also been reported in IL-3-deficient mice. Similar to the need for GM-CSF in 
the generation of dendritic cells in vitro, IL-3 has been shown to augment stem cell factor-
dependent mast cell development in vitro (Tsuji et al, 1991; Mayer et al, 1989). Using IL-
3-deficient mice, Lantz et al ( 1998) demonstrate that IL-3 is not essential for the 
development of mast cells or basophils under physiological conditions. However, when 
infected with the nematode Strongyloides venezuelensis, IL-3-deficient mice show 
impaired parasite expulsion and mast cell development. Thus, like GM-CSF, IL-3 is 
redundant for basal hematopoiesis but required during an immune response. Overall, 
these results suggest that the physiological function of GM-CSF only comes into 
prominence during an immune response directed against infectious agents or possibly 
endogenous tissue. 
In addition to promoting hematopoiesis under inflammatory conditions, GM-CSF 
may also be involved in the more subtle processes of myeloid cell differentiation during 
normal hematopoiesis. As previously mentioned, impaired alveolar macrophage function 
may be responsible for surfactant accumulation in the lungs of GM-CSF- or ~c-deficient 
mice (Scott et al, 1998). Findings from the current study show the presence of putative 
immature dendritic cells, present in relative excess, in the thymus and spleen of NOD.H-
2k mice. These immature dendritic cells expressed intermediate/low levels of cell surface 
MHC class II molecules. These immature dendritic were not deteced in B/N->B mixed 
bone marrow chimeric mice, suggesting that the presence of immature dendritic cells was 
* not a cell-intrinsic feature of NOD.H-2k hematopoietic stem cells . However, the relative 
abundance of immature dendritic cells was unique to the NOD.H-2k background. 
Furthermore, immature dendritic cells were exclusively contained in the CD8a- dendritic 
# 
cell subset. In contrast, the CD8a+ dendritic cells uniformly expressed high levels of cell 
surface MHC class II molecules. These results may suggest a potential precursor-progeny 
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relationship between CDSa- and CDSa+ dendritic cell subsets, with the CDsa+ dendritic 
cell representing a terminally differentiated form of dendritic cells. Thus, by exerting its 
influence on dendritic cell differentiation in vivo, GM-CSF may also determine the 
balance between dendritic cell subsets. 
There are a number of possibilities that could potentially explain the cell-intrinsic 
bias, mediated by non-MHC NOD genes, towards the CDSa- dendritic cell subset in 
NOD.H-2k mice. It is likely that NOD.H-2k hematopoietic stem cells preferentially 
commit to the production of myeloid cells in the bone marrow, resulting in more myeloid 
cells in the periphery as evidenced by results from this study. This bias towards the 
generation of myeloid cells could be due to impaired negative regulatory signals or too 
much positive signalling or both for myeloid cell production. Furthermore, enhanced 
survival and/or proliferation of circulating monocyte precursors in the periphery 
(Randolph et al, 1999) could account for the relative excess of the CDSa- dendritic cell 
subset. From the results in this study it is interesting to speculate a possible precursor-
progeny relationship between CDSa- and CDSa+ dendritic cells, with the CDSa+ 
dendritic cells representing the terminally differentiated subset. Thus, defective 
differentiation processes, underpinned by impaired GM-CSF signalling, may contribute 
towards the accumulation of the CDS a- dendritic cell subset. Alternatively, if the CDS a+ 
dendritic cell subset belongs to a distinct lineage, then under-production and reduced 
survival could explain their relative deficiency. The bias towards myeloid cells could also 
be coupled to the under-production of B cells, as indicated by results from this study. 
This could be due to deficiencies in lineage commitment, survival or proliferation of B 
cell precursors. 
It is conceivable that the reduced dendritic cell yield in NOD.H-2k cultures is a 
result of NOD.H-2k rnyeloid precursors receiving an exaggerated initial proliferative 
burst which in vitro is not matched by complementary survival and/or differentiation 
signals. The apparent contradiction between reduced dendritic cell yield observed in 
NOD.H-2k cultures and the preferential generation of NOD.H-2k-derived myeloid 
lineage of cells in vivo can be reconciled in this context. 
6.3.3 Dysregulation in the RelB Pathway as an Alternative 
Cause for the Bias towards the CDSa· Splenic 
Dendritic Cell Subset in NOD.H-2k Mice 
91 
While GM-CSF appears not to be essential to form dendritic cells in vivo, another 
molecular pathway has been identified as being essential. Important molecular evidence 
supporting functional differences between CD8a- and CD8a+ splenic dendritic cells has 
come from a recent study with the RelB mutant (RelB-1-) mice (Wu et al, 1998). The 
RelB-/- mice have a complex phenotype which include thymic dendritic cell deficiency. 
Development of lymphoid cells in the mutant mice is unaffected. The in vivo 
differentiation capacity of RelB-/- stem cells was determined by constructing bone 
marrow chimeric mice using wild type recipients congenically marked with the Ly5a 
allotype to distinguish between host and donor cells. Normal numbers of donor-derived 
thymic dendritic cells were produced in recipient mice indicating that the absence of 
thymic dendritic cells in RelB-/- mice may be secondary phenomenon caused by systemic 
inflammation and disrupted thymic architecture. Interestingly, reconstituted mice 
displayed a marked reduction in the splenic CD8a- dendritic cell subset compared with 
the CD8a+ dendritic cell subset which was present at control levels. This phenotype was 
attributed to a consequence of a cell-intrinsic effect of the RelB mutation. RelB, therefore, 
appears to selectively regulate the CD8a- dendritic cell subset in the spleen. The 
deficiency of CD8a- dendritic cells in RelB-/- mice is opposite to the expanded pool of 
these cells in the spleen of unmanipulated NOD.H-2k mice and in B/N->B mixed bone 
marrow chimeric mice. It is therefore interesting to consider the possibility that 
enhancement of signalling pathways connected to RelB may be involved in the dendritic 
cell imbalance seen in the NOD.H-2k spleen. 
The NFKB family of transcription factors includes p50, p52, p65 (RelA), RelB 
and c-Rel (Ghosh et al, 1998; May and Ghosh, 1998). Transcriptionally active complexes 
are formed as a result of dimers formed between family members. In quiescent cells, 
these complexes are sequestered in the cytoplasm by the inhibitory IKBa and IKBb. IKB 
molecules mask the nuclear localization signal of NFKB and preclude its nuclear 
translocation. Signals that induce NFKB activity cause the dissociation and the 
subsequent degradation of IKB proteins. Degradation of IKB proteins enables NFKB to 
translocate to the nucleus and induce gene expression. 
In addition to its role in the development of CD8a- splenic dendritic cells in mice, 
in vitro studies suggest that RelB is important in dendritic cell differentiation and 
functional maturity in both humans and in mice. In humans, RelB mRNA is constitutively 
expressed by lymphocytes but not by myeloid cells. Upon activation, however, both 
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myeloid and lymphoid cells up-regulate RelB expression. Immunohistochemical staining 
of human tissue revealed that RelB is expressed by lymph node but not resting tissue 
(skin and synovial tissue) dendritic cells (Pettit et al, 1997). In the paracortex, RelB and 
HLA-DR are co-expressed in interdigitating dendritic cells, with RelB staining localized 
in the nucleus and HLA-DR staining on the cytoplasmic processes or dendrites. Staining 
with anti-CD3 monoclonal antibody revealed that RelB+ interdigitating dendritic cells 
were clustered with RelB- T cells. Translocation of RelB to the nucleus of in vitro 
cultured monocyte-derived dendritic cells and activated B cells correlated with these cells 
acquiring efficient in vitro antigen presenting cell function. Interestingly, a recent study 
demonstrated that IL-12 acts directly on murine dendritic cells, via a dendritic cell-
expressed IL-12 receptor, and induces nuclear translocation of RelB and NFKB p50 
(Grohmann et al, 1998). This stimulation resulted in enhanced cell surface MHC class II 
expression and induction of endogenous IL-12 production. 
6.3.4 Functional Specialization within Splenic Dendritic Cell 
Subsets and its Possible Relevance to Autoimmune 
Diabetes 
Although the existence of splenic dendritic cell subsets is well established, it 
remains unclear whether these cells represent one cell type in distinct states of 
differentiation or whether they are distinct cell types performing distinct functions. 
Preliminary in vitro data has led to the suggestion that CD8a + may possess 
regulatory/tolerogenic function while their CD8a- counterparts perform pro-immunity 
functions (Suss and Shortman, 1996; Kronin et al, 1996). It has been demonstrated that 
CD8a+ dendritic cells are less efficient in inducing proliferation of purified allogeneic 
CD4 T cells compared to CD8a- dendritic cells (Suss and Shortman, 1996). More dead 
cells were observed in CD8a+ dendritic cell MLR cultures than in CD8a- dendritic cell 
MLR cultures. The mechanisms for reduced cell viability in CD8a+ dendritic cell MLR 
cultures remain to be elucidated. A similar regulatory role of CD8a+ dendritic cells was 
also observed in MLR cultures containing purified allogeneic CDS T cells (Kronin et al, 
1996). Again, the proliferative capacity of CDS T cells stimulated with CD8a+ dendritic 
cells was relatively reduced. This reduced proliferation of CDS T cells correlated with 
relatively reduced IL-2 secretion in the MLR cultures. It was concluded from this study 
that CD8a+ dendritic cells regulated CDS T cell proliferation by limiting their IL-2 
production. 
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Further evidence for functional differences between the two dendritic cell subsets 
was demonstrated in their ability to secrete IL-12 (Sousa et al, 1997). This study showed 
that in response to microbial stimulation in vivo, the majority of IL-12 secreting dendritic 
cells in the spleen were CDS a+, as determined by flow cytometry. IL-12 secretion in this 
model was rapid and independent of CD40 ligand. Most recently, a number of studies 
have attempted to demonstrate delineation of function between the two dendritic cell 
subsets both in vitro (Ohteki et al, 1999) and in vivo (Pulendran et al, 1999; Maldonado-
Lopez et al, 1999, Smith and Fazekas de St. Groth, 1999). Ohteki et al (1999) reported 
that IL-12 impacts differentially on the two dendritic cell subsets in vitro. CDSa+ 
dendritic cells secrete approximately 5-fold higher level of IFNy than do CDSa- dendritic 
cells, when both subsets are sorted and cultured in the presence of IL-12. This results 
suggest that IL-12 secreted by CD8a+ dendritic cells acts in autocrine manner for IFNy 
production and subsequent generation of a Th I -type response. 
In vivo results from reports by Maldonado-Lopez et al (1999), Pulendran et al 
( 1999), and Smith and Fazekas de St. Groth ( 1999) seem to contradict the the regulatory 
role of CD8a + dendritic cells observed in vitro by Stiss and Shortman ( 1996). 
Maldonado-Lopez et al ( 1999) reported that administration into syngeneic recipients of 
purified CD8a+ or CDSa- dendritic cells, loaded ex vivo with antigen, resulted in 
antigen-specific T cell priming in draining lymph node, as assessed by antigen-dependent 
proliferation in culture. It is notable that the dendritic cell purification protocol involved 
overnight culture in GM-CSF of low density spleen cells. It was during this overnight 
culture that dendritic cells were pulsed with antigen. Analysis of cytokine profiles of 
draining lymph node cells cultured in vitro revealed that each dendritic cell subset could 
differentially skew cytokine production towards either a Thl or Th-2-type response. It 
was shown that CDSa+ dendritic cells promoted a Th I-type response while CDsa-
dendritic cells promoted a Th-2-type response. The capacity of CD8a+ dendritic cells to 
mediate a Thl-type response correlated with its ability to secrete relatively large amounts 
of IL-12 in response to in vitro stimulation. 
Similar findings were reported in the study by Pulendran et al (1999). Pulendran 
et al (1999) administered Flt-3 ligand into mice to expand dendritic cell numbers in vivo. 
Flt-3 ligand induces expansion of both the putative myeloid- and lymphoid-related 
dendritic cell subsets. The ability of these dendritic cell subsets to prime antigen specific 
transgenic T cells in vivo was investigated in an adoptive transfer model. Detectable 
numbers of T cell receptor transgenic T cells derived from the DO.11.10/SCID mice were 
adoptively transferred into syngeneic Balb/c recipients. The DO.11 T cell receptor 
transgenic mice encode a T cell receptor specific for OVA323-339 and restricted to I-Ad 
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(Murphy et al, 1990). Dendritic cell subsets, sorted from the spleen of Flt-3 ligand treated 
mice on the basis of CDl lc and CDl lb expression, were pulsed with OVA323-339 in 
vitro and injected into the footpads of mice that had already received DO.11 T cell 
receptor transgenic T cells. Specific T cell response in draining lymph node was 
monitored by flow cytometry. Results obtained demonstrated that both dendritic cell 
subsets could prime antigen specific T cells with similar kinetics and magnitude. 
However, assessment of cytokine production by antigen specific T cells during in vitro 
restimulation with antigen revealed that the myeloid-related dendritic cell subset (CDSa-) 
always induced secretion of much greater levels of IL-10 and IL-4. Both dendritic cell 
subsets appeared to induce equal levels of IFNy and IL-2 secretion. 
An analogous study, but with different results and interpretations, was reported 
by Smith and Fazekas de St. Groth (1999). This study employed the adoptive transfer of 
freshly-purified, moth cytochrome c peptide-pulsed CD8a+ or - dendritic cells into 
recipient mice which had been injected with antigen-specific transgenic T cells 2 days 
earlier. In this model, only donor dendritic cells could present antigen as host antigen 
presenting cells lacked the MHC corresponding to the restriction of responding T cells. 
The antigen-specific T cell response in draining lymph node was almost identical 
regardless of which dendritic cell subset was used as antigen presenting cells. Inspite of 
this T cell response to both dendritic cell subsets, only the CDSa- dendritic cells were 
capable of homing into draining lymph node. This result suggests that differential Th 
priming may not result from direct Th activation by CD8a+ versus CDSa- dendritic cells. 
The authors invoke a mechanism of MHC-peptide transfer from CD8a+ to CDSa-
dendritic cells for T cell activation in vivo. Neither of the two preceding studies directly 
address the physiological function of the CD8a+ dendritic cells resident in T cell zones of 
secondary lymphoid tissue. 
To date functional specialization within dendritic cell subsets remains controversial 
and obscure. It is, therefore, difficult to postulate the functional relevance, if any, of a 
bias towards the CDSa- dendritic cell subset observed in the spleen of NOD.H-2k mice. 
If the CD8a+ dendritic cell subset is the major producers of IL-12 in vivo, it is interesting 
to speculate that a dysregulation in the balance of splenic dendritic cell subsets (relative 
excess or deficiency of CDSa- or+ dendritic cells, respectively) could impair the ability 
of NOD mouse to evoke IL-12-mediated immunosuppressive mechanisms (Falcone and 
Sarvetnick, 1999). Systemic administration of high doses of IL-12 into NOD mice 
accelerates diabetes (Trembleau et al, 1995), whereas low doses suppress diabetes 
development (O' Hara et al, 1996). One possible mechanism by which IL-12 may 
mediate immunosuppression in the mouse is through the antagonist effect of the IL-12 
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p40 homodimer [(p40)2] on the biologically-active IL-12 p75 heterodimer (Mattner et al, 
1993; Trinchieri G., 1995). Cells secreting the biologically-active IL-12 p75 heterodimer 
also secrete an excess of monomeric p40 and (p40)2 (D'Andrea et al, 1992; Heinzel et al, 
1997). The (p40)2 specifically antagonizes mouse IL-12 (Mattner et al, 1993). As 
previously mentioned, IL-12 (p40)-deficient NOD mice, although possessing reduced 
ability to mount Th 1 responses, develop diabetes to the same extent as control NOD mice 
(Trembleau et al, 1999). Thus, IL-12 is not essential for diabetes development. 
Interestingly, administration of (p40)2 into young NOD mice results in the reduction of 
spontaneous and cyclophosphamide-induced diabetes (Trembleau et al, 1997). These 
findings suggest that IL-12 induced regulatory mechanisms can inhibit diabetes 
development. 
Interestingly, the daily administration of the IL-12-related IL-18 into NOD mice 
inhibits diabetes development (Rothe et al, 1999). IL-18 is a recently described cytokine 
which shares biological activities with IL-12 (Takeda et al, 1998). It has recently been 
shown that cultured dendritic cells from humans and mice and primary dendritic cells 
from mice secrete functional IL-18 (Stoll et al, 1998). It is conceivable that impaired IL-
12/18-mediated immunosuppressive responses could result from an imbalance in 
dendritic cell subsets. 
As previously mentioned, a recent study demonstrated that IL-12 acts directly on 
murine dendritic cells, via a dendritic cell-expressed IL-12 receptor, and induces nuclear 
translocation of RelB and NFKB p50 (Grohmann et al, 1998). This stimulation resulted 
in enhanced cell surface MHC class II expression and induction of endogenous IL-12 
production. Significant message for the IL-12 receptor was detected only on the CD8a-
dendritic cell subset. Consistent with this observation, syngeneic CD8a- dendritic cells 
pulsed with a poorly immunogenic tumor peptide and exposed to rIL-12 in vitro are able 
to elicit efficient responses in vivo (Grohmann et al, 1999). Overall, these results indicate 
that IL-12 modulates dendritic cell phenotype by signalling through RelB. It is interesting 
to speculate that IL-12, secreted by CD8a+ dendritic cells, could prime the pool of 
CD8a- subset present in relative excess in NOD.H-2k mice, to initiate proimmunity 
rather than tolerogenic responses. 
In light of the preceding evidence and findings from the current study, it is 
interesting to postulate a role for RelB in the bias towards CD8a- splenic dendritic cell in 
NOD.H-2k mice. Dysregulation of RelB function in NOD.H-2k mice could occur as a 
result of impaired negative regulatory signals or excessive positive signals, or both, being 
transduced. The process of dendritic cell generation from myeloid precursors is delayed 
when myeloid precursors from the Rern-/- mice are stimulated with GM-CSF (DiMolfetto 
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et al, 1997). Dysregulated RelB could potentially acceletate the process of dendritic cell 
generation by making myeloid precursors more responsive to GM-CSF. Consequently, a 
potential scenario is that the relative excess of one dendritic cell subset may tilt the balance 
of immune responses in favor of autoimmunity rather than tolerance. 
PART C: Relevance to Autoimmune Diabetes 
6.4 Causal Link with Autoimmune Diabetes? 
The current study demonstrates cell-intrinsic effects of non-MHC NOD genes on 
dendritic cell generation in vitro and in vivo. Furthermore, a prevalence of immature 
dendritic cells in NOD.H-2k mice was unique to the NOD.H-2k background among a 
number of H-2k strains examined. These differences between the autoimmune-resistant 
B 10.H-2k and the autoimmunity-prone NOD.H-2k mice, however, do not establish a 
causal link between these differences and autoimmune diabetes. On the one hand, there 
are likely to be numerous functional polymorphisms between the strains that are unrelated 
to diabetes susceptibility. On the other hand, dendritic cells play a key role in immune 
regulation and hence a good candidate cell type. 
Important evidence for the role of dendritic cells in autoimmune response against 
peripheral tissue came in a study by Ludewig et al ( 1998). This study employs transgenic 
mice which express lymphocytic choriomeningitis virus glcoprotein (LCMV-GP) in 
pancreatic islets using the rat insulin promoter (RIP). RIP-GP mice do not spontaneously 
develop diabetes. However, when infected with LCMV, these mice develop an acute 
form of non-lethal diabetes (Ohashi et al, 1991; Oldstone et al, 1991). The Ludewig et al 
( 1998) study investigated the role of dendritic cells in the initiation and maintenance of 
autoimmune diabetes, by repeatedly priming RIP-GP mice with dendritic cells 
constitutively expressing the immunodominant cytotoxic T lymphocyte (CTL) epitope of 
LCMV-GP. This regime of repeated CTL, and quite possibly helper T cell, activation by 
dendritic cells results in severe and destructive mononuclear infiltration of islets . A 
notable feature of this process is the formation of islet-associated secondary lymphoid-
like structures, observed in other autoimmune syndromes, including Hashimoto's 
thyroiditis (Iwatani et al, 1993) and rheumatoid arthritis (Randen et al, 1995). Similar 
secondary lymphoid-like structures are observed in the islets of NOD.H-2k mice which 
become diabetic as a result of transgenic expression of HEL in the islets and the 3A9 T 
cell receptor (Hartley S. and Goodnow C., unpublished observations). Thus, repeated 
priming by dendritic cells bearing peripheral antigen can induce formation of de novo 
lymphoid structures and tissue autoimmunity. 
97 
Alternatively, the cell-intrinsic and unique features of NOD.H-2k mice may be 
unlinked to autoimmune diabetes. There is precedence for such a possibility. Until 
recently, it was postulated that the chromosome 3 encoded Fe receptor for IgG (FcyRI) 
was a candidate gene for the induction of autoimmune diabetes (Prins et al, 1993). The 
NOD Fcgr I allele carries mutations resulting in 17 amino acid differences compared with 
the wild-type B 10 allele, and a substantial truncation in the cytoplasmic domain of the 
receptor. These structural differences in the NOD FcyRI contributed to lower clearance of 
IgG from the surface of NOD cells than from B 10 cells. This functional difference and 
the localization of Fcgr I to the lddl 0 region led to the postulated role of FcyRI in 
diabetes development. However, congenic mapping of lddl 0 revealed the presence of 
two linked loci within lddl0: lddl0 and Iddl7 (Podolin et al, 1997). Neither of these 
intervals contained the Fcgr I allele. The Fcgr I allele was therefore eliminated as a 
candidate gene, even though the NOD strain expresses a mutant form of the receptor. 
Similarly, the Slc9al ( formerly known as Nhe-1) gene linked with lddl 1, located 
on mouse chromosome 4, was initially proposed to be a candidate gene for diabetes 
susceptibility (Morahan et al, 1994). The Slc9al gene encodes a Na+/H+ exchanger-1 
which was found to be genetically and physiologically associated with diabetes 
susceptibility. The NOD Slc9al allele is distinct from that expressed by diabetes-resistant 
strains. Furthermore, NOD lymphocytes exhibited higher Na+ /H+ exchange activity 
compared with B6 or SJL mice lymphocytes, resulting in NOD lymphocytes having a 
higher resting intracellular pH. However, a recent study using NOD-lddl 1 congenic 
strains shows that introduction of the B6-derived lddl 1 chromosomal interval, 
containing the diabetes-resistant Slc9al allele, onto the NOD background did not confer 
diabetes protection to the NOD congenic strain (Brodnicki et al, 2000). The Slc9al gene 
was as a result eliminated as a candidate gene for autoimmune diabetes. 
A similar strategy of genetic mapping of loci contributing to the myeloid/dendritic 
cell abnormalities, detected in this study, would be needed to examine whether these 
abnormalities are related to autoimmune diabetes. This strategy is outlined in the Future 
Directions section (6.4.2). 
6.4.1 Proposed Model of the Role of Dendritic Cells in 
Autoimmune Diabetes 
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In order to consider how the observed myeloid/dendritic cell abnormalities might 
confer susceptibility to autoimmunity, I have proposed a hypothesis as follows. As yet 
undefined danger signals emanating from the pancreatic islets will activate resident 
antigen presenting cells and recruit dendritic cells on immunosurveillance and their 
precursors from blood. Monocytes provide a ready reservoir of precursors that could 
differentiate into lymphoid organ or tissue dendritic cells (Randolph et al, 1999). 
Activated dendritic cells will acquire islet antigen/s and migrate to the draining lymph 
nodes. Chemokines secreted by dendritic cells recruit lymphocytes to both the islets and 
the draining lymph nodes, both of which are potential sites for antigen presentation 
(Kurts et al, 1999). Dysregulated RelB function could contribute towards the exaggerated 
and continual antigen presenting cell response in the islets by influencing the balance 
between dendritic cell subsets and IL-12 secretion (See Figure 6.1). The relative 
deficiency in CD8a+ dendritic cells in NOD.H-2k mice would result in reduced levels of 
IL-12 secreted during an immune response. The impact of reduced IL-12 secretion would 
be two-fold: i) the immunosuppressive effects of IL-12 would be mitigated; and (ii) the 
ability of bioactive IL-12 to appropriately modulate phenotype/function of the relatively 
abundant CD8a- dendritic cell subset would be reduced. The relative excess of CD8a-
dendritic cells would mean the presence of more 'immature' antigen presenting cells. 
These immature dendritic cell population, present due to dysregulated RelB function, 
would also amplify immune responses by being hyper-responsive to T cell-secreted 
factors, like GM-CSF. The combined effect of these features is an unshackled cycle of 
self-destruction as a seemingly perpetual recruitment of antigen presenting cells and 
lymphocytes into islets occurs, with the ultimate outcome being the transformation of the 
pancreas into a lymph node-like structure. 
Figure 6.1 
Model for the role of dendritic cells in autoimmune diabetes 
See text for details. 
RelB Dysregulation 
+ 
Imbalance in Dendritic Cell Subsets 
/ 
Excess of CDSa· 
Dendritic Cells 
- Hyperresponsive to GM-CSF 
- Impaired IL-12-mediated modulation 
of phenotype/function 
~ 
Deficiency in CDSa+ 
Dendritic Cells 
+ 
Reduced IL-12 secretion 
+ 
Reduced production of the 
[(p40)]2 antagonist 
Susceptibility to tissue autoimmunity? 
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6.4.2 Future Directions 
6. 4. 2 .1 Genetic Mapping 
The key objective of future experiments would be to establish whether the bias 
towards CDSa- splenic dendritic cells in NOD.H-2k mice is causally-linked to 
autoimmune diabetes. This could be achieved by an initial linkage mapping strategy to 
determine whether the gene/s responsible for the splenic dendritic cell bias in NOD.H-2k 
mice overlap with known ldd. Large numbers of progeny generated by intercrossing 
(B 1 O.H-2k x NOD.H-2k) Fl hybrids or by backcrossing (B 10.H-2k x NOD.H-2k) Fl 
hybrids to NOD.H-2k can be typed for the association of splenic dendritic cell ratios with 
ldd. ldd can be readily detected by PCR using the locus-specific microsatellite map 
generated by Todd et al (1991). The splenic CDSa-: CDSa+ dendritic cell ratio could be 
used as a surrogate marker. As previously mentioned, this phenotype is a quantitative trait 
as CDSa-: CDSa+ dendritic cell ratio is high in the NOD.H-2k strain, low in the B l0.H-
2k strain and intermediate in the (B 10.H-2k x NOD.H-2k) Fl hybrids. Since the trait is 
semi-dominant it would be easier to carry out the mapping study in the intercross F2 
progeny. Intercross F2 progeny will be expected to express the full range of phenotypes 
and genotypes of each parental strain and of the (B 10.H-2k x NOD.H-2k) Fl hybrids. 
The presence of excess homozygotes at a particular ldd in the progeny with a CDSa-
dendritic cell bias, would indicate a linked locus. No linkage to dendritic cell ratios would 
be indicated by the presence of equal numbers of progeny which are homozygotes and 
heterozygotes at a particular ldd. Alternatively, the elevated levels of apoptosis and 
heterogeneous proliferation seen in NOD.H-2k bone marrow cultures could be used as 
surrogate markers. The bone marrow culture approach would, however, be a tedious 
one. 
Another linkage mapping strategy could be carried out using NOD.H-2k-Jdd 
-resistance (lddr) and B 10.H-2k-Jdd-susceptibility (ldd8 ) congenic strains. Again, the 
splenic dendritic cell ratios could be employed as a surrogate marker. Congenic strains 
can be made by introducing an ldd8 (from NOD.H-2k)or Iddr (from B 10.H-2k) locus 
onto the B 10.H-2k or NOD.H-2k background, respectively. The influence of ldd8 or 
lddr on the balance between splenic dendritic cell subsets could then be monitored. If an 
individual ldd8 is responsible for dendritic cell ratios, its replacement by congenic 
introduction of the equivalent lddr onto the NOD.H-2k background should eliminate the 
CDSa- dendritic cell bias in the NOD.H-2k strain. Conversely, introduction of the Idd8 
responsible for the dendritic cell ratios onto the B 10.H-2k background should confer the 
CDSa- dendritic cell bias to the B 10.H-2k strain. Obviously, such a mapping strategy 
would be extremely useful if a single ldd is responsible for the splenic dendritic cell bias. 
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In the event of an epistatic interaction between Idd creating the splenic dendritic cell bias, 
various permutations of double or multiple Idd congenic strains would be required. 
6. 4. 2. 2 Bone Marrow Reconstitution Assays to Causally-Link Dendritic 
Cells with Autoimmune Diabetes Induction 
While at least some NOD strain / dd8 alleles have been shown to act within 
hematopoietic cells, it is not known whether these susceptibility genes act within T cells, 
B cells, macrophages or dendritic cells. Testing whether Idd8 act on CDSa- dendritic 
cells in autoimmune diabetes induction could be done in diabetes transfer assays. In order 
to determine the role of dendritic cell subsets in the transfer of autoimmune diabetes, 
irradiated recipient mice expressing model autoantigen in the islet can be reconstituted 
with a mixture of bone marrow cells from dendritic cell-deficient mice and mice 
expressing a transgenic T cell receptor specific for the model autoantigen. As positive 
control group, a mixture of donor bone marrow cells from NOD.H-2k.SCID mice and 
B 10.H-2k.scID mice carrying the 3A9 T cell receptor transgene (B lO.H-2k.scID.TCR) 
could be used to reconstitute B 10.H-2k mice expressing islet HEL (iHEL.B 10.H-2k). In 
the control group, antigen will be presented by myeloid-derived antigen presenting cells 
from the B 10.H-2k background (See Figure 6.2 for schematic of experiment). The SCID 
mutation eliminates the role of endogenous and donor B and T (non-transgenic) cells in 
diabetes induction. The test group would comprise the same recipients reconstituted with 
a mixture of bone marrow from NOD.H-2k.sCID mice carrying the RelB mutation 
(NOD.H-2k.SCID.RelB-I-) and from the B 10.H-2k.SCID.TCR mice. In the test group, 
antigen will be presented by CDSa- dendritic cell-deficient myeloid-derived antigen 
presenting cells from the NOD.H-2k background. Both groups should then be screened 
for incidence of diabetes by measuring glucose levels in blood and for islet pathology by 
immunohistochemistry. The predicted outcome would be a significantly lower incidence 
of diabetes in the test group compared with that in the control group. However, residual 
CDSa- dendritic cells may be sufficient in inducing control levels of diabetes in the test 
group since the RelB mutation does not completely abrogate the development CDSa -
dendritic cells. 
Figure 6.2 
Schematic to investigate the role of dendritic cell subsets in autoimmune 
diabetes. 
See text for details. 
1) Control Group - Myeloid-derived antigen presenting cells from the 
B 10 .H-2 k background present antigen 
Inoculum bone marrow: 50% NOD.H-2k.scID and 
50% B10.H-2k.scm. TCR 
~ 
iHEL.B10.H-2k 
2) Test Group - CDSa- dendritic cell-deficient myeloid-derived 
antigen presenting cells from the NOD.H-2k background present antigen 
Inoculum bone marrow: 50% NOD.H-2k.scID.RelB-/- and 
50% BlO.H-2k.scID. TCR 
~ 
iHEL.BlO.H-2k 
Readout: Diabetes, Islet Histology 
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6.4.3 Concluding Remarks 
Overall, the results described herein demonstrate for the first time cell-intrinsic 
effects of non-MHC NOD genes on hematopoietic stem cells which alter dendritic cell 
generation, both in vitro and in vivo. These effects were manifested by: 
a) elevated levels of apoptosis and heterogeneous proliferation, resulting in reduced 
dendritic cell yield during in vitro cultures; 
b) skewing towards the myeloid lineage of cells in vivo; and 
c) selective bias of splenic dendritic cells towards the CD8a- subset in vivo. 
Furthermore, this study demonstrates the prevalence of immature dendritic cells in the 
NOD.H-2k strain. This is not a cell-intrinsic feature of NOD.H-2k hematopoietic stem 
cells but a unique feature of the NOD.H-2k strain. Further studies must be aimed at 
unravelling the genetic basis of these differences, and determining whether contributory 
gene/s coincide with known Idd. Such studies may elucidate molecular/biochemical 
pathways amenable to therapeutic intervention, genetic or pharmacologic, for the 
prevention, treatment and cure of Type I diabetes in humans. 

Appendices 
Al Common Reagents and Suppliers 
Rea2ent 
Acetic acid (glacial) 
Ag arose (Ultrapure) 
Ammonium chloride 
P-mercaptoethanol 
CFSE 
Dimethylsulfoxide (DMSO) 
dNTPs 
Ficoll Paque 
Ethylenediamine tetra-acetic acid 
Ethidium bromide 
Foetal bovine serum (FBS) 
Glutamine 
Lysozyme 
Magnesium Chloride 
Merocyanin 540 
Metrizamide 
Neomycin 
Ovalbumin 
Polymyxin B 
Proteinase K 
Paraformaldehyde 
RPMI 1640 
Sf9-900 insect cell medium 
Sodium dodecyl sulphate (SDS) 
Sodium chloride 
Sodium azide 
Taq DNA polymerase 
Taq DNA polymerase buffer 
Tris 
Triton X-100 
Trypan blue 
Supplier 
BDH Laboratory Supplies, Poole, England 
GibcoBRL 
BDH Laboratory Supplies 
GibcoBRL 
Molecular Probes 
Sigma Chemical Co. 
Pharmacia Biotech 
Pharmacia Biotech 
BDH Laboratory Supplies 
Amresco, OH, USA 
Trace Biosciences 
GibcoBRL 
Sigma Chemical Co. 
BDH Laboratory Supplies 
Sigma Chemical Co. 
Nycomed Pharma 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
BDH Laboratory Supplies 
JCSMR, GibcoBRL 
GibcoBRL 
GibcoBRL 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
Stratagene USA, CA, USA 
Stratagene USA 
Boehringer Mannheim 
Sigma Chemical Co. 
Sigma Chemical Co. 
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A2 Buffers, Media and Stock Solutions 
A2.1 Buffers 
a) FACS Buffer 
2% FBS (v/v) and 0.01 % sodium azide (v/v) in PBS. Stored at 4°C. 
b) FACS Fix Buffer 
FACS buffer with 0.1 % (w/v) paraformaldehyde. Stored at 4°C. 
d) Tris Ammonium Chloride Red Blood Cell Lysis Buffer 
Lysis buffer contains 0.02mM Tris and 0. lM ammonium chloride in PBS. 
1.03g Tris and 3.375g ammonium chloride dissolved in 500mL PBS. Adjust pH to 7.2 
with concentrated hydrochloric acid. Buffer autoclaved and stored at room temperature. 
A2.1.2 DNA Buffers and Gels 
a) TAE DNA Running Buffer 
TAB (Ix) 
-40 mM Tris 
- 40mM Acetic acid 
-lmMEDTA 
b) DNA Loading Buffer 
- 50% (v/v) glycerol in l0x TAE 
- 2mg/mL bromophenol blue 
Stored at -20°C. 
c) DNA Gel 
- 1 % agarose gel ( w /v) in T AE buffer 
- 0.5µg/mL ethidium bromide 
A2.2 Media 
RPMI 1640 
For 20 L stock: 
208.8g RPMI powder 
40g Sodium bicarbonate 
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Dissolve ingredients in in 20 L double distilled water. Microfilter (0.2µm) and aseptically 
dispense into sterile Schott bottles. 
For cell culture, RPMI 1640 is supplemented with: 
- 10% (v/v) heat inactivated (1-4 hr at 57°C) foetal bovine serum 
- 0.05mM P-mercaptoethanol 
- 2mM L-Glutamine 
- l0mMHEPES 
- 1 00U/mL penicillin, 1 00µg/mL streptomycin. 
A2.3 Stock Solutions 
a) Alsevers Solution 
In 1 L stock: 
8g sodium citrate 
4.2g sodium chloride 
20.5g glucose 
0.8g citric acid 
Dissolve ingredients in lL distilled water. Adjust pH to 6.1 with 10% citric acid. 
Autoclave and store at 4°C in l00mL aliquots. 
b) Antibiotics Solution 
Dissolve 8.5xlo5 U/mL Polymyxin B and 1.1 mg/mL Neomycin. Add food color to 
distinguish from antibiotics-free water. Dispense into 2mL aliquots and store at -20°C. 
One aliquot used per 550mL water. 
c) CFSE 
5 mM stock made by reconstituting in DMSO. 50µL aliquots stored at -70°C. 
d) Collagenase 
1 mg/mL stock made reconstituting in Hank's buffered saline. lmL aliquots stored at 
-20°C. 
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e) Merocyanin 540 
lmg/mL stock made by reconstituting in double distilled water. Microfiltered and stored 
in the dark at 4°C. 
f) Metrizamide 
14.5% (w/v) stock made by dissolving in RPMI 1640 (10% FBS). Microfiltered and 
dispensed into 5mL aliquots. Stored at -20°C. 
g) Rabbit Complement 
Reconstituted in lmL ice-cold double distilled water. l00µL aliquots were frozen at 
-20°c. 1 in 10 dilution of complement was used for lysis. 
h) White Blood Cell Counting Stain 
1.5% v/v acetic acid and 0.01 % w/v Gentian Violet in distilled water. Stored at room 
temperature. 
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